DENTSPLY SIRONA (XRAY) 10-K/A 7 Nov 22 2021 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 21, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	Dentsply Sirona Inc. (“Dentsply Sirona” or the “Company”) is filing this Amendment No. 1 to the Annual Report on Form 10-K (this “Form 10-K/A”) for the fiscal year ended December 31, 2021, originally filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2022 (the “2021 Form 10-K” or “Original Filing”), to make certain changes described below. Restatement On October 29, 2022, the Company, in consultation with the Audit and Finance Committee of its Board of Directors (the “Audit and Finance Committee”), reached a determination that the Company’s consolidated financial statements and related disclosures for the three and nine months ended September 30, 2021 and for the fiscal year ended December 31, 2021 should no longer be relied upon because of certain misstatements contained in those financial statements. The Company has determined that it is appropriate to correct the misstatements in the Company’s previously issued financial statements by amending the Original Filing and its Quarterly Report on Form 10-Q for the period ended September 30, 2021. As first disclosed in the Company’s Form 12b-25 filed on May 10, 2022, the Audit and Finance Committee has been conducting an internal investigation into certain financial reporting matters. That investigation has been completed, and the results are discussed in this Explanatory Note. As a result of a separate but concurrent review by the Company of the accounting for various customer incentive arrangements unrelated to the transactions subject to the internal investigation (the “Accounting Review”), management identified errors related to certain customer incentive programs. During the Accounting Review, it was also determined that the Company utilized incorrect accounting and assumptions in the determination of estimates related to its sales returns provisions, warranty reserve provisions and variable consideration. Management identified misstatements for the three and nine months ended September 30, 2021 and for the fiscal year ended December 31, 2021, in each case, that the Company deemed to be material when considered together with certain quantitative and qualitative considerations such as the fact that the misstatements masked a failure to meet internal financial targets and external financial analyst expectations for the three months ended September 30, 2021 and due to the material weaknesses identified through the course of the Audit and Finance Committee’s investigation. For a more detailed discussion of the correction of these accounting errors, refer to Note 1 Significant Accounting Policies and Restatement included in Part II, Item 8, Notes to the Consolidated Financial Statement, of this Form 10-K/A. For more information about the specific material weaknesses in internal control over financial reporting and the Company’s remedial actions, please see Management’s Report on Internal Control Over Finanical Reporing within Part II, Item 8 Financial Statements and Supplementary Data of this Form 10-K/A. Audit and Finance Committee Investigation North America Investigation On May 10, 2022, the Company announced that the Audit and Finance Committee, assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company. The Audit and Finance Committee’s investigation was focused on the Company’s use of incentives to sell products to certain distributors in North America in the third and fourth quarters of 2021, whether those incentives were appropriately accounted for, and whether the impact of the sales to which they were applied were adequately disclosed in the Company’s periodic reports filed with the SEC. The Audit and Finance Committee also investigated allegations that certain former members of senior management may have directed the Company’s use of these incentives and other actions to achieve executive compensation targets in 2021. We refer to this portion of the Audit and Finance Committee’s investigation as the North America Investigation. In the North America Investigation, the Audit and Finance Committee concluded that there was no evidence of intentional wrongdoing or fraud. The Audit and Finance Committee determined that certain former members of senior management, including the Company’s former Chief Executive Officer and former Chief Financial Officer, violated provisions of the Company’s Code of Ethics and Business Conduct. In addition, these former members of senior management did not maintain and promote an appropriate control environment focused on compliance in areas of the Company’s business, nor did they sufficiently promote, monitor or enforce adherence to the Code of Ethics and Business Conduct. The North America Investigation found that certain former members of senior management, including the former Chief Executive Officer and the former Chief Financial Officer, created a culture where employees did not feel comfortable raising concerns without fear of retaliation. In addition, the North America Investigation substantiated certain allegations regarding inappropriate tone at the top by the former Chief Executive Officer and the former Chief Financial Officer. The North America Investigation identified instances in which the Company’s distributors in North America were offered incremental incentives, including extended payment terms, to purchase products in order for the Company to attempt to meet certain internal sales targets in the third and fourth quarters of 2021. These incentives were offered in conjunction with Net sales transactions amounting to approximately $38 million and $70 million in the third and fourth quarters of 2021, respectively, which in turn contributed to higher levels of distributor inventory at the end of such periods, and lower sales to these distributors in the first and second quarters of 2022. The North America Investigation’s analysis of the incremental incentives and related sales, which included examination of documents supporting the accounting and revenue recognition for both the incentives and related sales, identified two insignificant accrual errors. However, these incremental incentives and the sales to which they applied contributed to the Company’s ability to meet external financial analyst expectations in the third quarter of 2021. The North America Investigation also found that there were inadequate processes in place for approval of these incentives and that the Company also had inadequate processes for maintaining or providing copies of agreements or arrangements with distributors to the accounting department. The North America Investigation noted potential omissions in public disclosures made by the Company regarding the use of these incentives or their potential future impacts in the third and fourth quarters of 2021. However, the North America Investigation did not find evidence that the former Chief Executive Officer and former Chief Financial Officer specifically directed the Company’s use of incentives to achieve executive compensation targets in 2021. Additionally, the investigation noted that the Company’s independent registered accounting firm was not informed of these incremental incentive arrangements in conjunction with the 2021 audit of the consolidated financial statements. Finally, the North America Investigation also identified findings regarding potential control deficiencies. For more information about these material weaknesses and other identified material weaknesses in internal control over financial reporting and the Company’s remedial actions, please see Part II, Item 8 Management’s Report on Internal Control Over Financial Reporting. Based on the results of the North America Investigation, the Company further analyzed these product shipments and corresponding incentive arrangements between the Company and its distributors and determined that, with the exception of the errors pertaining to the Accounting Review described above, sales were properly recorded in each of the respective periods in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). China Investigation While the North America Investigation was ongoing, the Audit and Finance Committee was informed in June 2022 that the Company had identified higher returns of products from distributors in China during the fourth quarter of 2021 that did not align with historical trends identified through an operational audit executed by the Company’s Corporate Audit department. Accordingly, the Audit and Finance Committee determined that the scope of the internal investigation should be expanded to analyze the increase in returns of products in China during the fourth quarter of 2021. We refer to this portion of the Audit and Finance Committee’s investigation as the China Investigation. The China Investigation found that the Company processed returns and/or exchanges that were not in accordance with the return and/or exchange provisions contained in existing distributor agreements and sales contracts in China. The China Investigation also found that members of the Company’s local commercial team in China failed to provide information requested by the Company’s local accounting organization in connection with the return and/or exchange of products in China during the fourth quarter of 2021. The China Investigation concluded that these employees, as well as the head of the Company’s Asia-Pacific commercial organization, committed intentional wrongdoing by failing to provide requested information to the Company’s local accounting organization, by obstructing the work of the accounting team, and by lacking truthfulness in providing information to the Company and to the Audit and Finance Committee as part of the China Investigation. The China Investigation also determined that these actions by certain members of the Company’s local commercial team in China, as well as the former Chief Financial Officer and the head of the Company’s Asia-Pacific commercial organization violated the Company’s Code of Ethics and Business Conduct. These employees, including the head of the Company’s Asia-Pacific commercial organization, also did not maintain and promote an appropriate control environment in certain areas of the Company’s business focused on compliance, nor did they sufficiently promote, monitor or enforce adherence to the Company’s Code of Ethics and Business Conduct. The China Investigation also identified concerns regarding control deficiencies, including ineffective communication among the China commercial operations, financial planning & analysis (“FP&A”) and accounting teams, resulting in a heightened risk of incomplete or insufficient information required to maintain accurate books and records related to incentive provisions, specifically concerning expanded concessions regarding the return or exchange of products from distributors. For more information about the specific material weaknesses in internal control over financial reporting and the Company’s remedial actions, please see Part II, Item 8 Management’s Report on Internal Control Over Financial Reporting within this Form 10-K/A. The failure to appropriately account for these returns and/or exchanges and allowing for the product exchanges referred to above resulted in an overstatement of Net sales in the third quarter of 2021 of approximately $4 million which should have been recorded in the fourth quarter of 2021, and is reflected in the restated interim financial statements for the three and nine month periods ended September 30, 2021 included in the Company’s Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Form 10-Q/A”). For a more detailed discussion of the correction of these accounting errors, refer to Note 1, Significant Accounting Policies and Restatement, to the consolidated financial statements of the Company included in Part II, Item 8 of this Form 10-K/A. Controls and Procedures In connection with the restatement of the financial statements and related disclosures for the three and nine months ended September 30, 2021 and for the fiscal year ended December 31, 2021, management re-evaluated the effectiveness of the Company’s internal control over financial reporting and identified material weaknesses in the Company’s internal control over financial reporting as of September 30, 2021 described in Part II, Item 8 Management’s Report on Internal Control Over Financial Reporting of this Form 10-K/A. These material weaknesses remained in place as of December 31, 2021. The Company’s current Chief Executive Officer and current Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective as of December 31, 2021, due to the material weaknesses described in Part II, Item 8 Management’s Report on Internal Control Over Financial Reporting of this Form 10-K/A. Accordingly, the Company is filing this Form 10-K/A to amend management’s assessment of the Company’s disclosure controls and procedures to conclude that they were not effective due to the identification of material weaknesses as of December 31, 2021. Additionally, PwC is amending its Report of Independent Registered Public Accounting Firm to reflect the identification of these material weaknesses in the Company’s internal control over financial reporting as of December 31, 2021. Amendment to Form 10-K In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the following Items of the Original Filing have been amended and restated and the complete text of those is set out in this Form 10-K/A: Part I - Item 1A. Risk Factors Part II - Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Part II - Item 8. Financial Statements and Supplementary Data Part II - Item 9A. Controls and Procedures Part IV - Item 15. Exhibits and Financial Statement Schedules Please note that the only changes to the Original Filing are those related to the matters described herein and only in the Items listed above. Item 1A “Risk Factors” has been updated to reflect risks as of the date of this amended filing. Except as described above, no changes have been made to the Original Filing, and this Form 10K/A does not modify, amend or update any of the other financial information or other information contained in the Original Filing. In addition, in accordance with SEC rules, this Form 10-K/A includes updated certifications from our Chief Executive Officer and Chief Financial Officer as Exhibits 31.1, 31.2 and 32. Otherwise, the information contained in this Form 10-K/A is as of the date of the Original Filing and does not reflect any information or events occurring after the date of the Original Filing. Such subsequent information or events include, among others, the information and events described in our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2022 and June 30, 2022, each of which are being filed concurrently with this Form 10-K/A, and the information and events described in our Current Reports on Form 8-K filed subsequent to the date of the Original Filing. For a description of such subsequent information and events, please read our reports filed pursuant to the Exchange Act subsequent to the date of the Original Filing, which update and supersede certain information contained in the Original Filing and this Form 10-K/A.
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Document Transition Report	false
Entity File Number	0-16211
Entity Registrant Name	DENTSPLY SIRONA Inc.
Entity Central Index Key	0000818479
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	39-1434669
Entity Address, Address Line One	13320 Ballantyne Corporate Place
Entity Address, City or Town	Charlotte
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28277-3607
City Area Code	844
Local Phone Number	848-0137
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	XRAY
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 13,791,201,522
Entity Common Stock, Shares Outstanding		217,554,303
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement for its 2022 Annual Meeting are incorporated by reference into Part III of this Form 10-K/A.
Auditor Firm ID	238
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Charlotte, North Carolina

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Total net sales	$ 1,103,000,000	$ 1,040,000,000	$ 1,062,000,000	$ 1,026,000,000	$ 1,076,000,000	$ 883,000,000	$ 499,000,000	$ 881,000,000	$ 4,231,000,000	$ 3,339,000,000	$ 4,022,000,000
Cost of products sold	499,000,000	471,000,000	467,000,000	447,000,000	509,000,000	451,000,000	317,000,000	406,000,000	1,884,000,000	1,683,000,000	1,858,000,000
Gross profit	604,000,000	569,000,000	595,000,000	579,000,000	567,000,000	432,000,000	182,000,000	475,000,000	2,347,000,000	1,656,000,000	2,164,000,000
Selling, general, and administrative expenses	377,000,000	395,000,000	393,000,000	386,000,000	373,000,000	313,000,000	259,000,000	357,000,000	1,551,000,000	1,302,000,000	1,587,000,000
Research and development expenses	49,000,000	39,000,000	43,000,000	40,000,000	38,000,000	29,000,000	20,000,000	36,000,000	171,000,000	123,000,000	143,000,000
Goodwill impairment				0				157,000,000	0	157,000,000	0
Restructuring and other costs	6,000,000	3,000,000	5,000,000	3,000,000	15,000,000	18,000,000	2,000,000	42,000,000	17,000,000	77,000,000	81,000,000
Operating income (loss)	172,000,000	132,000,000	154,000,000	150,000,000	141,000,000	72,000,000	(99,000,000)	(117,000,000)	608,000,000	(3,000,000)	353,000,000
Other income and expenses:
Interest expense, net	12,000,000	14,000,000	15,000,000	14,000,000	15,000,000	14,000,000	11,000,000	6,000,000	55,000,000	46,000,000	27,000,000
Other expense (income), net	4,000,000	5,000,000	8,000,000	(9,000,000)	(3,000,000)	1,000,000	4,000,000	(1,000,000)	8,000,000	1,000,000	(12,000,000)
Income (loss) before income taxes	156,000,000	113,000,000	131,000,000	145,000,000	129,000,000	57,000,000	(114,000,000)	(122,000,000)	545,000,000	(50,000,000)	338,000,000
Provision for income taxes	37,000,000	29,000,000	35,000,000	33,000,000	24,000,000	9,000,000	(22,000,000)	12,000,000	134,000,000	23,000,000	82,000,000
Net income (loss)	119,000,000	84,000,000	96,000,000	112,000,000	105,000,000	48,000,000	(92,000,000)	(134,000,000)	411,000,000	(73,000,000)	256,000,000
Less: Net income (loss) attributable to noncontrolling interests	0		0	0	0		(1,000,000)	0	0	0	0
Net income (loss) attributable to Dentsply Sirona	$ 119,000,000	$ 84,000,000	$ 96,000,000	$ 112,000,000	$ 105,000,000	$ 47,000,000	$ (91,000,000)	$ (134,000,000)	$ 411,000,000	$ (73,000,000)	$ 256,000,000
Net income (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ 0.55	$ 0.39	$ 0.44	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.88	$ (0.33)	$ 1.15
Diluted (in dollars per share)	$ 0.54	$ 0.38	$ 0.43	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.87	$ (0.33)	$ 1.14
Weighted average common shares outstanding:
Basic (in shares)									218.4	219.2	223.1
Diluted (in shares)									220.2	219.2	224.4

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 411	$ (73)	$ 256
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(181)	184	(83)
Net gain (loss) on derivative financial instruments	25	(32)	(1)
Pension liability adjustments	26	(13)	(26)
Total other comprehensive (loss) income	(130)	139	(110)
Total comprehensive income	281	66	146
Less: Comprehensive (loss) income attributable to noncontrolling interests	(2)	1	1
Comprehensive income attributable to Dentsply Sirona	$ 283	$ 65	$ 145

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 339	$ 438
Accounts and notes receivable-trade, net	750	667
Inventories, net	515	476
Prepaid expenses and other current assets	248	217
Total Current Assets	1,852	1,798
Property, plant and equipment, net	773	791
Operating lease right-of-use assets, net	198	176
Identifiable intangible assets, net	2,319	2,504
Goodwill, net	3,976	3,986
Other noncurrent assets	121	95
Total Assets	9,239	9,350
Current Liabilities:
Accounts payable	262	302
Accrued liabilities	760	712
Income taxes payable	57	59
Notes payable and current portion of long-term debt	182	299
Total Current Liabilities	1,261	1,372
Long-term debt	1,913	1,978
Operating lease liabilities	149	130
Deferred income taxes	391	381
Other noncurrent liabilities	528	554
Total Liabilities	4,242	4,415
Commitments and contingencies (Note 22)
Equity:
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued	0	0
Common stock, $.01 par value; 400.0 million shares authorized at December 31, 2021 and 2020; 264.5 million shares issued at December 31, 2021 and 2020; 217.4 million and 218.7 million shares outstanding at December 31, 2021 and 2020, respectively	3	3
Capital in excess of par value	6,606	6,604
Retained earnings	1,514	1,198
Accumulated other comprehensive loss	(592)	(464)
Treasury stock, at cost, 47.1 million and 45.8 million shares at December 31, 2021 and 2020, respectively	(2,535)	(2,409)
Total Dentsply Sirona Equity	4,996	4,932
Noncontrolling interests	1	3
Total Equity	4,997	4,935
Total Liabilities and Equity	$ 9,239	$ 9,350

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par or stated value per share (in dollars per share)	$ 1	$ 1
Preferred stock, shares authorized (in shares)	250,000	250,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par or stated value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	264,500,000	264,500,000
Common stock, shares outstanding (in shares)	217,400,000	218,700,000
Treasury stock, shares (in shares)	47,100,000	45,800,000

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions	Total	Total Dentsply Sirona Equity	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interests
Beginning Balance at Dec. 31, 2018	$ 5,083	$ 5,071	$ 3	$ 6,522	$ 1,188	$ (491)	$ (2,151)	$ 12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	256	256			256			0
Other comprehensive income	(110)	(111)				(111)		1
Divestiture of noncontrolling interest	(11)	0		0				(11)
Exercise of stock options	109	109		13			96
Stock based compensation expense	66	66		66
Funding of employee stock purchase plan	5	5		1			4
Treasury shares purchased	(260)	(260)					(260)
Restricted stock unit distributions	(6)	(6)		(16)			10
Restricted stock unit dividends	0			1	(1)
Cash dividends declared	(84)	(84)			(84)
Ending Balance at Dec. 31, 2019	5,048	5,046	3	6,587	1,359	(602)	(2,301)	2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(73)	(73)			(73)			0
Other comprehensive income	139	138				138		1
Exercise of stock options	11	11		1			10
Stock based compensation expense	47	47		47
Funding of employee stock purchase plan	5	5		2			3
Treasury shares purchased	(140)	(140)					(140)
Restricted stock unit distributions	(15)	(15)		(34)			19
Restricted stock unit dividends	0			1	(1)
Cash dividends declared	(87)	(87)			(87)
Ending Balance at Dec. 31, 2020	4,935	4,932	3	6,604	1,198	(464)	(2,409)	3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	411	411			411			0
Other comprehensive income	(130)	(128)				(128)		(2)
Exercise of stock options	52	52		15			37
Stock based compensation expense	49	49		49
Funding of employee stock purchase plan	5	5		2			3
Treasury shares purchased	(200)	(200)					(200)
Restricted stock unit distributions	(31)	(31)		(65)			34
Restricted stock unit dividends	0			1	(1)
Cash dividends declared	(94)	(94)			(94)
Ending Balance at Dec. 31, 2021	$ 4,997	$ 4,996	$ 3	$ 6,606	$ 1,514	$ (592)	$ (2,535)	$ 1

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Cash dividends declared (in dollars per share)	$ 0.43	$ 0.4	$ 0.38

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 411,000,000	$ (73,000,000)	$ 256,000,000
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	124,000,000	142,000,000	133,000,000
Amortization of intangible assets	222,000,000	192,000,000	190,000,000
Fixed asset impairment	0	3,000,000	33,000,000
Goodwill impairment	0	157,000,000	0
Indefinite-lived intangible asset impairment	0	39,000,000	9,000,000
Deferred income taxes	(25,000,000)	(62,000,000)	(40,000,000)
Stock based compensation expense	48,000,000	47,000,000	66,000,000
Other non-cash (income) expense	34,000,000	3,000,000	6,000,000
(Gain) loss on sale on non-strategic businesses and product lines	(14,000,000)	1,000,000	2,000,000
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net	(117,000,000)	131,000,000	(90,000,000)
Inventories, net	(64,000,000)	123,000,000	11,000,000
Prepaid expenses and other current assets, net	(32,000,000)	39,000,000	12,000,000
Other noncurrent assets	(10,000,000)	1,000,000	(9,000,000)
Accounts payable	(49,000,000)	(28,000,000)	27,000,000
Accrued liabilities	100,000,000	(10,000,000)	59,000,000
Income taxes	17,000,000	(41,000,000)	(14,000,000)
Other noncurrent liabilities	12,000,000	(15,000,000)	(12,000,000)
Net cash provided by operating activities	657,000,000	649,000,000	639,000,000
Cash flows from investing activities:
Cash paid for acquisitions of businesses and equity investments, net of cash acquired	(248,000,000)	(1,078,000,000)	(3,000,000)
Cash received on sale of non-strategic businesses or product lines	28,000,000	1,000,000	11,000,000
Capital expenditures	(142,000,000)	(87,000,000)	(123,000,000)
Cash received on derivative contracts	2,000,000	58,000,000	40,000,000
Other investing activities, net	2,000,000	0	6,000,000
Net cash used in investing activities	(358,000,000)	(1,106,000,000)	(69,000,000)
Cash flows from financing activities:
Proceeds from long-term borrowings, net of deferred financing costs	16,000,000	1,448,000,000	120,000,000
Repayments on long-term borrowings	(297,000,000)	(701,000,000)	(251,000,000)
Net borrowings (repayments) on short-term borrowings	179,000,000	2,000,000	(69,000,000)
Payments on terminated derivative instruments	0	(30,000,000)	0
Proceeds from exercised stock options	51,000,000	11,000,000	109,000,000
Cash paid for treasury stock	(200,000,000)	(140,000,000)	(260,000,000)
Cash dividends paid	(92,000,000)	(88,000,000)	(81,000,000)
Other financing activities, net	(36,000,000)	(26,000,000)	(40,000,000)
Net cash (used in) provided by financing activities	(379,000,000)	476,000,000	(472,000,000)
Effect of exchange rate changes on cash and cash equivalents	(19,000,000)	14,000,000	(3,000,000)
Net (decrease) increase in cash and cash equivalents	(99,000,000)	33,000,000	95,000,000
Cash and cash equivalents at beginning of period	438,000,000	405,000,000	310,000,000
Cash and cash equivalents at end of period	339,000,000	438,000,000	405,000,000
Supplemental disclosures of cash flow information:
Interest paid, net of amounts capitalized	64,000,000	45,000,000	30,000,000
Income taxes paid, net of refunds	148,000,000	82,000,000	112,000,000
Non-cash investing activities:
Property, plant and equipment in accounts payable at end of period	33,000,000	14,000,000	14,000,000
Exchange of inventory for naming rights	$ 2,000,000	$ 4,000,000	$ 3,000,000

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES AND RESTATEMENT Description of Business DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”), is the world’s largest manufacturer of dental products and technologies, with a 134-year history of innovation and service to the dental industry and patients worldwide. The Company’s principal product categories include dental consumable products, dental equipment, dental technologies and certain healthcare consumable products. The Company sells its products in over 150 countries under some of the most well-established brand names in the industry. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ materially from those estimates. Specifically, for the year ended December 31, 2021, some of these estimates and assumptions continue to be based on an ongoing evaluation of expected future impacts from the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly have a negative material impact on the Company’s financial condition, liquidity, or results of operations in future periods is highly uncertain and difficult to predict. More specifically, the demand for the Company’s products has been, and continues to be, affected by social distancing guidelines, dental practice safety protocols which reduce patient traffic, and some lingering patient reluctance to seek dental care. The Company’s 2020 results were materially impacted by the preventative measures implemented at the outset of the pandemic, including the closure or reduced operations of dental practices. During 2021, demand for the Company’s products has largely recovered, although impacts from the pandemic continue to be experienced as evidenced by the more recent shortages and higher prices of raw materials such as electronic components, higher related transportation costs, and labor shortages. In the current year, the Company has experienced supply chain constraints, which has impacted its ability to timely produce and deliver certain products, and has also resulted in increases in shipping rates. To address these issues, the Company has taken steps to mitigate the impact of these trends, including continued emphasis on cost reduction and supply chain efficiencies. However, uncertainties remain regarding how long these impacts will continue, whether customer demand will fully return to pre-COVID-19 levels upon lifting of remaining government restrictions, or whether future variants of the virus may have an adverse impact on demand in affected markets. Basis of Presentation The consolidated financial statements include the results of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. The consolidated financial statements include corrections of previously issued statements which are presented below for annual periods and in Note 23 for quarterly periods. Additi onally, research and development (“R&D”) expenses for the years ended December 31, 2020 and 2019 have been separately presented on the Consolidated Statement of Operations to conform to the current year presentation. Restatement and Other Corrections of Previously Issued Consolidated Financial Statements Subsequent to the issuance of the Company’s consolidated financial statements as of December 31, 2021 and 2020 and for each of the three fiscal years in the period ended therein (the “previously issued financial statements”), management identified errors related to certain incentive programs. It was also determined that the Company utilized incorrect accounting and assumptions in the determination of certain estimates related to its sales return provisions In conjunction with making these corrections, the Company has also made certain other restatements and revisions for previously identified errors. As a result of these collective errors, Net sales and Net Income were overstated in the Company’s financial statements for the fiscal year ended December 31, 2021 by approximately $20 million, and $10 million, respectively with errors to both Net sales and Net income (loss) for the fiscal years ended December 31, 2020 and 2019 as shown in the tables below. Additionally, the correction of errors pertaining to periods prior to 2019 required an adjustment to opening retained earnings at January 1, 2019 of $38 million as reflected in the Consolidated Statements of Equity. Those errors related primarily to the timing, recognition, and estimation of variable consideration associated with certain sales orders in the historical periods. These errors in the previously issued financial statements were deemed to be material when considered together with certain qualitative and quantitative considerations such as the fact that the misstatements masked a failure to meet internal financial targets and external financial analyst expectations for the three months ended September 30, 2021 and due to the material weaknesses identified through the course of the Audit and Finance Committee’s investigation. In conjunction with correcting these errors, management has therefore restated the accompanying financial statements for the year ended December 31, 2021 and has revised the financial statements for the years ended December 31, 2020 and 2019, as shown below. The Company has also updated all accompanying footnotes and disclosures affected by the restatements and revisions, Additionally, the Company has provided Note 23 Correction of Previously Issued Quarterly Financial Information in order to present the corresponding restatements and revisions to each of the quarters of 2021 and 2020. The following tables present the effect of correcting these accounting errors on the Company’s previously issued financial statements: CONSOLIDATED STATEMENTS OF OPERATIONS Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions, except per share amounts) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Net sales $ 4,251 $ (20) $ 4,231 $ 3,342 $ (3) $ 3,339 $ 4,029 $ (7) $ 4,022 Cost of products sold 1,890 (6) 1,884 1,685 (2) 1,683 1,864 (6) 1,858 Gross profit 2,361 (14) 2,347 1,657 (1) 1,656 2,165 (1) 2,164 Selling, general, and administrative expenses 1,551 — 1,551 1,312 (10) 1,302 1,580 7 1,587 Research and development expenses 171 — 171 123 — 123 143 — 143 Goodwill impairment — — — 157 — 157 — — — Restructuring and other costs 17 — 17 77 — 77 81 — 81 Operating income (loss) 622 (14) 608 (12) 9 (3) 361 (8) 353 Other income and expenses: Interest expense, net 55 — 55 47 (1) 46 28 (1) 27 Other expense (income), net 8 — 8 1 — 1 (12) — (12) Income (loss) before income taxes 559 (14) 545 (60) 10 (50) 345 (7) 338 Provision for income taxes 138 (4) 134 23 — 23 82 — 82 Net income (loss) 421 (10) 411 (83) 10 (73) 263 (7) 256 Less: Net income (loss) attributable to noncontrolling interests — — — — — — — — — Net income (loss) attributable to Dentsply Sirona $ 421 $ (10) $ 411 $ (83) $ 10 $ (73) $ 263 $ (7) $ 256 Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 1.93 $ (0.05) $ 1.88 $ (0.38) $ 0.05 $ (0.33) $ 1.18 $ (0.03) $ 1.15 Diluted $ 1.91 $ (0.04) $ 1.87 $ (0.38) $ 0.05 $ (0.33) $ 1.17 $ (0.03) $ 1.14 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Net income (loss) $ 421 (10) $ 411 $ (83) 10 $ (73) $ 263 (7) $ 256 Pension liability adjustments 26 — 26 (13) — (13) (36) 10 (26) Total other comprehensive (loss) income (130) — (130) 137 2 139 (120) 10 (110) Total comprehensive income 291 (10) 281 54 12 66 143 3 146 Comprehensive income attributable to Dentsply Sirona 293 (10) 283 53 12 65 142 3 145 CONSOLIDATED BALANCE SHEETS December 31, 2021 December 31, 2020 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Accounts and notes receivable-trade, net $ 747 $ 3 $ 750 $ 673 $ (6) $ 667 Inventories, net 504 11 515 466 10 476 Prepaid expenses and other current assets 247 1 248 214 3 217 Total Current Assets 1,837 15 1,852 1,791 7 1,798 Operating lease right-of-use assets, net 193 5 198 176 — 176 Other noncurrent assets 122 (1) 121 94 1 95 Total Assets 9,220 19 9,239 9,342 8 9,350 Accounts payable 268 (6) 262 305 (3) 302 Accrued liabilities 679 81 760 653 59 712 Income taxes payable 57 — 57 60 (1) 59 Total Current Liabilities 1,186 75 1,261 1,317 55 1,372 Operating lease liabilities 145 4 149 130 — 130 Deferred income taxes 408 (17) 391 393 (12) 381 Total Liabilities 4,177 65 4,242 4,372 43 4,415 Retained earnings 1,560 (46) 1,514 1,233 (35) 1,198 Total Dentsply Sirona Equity 5,042 (46) 4,996 4,967 (35) 4,932 Total Equity 5,043 (46) 4,997 4,970 (35) 4,935 Total Liabilities and Equity 9,220 19 9,239 9,342 8 9,350 CONSOLIDATED STATEMENT OF CASH FLOWS Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Cash flows from operating activities: Net income (loss) $ 421 $ (10) $ 411 $ (83) $ 10 $ (73) $ 263 $ (7) $ 256 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Deferred income taxes (20) (5) (25) (64) 2 (62) (37) (3) (40) Other non-cash (income) expense 34 — 34 2 1 3 (6) 12 6 Changes in operating assets and liabilities, net of acquisitions: Accounts and notes receivable-trade, net (109) (8) (117) 126 5 131 (91) 1 (90) Inventories, net (63) (1) (64) 124 (1) 123 14 (3) 11 Prepaid expenses and other current assets, net (35) 3 (32) 42 (3) 39 13 (1) 12 Accounts payable (46) (3) (49) (23) (5) (28) 26 1 27 Accrued liabilities 78 22 100 (17) 7 (10) 45 14 59 Income taxes 17 — 17 (39) (2) (41) (16) 2 (14) Other noncurrent liabilities 10 2 12 (15) — (15) (2) (10) (12) Net cash provided by operating activities 657 — 657 635 14 649 633 6 639 Cash flows from financing activities: Other financing activities, net (36) — (36) (12) (14) (26) (34) (6) (40) Net cash (used in) provided by financing activities (379) — (379) 490 (14) 476 (466) (6) (472) Cash and Cash Equivalents Cash and cash equivalents include deposits with banks as well as highly liquid time deposits with original maturities of ninety days or less. Short-term Investments Short-term investments are highly liquid time deposits with original maturities greater than ninety days and with remaining maturities of one year or less. Accounts Receivable The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. Payment terms are typically 30 days in the U.S. but may be longer in international markets. In general, contracts containing significant financing components are not material to the Company’s financial statements. The Company establishes an allowance for doubtful accounts based on an estimate of current expected credit losses resulting from the inability of its customers to make required payments. The allowance is determined based on a combination of factors, including the length of time that the receivable is past due, history of write-offs, and the Company’s knowledge of circumstances relating to specific customers’ ability to meet their financial obligations. Provision for doubtful accounts are included in Selling, general and administrative expenses in the Consolidated Statements of Operations. For customers on credit terms, the Company performs ongoing credit evaluation of those customers’ financial condition and generally does not require collateral from them. Accounts receivable are stated net of allowances for doubtful accounts of $13 million and $18 million at December 31, 2021 and 2020, respectively. For the years ended December 31, 2021 and 2020, the Company wrote-off $2 million and $12 million, respectively, of accounts receivable that were previously reserved. The Company increased the provision for doubtful accounts by $2 million and $1 million during 2021 and 2020, respectively. Inventories Inventories are stated at the lower of cost and net realizable value. The cost of inventories is based upon the First In First Out Method (“FIFO”) or average cost methods, except for $3 million and $5 million of inventories that was determined by the last-in, first-out (“LIFO”) method as of December 31, 2020 and 2019, respectively. During the current fiscal year 2021, the method of accounting for these inventories was changed from LIFO to FIFO. This change in accounting is preferable as the value of inventory for which cost was previously determined using a LIFO cost flow assumption has declined from prior years due to changes in the business, and it also allows for a more consistent methodology being utilized across the Company, and provides improved comparability with industry peers. This change in accounting principle was effected during the second quarter, and resulted in an increase in inventories of $4 million and a corresponding reduction to Cost of products sold. The impact of this change was not material to the Company’s financial position as of December 31, 2020, the Company’s results of operations for any previously reported prior year nor is the cumulative effect of the change material to the results of operations for the year ended December 31, 2021. Therefore, prior year amounts have not been retrospectively adjusted. The Company establishes reserves for inventory estimated to be excess, obsolete or unmarketable based upon assumptions about future demand, market conditions, and expiration of products. Valuation of Goodwill and Indefinite-Lived and Definite-Lived Intangible Assets Effective 2021 and prospectively, the Company is performing its required annual goodwill impairment test as of April 1 rather than as of April 30 which was the Company’s previous practice. The Company believes this change is preferable as it more closely aligns with the timing of the Company’s strategic business planning process. This change did not result in any delay, acceleration or avoidance of impairment. Furthermore, a retrospective application to prior periods is impracticable as the Company is unable to objectively determine, without the use of hindsight, the assumptions which would be used in earlier periods. The following information outlines the Company’s significant accounting policies on long-lived assets by type. Goodwill Goodwill is the excess of the purchase price over the fair value of identifiable net assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. The Company conducts an impairment test as of April 1 of each year, or more frequently if events or circumstances indicate that the carrying value of goodwill may be impaired. This impairment assessment includes an evaluation of reporting units, which the Company has determined are either an operating segment or one level below its operating segments, as determined in accordance with ASC 350. The Company performs impairment tests by comparing the fair value of each reporting unit to its carrying amount to determine if there is a potential impairment. If the carrying value of a reporting unit with goodwill exceeds its fair value, an impairment charge is recognized for the excess amount. To determine the fair value of the Company’s reporting units, the Company uses a discounted cash flow model as its valuation technique to measure the fair value for its reporting units. The discounted cash flow model uses five- to ten-year forecasted cash flows plus a terminal value based on capitalizing the last period’s cash flows using a perpetual growth rate. The Company’s significant assumptions in the discounted cash flow models include, but are not limited to, the discount rates, revenue growth rates, perpetual revenue growth rates, and operating margin percentages of the reporting unit’s business. The Company considers the current market conditions when determining its assumptions. Lastly, the Company reconciles the aggregate fair values of its reporting units to its market capitalization, which include a reasonable control premium based on market conditions. Additional information related to the testing for goodwill impairment including results of the annual test performed at April 1, 2021 is provided in Note 12, Goodwill and Intangible Assets. Indefinite-Lived Intangible Assets Indefinite-lived intangible assets consists primarily of tradenames and trademarks and in-process research and development acquired during business combinations, and these are not subject to amortization. Valuations of indefinite life intangibles assets acquired are based on information and assumptions available at the time of their acquisition, using income and market approaches to determine fair value. The Company conducts an impairment test as of April 1 of each year, or more frequently if events or circumstances indicate that the carrying value of indefinite-lived intangible assets may be impaired. Potential impairment is identified by comparing the fair value of an intangible asset to its carrying value. For most indefinite-lived intangible assets, the Company performs impairment tests using an income approach, more specifically a relief from royalty method. In the development of the forecasted cash flows, the Company applies significant judgment to determine key assumptions, including revenue growth rates, perpetual revenue growth rates, royalty rates, and discount rates. For certain indefinite-lived intangible assets, the Company performs a qualitative assessment. If the carrying value exceeds the fair value, an impairment loss in the amount equal to the excess is recognized. Additional information related to the testing for indefinite-lived intangible asset impairment including results of the annual test performed at April 1, 2021 is provided in Note 12, Goodwill and Intangible Assets. Definite-Lived Intangible Assets Definite-lived intangible assets primarily consist of patents, tradenames, trademarks, licensing agreements, developed technology, and customer relationships. Valuation of definite-lived intangibles assets acquired in business combinations are based on information and assumptions available at the time of acquisition, using income and market model approaches to determine fair value. Identifiable definite-lived intangible assets are amortized on a basis that best reflects how their economic benefits are utilized over the life of the asset or on a straight-line basis if not materially different from actual utilization. The useful life is the period over which the asset is expected to contribute to the future cash flows of the Company. The Company uses the following useful lives for its definite-lived intangible assets: Definite-lived Intangible Asset Type Useful Life Patents Up to date patent expires Tradenames and trademarks Up to 20 years Licensing agreements Up to 20 years Customer relationships Up to 15 years Developed technology Up to 15 years When the expected useful life of an intangible is not known, the Company will estimate its useful life based on similar asset or asset groups, any legal, regulatory, or contractual provision that limits the useful life, the effect of economic factors, including obsolescence, demand, competition, and the level of maintenance expenditures required to obtain the expected future economic benefit from the asset. These assets are reviewed for impairment whenever events or circumstances suggest that the carrying amount of the asset may not be recoverable. The Company closely monitors all intangible assets, including those related to new and existing technologies, for indicators of impairment as these assets have more risk of becoming impaired. Impairment is based upon an initial evaluation of the identifiable undiscounted cash flows. If the initial evaluation identifies a potential impairment, a fair value of the asset is determined by using a discounted cash flows valuation. If impaired, the resulting charge reflects the excess of the asset’s carrying cost over its fair value. Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Assets acquired through acquisitions are recorded at fair value . The Company capitalizes costs incurred in the development or acquisition of software, whether for internal or external use. The Company expenses costs incurred in the preliminary project planning stage. E xcept for leasehold improvements, depreciation and amortization is computed by the straight-line method over the assets’ estimated useful lives: Property, Plant, and Equipment Assets Type Useful Life Buildings 40 years Machinery and Equipment 4 to 15 years Capitalized Software 2 to 10 years Leasehold Improvements Shorter of the estimated useful life or the term of the lease Maintenance and repairs are expensed as incurred; replacements and major improvements are capitalized. If events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable, the identifiable undiscounted cash flows of the asset group are compared to the carrying value of the asset. If the carrying value is in excess of the identifiable undiscounted cash flows, the excess of the asset group’s carrying cost over its fair value is recorded as an impairment charge. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) with subsequent amendments (collectively, “ASC 842”). The Company adopted the new leasing standards on January 1, 2019 using the modified retrospective approach transition method. The Company leases real estate, automobiles and equipment under various operating and finance leases. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the implicit rate is not readily determinable in most of the Company’s lease agreements, the Company uses its estimated secured incremental borrowing rate, based on the information available, at commencement of the lease to determine the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Beginning January 1, 2019, any new real estate and equipment operating lease agreements with lease and non-lease components, were accounted for as a single lease component; auto leases were accounted for as separate lease components. The Company determines if an arrangement is a lease or contains a lease at inception. The Company’s leases have remaining lease terms of approximately 1 year to 10 years. Many of the Company’s real estate and equipment leases have one or more options to renew, with terms that can extend primarily from 1 year to 3 years, which are not included in the initial lease term until deemed probable of renewal. The Company does not have lease agreements with residual value guarantees, sale-and-leaseback terms, or material restrictive covenants. The Company does not have any material sublease arrangements. Derivative Financial Instruments The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, and assets and liabilities denominated in foreign currencies. Additionally, the Company manages exposures to changes in interest rates by utilizing interest rate swaps that have the effect of converting floating rate debt to fixed rate, or vice versa. The Company records all derivative instruments at fair value and changes in fair value are recorded each period in the consolidated statements of operations or accumulated other comprehensive income (“AOCI”). The Company classifies derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less. The Company has elected to classify the cash flow from derivative instruments in the same category as the cash flows from the items being hedged. Should the Company enter into a derivative instrument that included an other-than-insignificant financing element then all cash flows will be classified as financing activities in the Consolidated Statements of Cash Flows as required by US GAAP. See Note 20, Financial Instruments for additional information on derivative instruments. Pension and Other Postemployment Benefits Some of the employees of the Company and its subsidiaries are covered by government or Company-sponsored defined benefit plans and defined contribution plans. Additionally, certain union and salaried employee groups in the United States are covered by postemployment healthcare plans. Projected benefit obligations and net periodic costs for Company-sponsored defined benefit and postemployment benefit plans are based on an annual actuarial valuation that includes assessment of key assumptions relating to expected return on plan assets, discount rates, employee compensation increase rates and health care cost trends. Expected return on plan assets, discount rates and health care cost trend assumptions are particularly important when determining the Company’s benefit obligations and net periodic benefit costs associated with postemployment benefits. Changes in these assumptions can impact the Company’s earnings. In determining the cost of postemployment benefits, certain assumptions are established annually to reflect market conditions and plan experience to appropriately reflect the expected costs as determined by actuaries. These assumptions include medical inflation trend rates, discount rates, employee turnover and mortality rates. The Company predominantly uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate bond yields in the respective economic regions of the plans. The expected return on plan assets is the weighted average long-term expected return based upon asset allocations and historic average returns for the markets where the assets are invested, principally in foreign locations. The Company reports the funded status of its defined benefit pension and other postemployment benefit plans on its consolidated balance sheets as a net liability or asset. Accruals for Self-Insured Losses The Company maintains insurance for certain risks, including workers’ compensation, and is self-insured for employee related healthcare benefits. The Company accrues for the expected costs associated with these risks by considering historical claims experience, demographic factors, severity factors and other relevant information. Costs are recognized in the period the claim is incurred, and the financial statement accruals include an estimate of claims incurred but not yet reported. The Company has stop-loss coverage to limit its exposure to any significant exposure on a per claim basis. Litigation The Company and its subsidiaries, from time to time, are parties to lawsuits arising from operations. The Company records liabilities when a loss is probable and can be reasonably estimated. If these estimates are in the form of ranges, the Company records the liabilities at the most likely outcome within the range. If no point within the range represents a better estimate of the probable loss, then the low point in the range is accrued. The ranges established by management are based on analysis made by internal and external legal counsel who considers the best information known at the time. If the Company determines that a contingency is reasonably possible, it considers the same information to estimate the possible exposure and discloses any material potential liability. These loss contingencies are monitored regularly for a change in fact or circumstance that would require an accrual adjustment. Legal costs related to these lawsuits are expensed as incurred. Foreign Currency Translation The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. Assets and liabilities of foreign subsidiaries are translated at foreign exchange rates on the balance sheet date; revenue and expenses are translated at the monthly average foreign exchange rates. The effects of these translation adjustments are reported within AOCI in the Consolidated Balance Sheets. During the year ended December 31, 2021, the Company had translation loss of $225 million and a gain of $46 million on its loans designated as hedges of net investments. During the year ended December 31, 2020, the Company had translation gains of $235 million and losses of $54 million on its loans designated as hedges of net investments. Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within Other expense (income), net in the Consolidated Statements of Operations. Revenue Recognition Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services in accordance with ASC 606-10, Revenues from Contracts with Customers . Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of products and services to its customers, which for products generally occurs when title and risk of loss transfers to the customer, and for services generally occurs as the customer receives and consumes the benefit. Sales, value-added, and other taxes collected concurrent with revenue-producing activities are excluded from revenue. Certain of our contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately may require significant judgment. The Company generally uses an observable price, typically average selling price, to determine the stand-alone selling price for separate performance obligations. The Company determines the stand-alone selling price, based on Company geographic sales locations’ database of pricing and discounting practices for the specific product or service when sold separately, and utilizes this data to arrive at average selling prices by product. In cases where an average selling price is not observable, the Company determines the stand-alone selling price using relevant information and applies suitable estimation methods including, but not limited to, the cost plus a margin approach. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each distinct performance obligation. The Company exercises judgment in estimating variable consideration, which primarily includes volume discounts, sales rebates, and product returns. The Company adjusts the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed. The Company estimates volume discounts by evaluating specific inputs and assumptions, including the individual customer’s historical and estimated future product purchases. Discounts are deducted from revenue at the time of sale or when the discount is offered, whichever is later. In estimating sales rebates, the Company evaluates inputs such as customer-specific trends, terms of the customers’ contracted rebate program, historical experience, and the forecasted performance of a customer and their expected level of achievement within the rebate programs. The accruals for these rebate programs are updated as actual results and updated forecasts impact the estimated achievement for customers within the rebate programs. When the Company gives customers the right to return eligible products and receive credit, returns are e

REVENUE

REVENUE	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Net sales disaggregated by product category were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Equipment & Instruments $ 728 $ 577 $ 686 CAD/CAM 574 455 523 Orthodontics 273 160 190 Implants 626 475 592 Healthcare 303 287 280 Technology & Equipment segment net sales $ 2,504 $ 1,954 $ 2,271 Endodontic & Restorative $ 1,261 $ 961 $ 1,203 Other Consumables 466 424 548 Consumables segment net sales $ 1,727 $ 1,385 $ 1,751 Total net sales $ 4,231 $ 3,339 $ 4,022 Technologies & Equipment Segment Equipment & Instruments The Equipment & Instruments product category consists of basic and high-tech dental equipment such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists. Imaging equipment serves as the starting point for the Company’s digital workflow offerings and consists of a broad range of diagnostic imaging systems for 2D or 3D, panoramic, and intra-oral applications. Treatment centers comprise a broad range of products from basic dentist chairs to sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, as well as specialist centers used in preventive treatment and for training purposes. This product group also includes other lab equipment such as amalgamators, mixing machines and porcelain furnaces. CAD/CAM Dental CAD/CAM technologies are products designed for dental offices to support numerous digital dental procedures including dental restorations. This product category includes a full-chairside economical restoration of aesthetic ceramic dentistry offering called CEREC, as well as stand-alone CAD/CAM, digital impressions (“DI”) intraoral scanners, mills, and services. The full-chairside offering enables dentists to practice same day or single visit dentistry. Orthodontics The company’s orthodontic product group primarily includes a dentist-directed clear aligner solution, SureSmile, and a direct-to-consumer clear aligner solution, Byte. The orthodontics product category also includes a High Frequency Vibration (“HFV”) technology device known as VPro or as HyperByte within Byte’s product offering. The clear aligners offerings include software technology that enables clear aligner treatment planning and for SureSmile seamless connectivity of a digital workflow from diagnostics through treatment delivery. Implants The Implants product offering includes technology to support signature digital workflows for implant systems, a portfolio of innovative dental implant products, bone regenerative and restorative solutions, and educational programs, all of which provide dental professionals with a completely new way of practicing implantology. The Implants business is supported by key technologies including custom abutments, advanced tapered immediate load screws and regenerative bone growth factor. Healthcare This category consists mainly of urology catheters and other healthcare-related consumable products. Consumables Segment Dental consumable products consist of value-added dental supplies and small equipment used in dental offices for the treatment of patients. It also includes specialized treatment products used within the dental office and laboratory settings including products used in the preparation of dental appliances by dental laboratories. Endodontic & Restorative Products The Company’s Endodontic and Restorative products frequently work together to provide a tandem solution in high-tech dental procedures. The Endodontic products include drills, filers, sealers, irrigation needles and other tools or single-use solutions which support root canal procedures. Restorative products include dental prosthetics, such as artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. Other Consumables The remaining consumables products include small equipment products such as intraoral curing light systems, dental diagnostic systems and ultrasonic scalers and polishers, as well as other dental supplies including dental anesthetics, prophylaxis paste, dental sealants, impression materials, tooth whiteners and topical fluoride. Net sales disaggregated by geographic region were as follows: Year Ended December 31, (in millions) 2021 2020 2019 United States $ 1,480 $ 1,115 $ 1,374 Europe 1,675 1,381 1,609 Rest of World 1,076 843 1,039 Total net sales $ 4,231 $ 3,339 $ 4,022 Contract Assets and Liabilities The Company normally does not have contract assets in the course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. At December 31, 2021, the Company had $68 million of deferred revenue recorded in Accrued liabilities in the Consolidated Balance Sheets. The Company expects to recognize significantly all of the deferred revenue within the next twelve months. Prior year deferred revenue of $53 million was recognized in the current year.

STOCK COMPENSATION

STOCK COMPENSATION	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK COMPENSATION	STOCK COMPENSATION The Company maintains the 2016 Omnibus Incentive Plan (the “Plan”) under which it may grant non-qualified stock options (“NQSOs”), incentive stock options, restricted stock, RSUs and stock appreciation rights, collectively referred to as “Awards.” Awards are granted at exercise prices that are equal to the closing stock price on the date of grant. The Company authorized grants under the Plan of 25 million shares of common stock, plus any unexercised portion of canceled or terminated stock options granted under the legacy DENTSPLY International Inc. 2010 and 2002 Equity Incentive Plans, as amended, and under the legacy Sirona Dental Systems, Inc. 2015 and 2006 Equity Incentive Plans, as amended. Each restricted stock and RSU issued is counted as a reduction of 3.09 shares of common stock available to be issued under the Plan. No key employee may be granted awards in excess of 1 million shares of common stock in any calendar year. The number of shares available for grant under the 2016 Plan at December 31, 2021 is 20 million. The amounts of stock compensation expense recorded in the Company’s Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019 were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Cost of products sold $ 3 $ 1 $ 2 Selling, general, and administrative expense 44 44 61 Research and development expense 2 1 2 Total stock based compensation expense $ 49 $ 46 $ 65 Related deferred income tax benefit $ 6 $ 5 $ 8 The Company uses the Black-Scholes option-pricing model to estimate the fair value of each option awarded. The average assumptions used to determine compensation cost for the Company’s NQSOs issued were as follows: Year Ended December 31, 2021 2020 2019 Weighted average fair value per share $ 15.90 $ 10.03 $ 12.20 Expected dividend yield 0.68 % 0.84 % 0.71 % Risk-free interest rate 0.79 % 0.77 % 2.36 % Expected volatility 31.5 % 24.0 % 22.6 % Expected life (years) 5.08 5.49 6.00 The total intrinsic value of options exercised for the years ended December 31, 2021, 2020 and 2019 was $16 million, $3 million and $37 million, respectively. The total fair value of shares vested for the years ended December 31, 2021, 2020 and 2019 was $76 million, $54 million and $44 million, respectively. The NQSO transactions for the year ended December 31, 2021 were as follows: Outstanding Exercisable (in millions, except per share amounts) Shares Weighted Average Exercise Price Aggregate Intrinsic Value Shares Weighted Average Exercise Price Aggregate Intrinsic Value December 31, 2020 4.0 $ 50.01 $ 17 2.7 $ 50.28 $ 12 Granted 0.5 58.85 Exercised (1.1) 46.81 Forfeited (0.2) 53.03 December 31, 2021 3.2 $ 52.44 $ 15 2.2 $ 52.05 $ 11 There were 1.0 million NQSOs unvested at December 31, 2021. The remaining unamortized compensation cost related to NQSOs is $9 million, which will be expensed over the weighted average remaining vesting period of the options, or 1.8 years. The weighted average remaining contractual term of all outstanding options is 5.6 years and the weighted average remaining contractual term of exercisable options is 4.2 years. Information about NQSOs outstanding for the year ended December 31, 2021 were as follows: Outstanding Exercisable Number Outstanding at December 31, 2021 Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable at December 31, 2021 Weighted Average Exercise Price Range of Exercise Prices (in millions, except per share amounts and life) 30.01 - 40.00 0.1 1.4 $ 37.29 0.1 $ 37.29 40.01 - 50.00 1.4 5.9 47.31 0.8 46.73 50.01 - 60.00 1.4 6.0 56.32 0.9 55.05 60.01 - 70.00 0.3 4.3 62.37 0.4 62.24 3.2 2.2 The unvested RSU transactions for the year ended December 31, 2021 were as follows: Unvested Restricted Stock Units Shares Weighted Average Grant Date Fair Value (in millions, except per share amounts) Unvested at December 31, 2020 4.2 $ 47.29 Granted 1.0 63.61 Vested (1.5) 45.08 Forfeited (0.6) 50.01 Unvested at December 31, 2021 3.1 $ 53.52 The unamortized compensation cost related to RSUs is $42 million, which will be expensed over the remaining weighted average restricted period of the RSUs, or 2.0 years.

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
EARNINGS PER COMMON SHARE	EARNINGS PER COMMON SHARE The computation of basic and diluted earnings (loss) per common share for the years ended December 31 were as follows: Basic Earnings (Loss) Per Common Share (in millions, except per share amounts) 2021 2020 2019 Net income (loss) attributable to Dentsply Sirona $ 411 $ (73) $ 256 Weighted average common shares outstanding 218.4 219.2 223.1 Earnings (loss) per common share - basic $ 1.88 $ (0.33) $ 1.15 Diluted Earnings (Loss) Per Common Share (in millions, except per share amounts) 2021 2020 2019 Net income (loss) attributable to Dentsply Sirona $ 411 $ (73) $ 256 Weighted average common shares outstanding 218.4 219.2 223.1 Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards 1.8 — 1.3 Total weighted average diluted shares outstanding 220.2 219.2 224.4 Earnings (loss) per common share - diluted $ 1.87 $ (0.33) $ 1.14 For the years ended December 31, 2021, 2020, and 2019, the Company excluded from the computation of weighted average diluted shares outstanding of 1.0 million, 3.1 million, and 3.1 million, respectively of equivalent shares of common stock from stock options and RSUs because their effect would be antidilutive. The calculation of weighted average diluted common shares outstanding excluded 0.9 million of potentially diluted common shares because the Company reported a net loss for year ended December 31, 2020.

COMPREHENSIVE (LOSS) INCOME

COMPREHENSIVE (LOSS) INCOME	12 Months Ended
	Dec. 31, 2021
Other Comprehensive Income (Loss), Net of Tax [Abstract]
COMPREHENSIVE (LOSS) INCOME	COMPREHENSIVE (LOSS) INCOME AOCI includes cumulative foreign currency translation adjustments related to consolidation of the Company’s foreign subsidiaries, fair value adjustments related to the Company’s derivative financial instruments, and actuarial gains and losses related to the Company’s pension plans. These changes are recorded in AOCI net of any related tax adjustments. For the years ended December 31, 2021, 2020 and 2019, these tax adjustments were $168 million, $216 million and $173 million, respectively, primarily related to foreign currency translation adjustments. The cumulative foreign currency translation adjustments included translation losses of $250 million and $25 million at December 31, 2021 and 2020, respectively, and which included losses of $116 million and $162 million, at December 31, 2021 and 2020, respectively, on inter-company loans designated as hedges of net investments. Changes in AOCI, net of tax, by component for the years ended December 31, 2021 and 2020 were as follows: (in millions) Foreign Currency Translation Gain (Loss) Gain and (Loss) on Cash Flow Hedges Gain and (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2020 $ (187) $ (25) $ (119) $ (133) $ (464) Other comprehensive (loss) income before reclassifications and tax impact (156) 3 22 26 (105) Tax expense (23) (1) (6) (8) (38) Other comprehensive (loss) income, net of tax, before reclassifications $ (179) $ 2 $ 16 $ 18 $ (143) Amounts reclassified from accumulated other comprehensive income, net of tax — 7 — 8 15 Net (decrease) increase in other comprehensive income (179) 9 16 26 (128) Balance, net of tax, at December 31, 2021 $ (366) $ (16) $ (103) $ (107) $ (592) (in millions) Foreign Currency Translation Gain (Loss) Gain and (Loss) on Cash Flow Hedges Gain and (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2019 $ (370) $ (11) $ (101) $ (120) $ (602) Other comprehensive income (loss) before reclassifications and tax impact 153 (17) (23) (26) 87 Tax benefit 30 1 5 7 43 Other comprehensive income (loss), net of tax, before reclassifications $ 183 $ (16) $ (18) $ (19) $ 130 Amounts reclassified from accumulated other comprehensive income, net of tax — 2 — 6 8 Net increase (decrease) in other comprehensive income 183 (14) (18) (13) 138 Balance, net of tax, at December 31, 2020 $ (187) $ (25) $ (119) $ (133) $ (464) Reclassification out of AOCI to the Consolidated Statements of Operations for the years ended December 31, 2021, 2020, and 2019 were as follows: Amounts Reclassified from AOCI Affected Line Item in the Consolidated Statements of Operations Year Ended December 31, (in millions) 2021 2020 2019 Loss on derivative financial instruments: Interest rate swaps $ (4) $ (4) $ (2) Interest expense, net Foreign exchange forward contracts (3) 2 1 Cost of products sold Net loss before tax $ (7) $ (2) $ (1) Tax impact — — — Provision for income taxes Net loss after tax $ (7) $ (2) $ (1) Amortization of defined benefit pension and other postemployment benefit items: Amortization of prior service benefits $ 1 $ 1 $ 1 (a) Amortization of net actuarial losses (12) (9) (6) (a) Net loss before tax $ (11) $ (8) $ (5) Tax impact 3 2 1 Provision for income taxes Net loss after tax $ (8) $ (6) $ (4) Total reclassifications for the period $ (15) $ (8) $ (5) (a) These AOCI components are included in the computation of net periodic benefit cost for the years ended December 31, 2021, 2020, and 2019, respectively.

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS Acquisitions 2021 Transactions On July 1, 2021, the effective date of the transaction, the Company paid $7 million to acquire the remaining interest in the dental business of a partially owned affiliate based in Switzerland that primarily develops highly specialized software with a focus on CAD/CAM systems. The acquisition is expected to further accelerate the development of the Company’s specialized software related to CAD/CAM systems. The preliminary fair values of the assets acquired and liabilities assumed in connection with the acquisition of the affiliate included $4 million of Other current assets, $3 million of Intangible assets, $2 million of Current Liabilities and $1 million of Other long-term liabilities. The cash paid and the $4 million fair value of the previously-held interest in the entity prior to the acquisition has been allocated on the basis of the preliminary estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $7 million in goodwill. This goodwill is considered to represent the value associated with the acquired workforce and synergies the two companies anticipate realizing as a combined company and is not expected to be deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 were immaterial to the financial statements, resulting in an increase to goodwill of $2 million. Management is continuing to finalize its valuation of certain assets and liabilities including other intangible assets and will conclude its valuation no later than one year from the acquisition date. Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) In-process R&D $ 3 Indefinite On June 1, 2021, the effective date of the transaction, the Company paid $132 million to acquire substantially all of the assets of Propel Orthodontics LLC, a privately-held company based in New York and California. Propel Orthodontics manufactures and sells orthodontic devices and provides in-office and at-home orthodontic accessory devices to orthodontists and their patients primarily within the clear aligner market. The acquisition is expected to further accelerate the growth and profitability of the Company’s combined clear aligners business. The preliminary fair values of the assets acquired and liabilities assumed in connection with the Propel Orthodontics acquisition were as follows: (in millions) Other current assets $ 4 Intangible assets 66 Current liabilities (1) Net assets acquired 69 Goodwill 63 Purchase consideration $ 132 The purchase price has been allocated on the basis of the preliminary estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $63 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the two companies anticipate realizing as a combined company. The goodwill is expected to be deductible for tax purposes. Management is continuing to finalize its valuation of certain assets including other intangible assets and will conclude its valuation no later than one year from the acquisition date. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 were immaterial to the financial statements, resulting in a reduction to goodwill of $2 million. Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 10 On January 21, 2021, the effective date of the transaction, the Company paid $94 million with the potential for additional earn-out provision payments of up to $10 million, to acquire 100% of the outstanding shares of Datum Dental, Ltd., a privately-held producer and distributor of specialized regenerative dental material based in Israel. The fair value of the earn-out provision has been valued at $9 million as of the transaction date, resulting in a total purchase price of $103 million. The fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows: (in millions) Cash and cash equivalents $ 2 Other current assets 2 Intangible assets 76 Current liabilities (2) Other long-term assets (liabilities), net (14) Net assets acquired 64 Goodwill 39 Purchase consideration $ 103 The purchase price has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $39 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the two companies anticipate realizing as a combined company. The goodwill is not deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 were immaterial to the financial statements, resulting in an increase to goodwill of $6 million. Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 15 In-process R&D 10 Indefinite Total $ 76 2020 Transactions On December 31, 2020, the effective date of the transaction, the Company acquired 100% of the outstanding interests of Straight Smile, LLC (“Byte”), a privately-held company, for approximately $1.0 billion using cash on hand. Byte is a doctor-directed, direct-to-consumer, clear aligner business. The acquisition is expected to enhance scale and accelerate the growth and profitability of the Company’s combined clear aligners business. The fair values of the assets acquired and liabilities assumed in connection with the Byte acquisition for the year ended December 31, 2020 were as follows: (in millions) Cash and cash equivalents $ 14 Current assets 16 Intangible assets 416 Current liabilities (28) Net assets acquired 418 Goodwill 627 Purchase consideration $ 1,045 The purchase price has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, which resulted in the recording of $627 million in goodwill. The amount of goodwill is considered to represent the value associated with the acquired workforce and synergies the two companies anticipate realizing as a combined company, including alignment with the Company’s existing clear aligner business, and is deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 were immaterial to the financial statements, resulting in a reduction to goodwill of $4 million. Intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Non-compete agreements $ 16 5 Technology know-how 210 10 Tradenames and trademarks 190 20 Total $ 416 The results of operations for each of the acquired businesses above upon the effective date of each transaction have been included in the accompanying financial statements. These results, as well as the historical results for the above acquired businesses for the years ended December 31, 2021, and 2020 are not material in relation to the Company’s net sales and earnings for those periods. The Company therefore does not believe these acquisitions represent material transactions either individually or in the aggregate requiring the supplemental pro-forma information prescribed by ASC 805 and accordingly, this information is not presented. Acquisition-related costs incurred for the year ended December 31, 2021 and 2020 were $8 million and $16 million, respectively, consisting primarily of legal and professional fees in relation to the Propel and Byte acquisitions, for their respective year of acquisition, and are recorded in SG&A expenses in the Consolidated Statements of Operations. Investment in Affiliates On June 4, 2021, the effective date of the transaction, the Company paid $16 million to acquire a minority interest in a U.K. based, privately-held provider of healthcare consumables. The investment is recorded as an equity method investment within Other noncurrent assets in the Consolidated Balance Sheets. During the three months ended December 31, 2020, the Company paid $45 million for interest in a privately-held dental services company. The investment is recorded as an equity-method investment and recorded in Other noncurrent assets in the Consolidated Balance Sheets. Divestitures On April 1, 2021, the Company disposed of certain orthodontics businesses based in Japan previously included as part of the Technologies & Equipment segment in exchange for a cash receipt of $8 million. The divestiture resulted in an immaterial loss recorded in Other expense (income), net in the Consolidated Statements of Operations for the year ended December 31, 2021. On February 1, 2021, the Company disposed of an investment casting business previously included as part of the Consumables segment in exchange for a cash receipt of $19 million. The divestiture resulted in a pre-tax gain of $13 million recorded in Other expense (income), net in the Consolidated Statements of Operations for the year ended December 31, 2021.

SEGMENT AND GEOGRAPHIC INFORMAT

SEGMENT AND GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION The Company has two operating segments that are organized primarily by product and generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight. These operating segments are also the Company’s reportable segments in accordance with how the Company’s chief operating decision-maker regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources. The Company evaluates performance of the segments based on the net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarters unallocated costs, restructuring and other costs, interest expense, interest income, other expense (income), net, amortization of intangible assets and depreciation resulting from the fair value step-up of property, plant, and equipment from acquisitions. A description of the products and services provided within each of the Company’s two reportable segments is provided below. Technologies & Equipment This segment is responsible for the design, manufacture, and sales of the Company’s dental technology and equipment products and healthcare products. These products include dental implants, CAD/CAM systems, orthodontic clear aligners, imaging systems, treatment centers, instruments, as well as medical devices. Consumables This segment is responsible for the design, manufacture, and sales of the Company’s consumable products which include various preventive, restorative, endodontic, and dental laboratory products. The Company’s segment information for the years ended December 31 was as follows: Net Sales Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment $ 2,504 $ 1,954 $ 2,271 Consumables 1,727 1,385 1,751 Total net sales $ 4,231 $ 3,339 $ 4,022 Depreciation and Amortization Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment $ 280 $ 261 $ 258 Consumables 52 61 54 All Other (a) 15 12 11 Total $ 347 $ 334 $ 323 (a) Includes amounts recorded at Corporate headquarters. Segment Adjusted Operating Income Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment (a) $ 543 $ 382 $ 460 Consumables (a) 539 316 447 Segment adjusted operating income $ 1,082 $ 698 $ 907 Reconciling items (income) expense: All other (a) (b) 229 269 277 Goodwill impairment — 157 — Restructuring and other costs 17 77 81 Interest expense, net 55 46 27 Other expense (income), net 8 1 (12) Amortization of intangible assets 222 192 189 Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations 6 6 7 Income (loss) before income taxes $ 545 $ (50) $ 338 (a) $38 million of charges related to discontinuance of product lines, incurred in 2019, which were previously reported in adjusted operating income for the reportable segments, have been reclassified to the “All other” category to conform to current year presentation and our internal reporting to our Chief Operating Decision Maker package (“CODM”). These amounts are not material to the measure of segment results for the years presented. (b) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations. Capital Expenditures Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment $ 100 $ 50 $ 73 Consumables 37 26 34 All Other (a) 22 11 16 Total $ 159 $ 87 $ 123 (a) Includes capital expenditures of Corporate headquarters. Assets Year Ended December 31, (in millions) 2021 2020 Technologies & Equipment $ 6,902 $ 7,014 Consumables 2,123 2,170 All Other (a) 214 166 Total $ 9,239 $ 9,350 (a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations. Geographic Information The following tables set forth information about the Company’s significant operations by geographic areas, for the years ended December 31, 2021, 2020, and 2019. Net Sales reported below represent revenues from external customers in those respective countries based on the destination of shipments. Year Ended December 31, (in millions) 2021 2020 2019 Net sales United States $ 1,484 $ 1,116 $ 1,377 Germany 482 432 472 Other Foreign 2,265 1,791 2,173 Total net sales $ 4,231 $ 3,339 $ 4,022 Property, plant and equipment, net, represents those long-lived assets held by the operating businesses located in the respective geographic areas. Year Ended December 31, (in millions) 2021 2020 2019 Property, plant, and equipment, net United States $ 166 $ 145 $ 168 Germany 309 337 327 Sweden 107 110 99 Other Foreign 191 199 208 Total property, plant, and equipment, net $ 773 $ 791 $ 802 Product and Customer Information For information on the Company’s net sales by product category, including a description of the revenue streams comprising each of the reportable segments, see Note 2, Revenue. Concentration Risk For the year ended December 31, 2021, no customer accounted for 10% or more of consolidated net sales or consolidated accounts receivable balance. Customers that accounted for 10% or more of net sales and accounts receivable for the years ended December 31, 2020 and 2019 were as follows: Year Ended December 31, 2020 2019 % of net sales % of accounts receivable % of net sales % of accounts receivable Henry Schein, Inc. 14 % N/A 13 % 12 % Patterson Companies, Inc. 10 % 18 % N/A 17 % For the years ended December 31, 2021, 2020, and 2019, third party export sales from the U.S. were less than ten percent of consolidated net sales.

OTHER EXPENSE (INCOME), NET

OTHER EXPENSE (INCOME), NET	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
OTHER EXPENSE (INCOME), NET	OTHER EXPENSE (INCOME), NET Other expense (income), net, were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Foreign exchange transaction (gain) loss $ (6) $ (13) $ (27) Other expense (income), net 14 14 15 Total other expense (income), net $ 8 $ 1 $ (12)

INVENTORIES, NET

INVENTORIES, NET	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
INVENTORIES, NET	INVENTORIES, NET Inventories, net were as follows: Year Ended December 31, (in millions) 2021 2020 Raw materials and supplies $ 139 $ 134 Work-in-process 72 68 Finished Goods 304 274 Inventories, net $ 515 $ 476 The Company’s inventory reserve was $86 million and $117 million at December 31, 2021 and 2020, respectively. Inventories are stated at the lower of cost and net realizable value.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment, net, were as follows: Year Ended December 31, (in millions) 2021 2020 Land $ 51 $ 54 Buildings and improvements 561 595 Machinery and equipment 982 1,075 Capitalized Software 353 339 Construction in progress 134 120 $ 2,081 $ 2,183 Less: Accumulated depreciation and amortization 1,308 1,392 Property, plant and equipment, net $ 773 $ 791

LEASES

LEASES	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	LEASES The net present value of finance and operating lease right-of-use assets and liabilities were as follows: Year Ended December 31, (in millions, except percentages) Location in the Consolidated Balance Sheets 2021 2020 Assets Finance leases Property, plant, and equipment, net $ 2 $ 1 Operating leases Operating lease right-of-use assets, net 198 176 Total right-of-use assets $ 200 $ 177 Liabilities Current liabilities Finance leases Notes payable and current portion of long-term debt $ 1 $ — Operating leases Accrued liabilities 50 48 Noncurrent liabilities Finance leases Long-term debt 1 1 Operating leases Operating lease liabilities 149 130 Total lease liabilities $ 201 $ 179 Supplemental information: Weighted-average discount rate Finance leases 3.2 % 3.7 % Operating leases 3.3 % 3.0 % Weighted-average remaining lease term in years Finance leases 4.3 6.5 Operating leases 5.3 5.2 The lease cost recognized in the Consolidated Statements of Operations for the year ended December 31, 2021 and 2020 were as follows: (in millions) 2021 2020 Operating lease cost $ 67 $ 57 Short-term lease cost 1 1 Variable lease cost 10 9 Total lease cost $ 78 $ 67 The contractual maturity dates of the remaining lease liabilities for the year ended December 31, 2021 were as follows: (in millions) Finance Leases Operating Leases Total 2022 $ 1 $ 58 $ 59 2023 1 46 47 2024 — 36 36 2025 — 24 24 2026 — 18 18 2027 and beyond — 38 38 Total lease payments $ 2 $ 220 $ 222 Less imputed interest — 21 21 Present value of lease liabilities $ 2 $ 199 $ 201 The supplemental cash flow information for the year ended December 31, 2021 and 2020 were as follows: (in millions) 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows paid for operating leases $ 65 $ 56 Right-of-use assets obtained in exchange for new lease liabilities: Finance leases $ 1 $ — Operating leases 79 43
Leases	LEASES The net present value of finance and operating lease right-of-use assets and liabilities were as follows: Year Ended December 31, (in millions, except percentages) Location in the Consolidated Balance Sheets 2021 2020 Assets Finance leases Property, plant, and equipment, net $ 2 $ 1 Operating leases Operating lease right-of-use assets, net 198 176 Total right-of-use assets $ 200 $ 177 Liabilities Current liabilities Finance leases Notes payable and current portion of long-term debt $ 1 $ — Operating leases Accrued liabilities 50 48 Noncurrent liabilities Finance leases Long-term debt 1 1 Operating leases Operating lease liabilities 149 130 Total lease liabilities $ 201 $ 179 Supplemental information: Weighted-average discount rate Finance leases 3.2 % 3.7 % Operating leases 3.3 % 3.0 % Weighted-average remaining lease term in years Finance leases 4.3 6.5 Operating leases 5.3 5.2 The lease cost recognized in the Consolidated Statements of Operations for the year ended December 31, 2021 and 2020 were as follows: (in millions) 2021 2020 Operating lease cost $ 67 $ 57 Short-term lease cost 1 1 Variable lease cost 10 9 Total lease cost $ 78 $ 67 The contractual maturity dates of the remaining lease liabilities for the year ended December 31, 2021 were as follows: (in millions) Finance Leases Operating Leases Total 2022 $ 1 $ 58 $ 59 2023 1 46 47 2024 — 36 36 2025 — 24 24 2026 — 18 18 2027 and beyond — 38 38 Total lease payments $ 2 $ 220 $ 222 Less imputed interest — 21 21 Present value of lease liabilities $ 2 $ 199 $ 201 The supplemental cash flow information for the year ended December 31, 2021 and 2020 were as follows: (in millions) 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows paid for operating leases $ 65 $ 56 Right-of-use assets obtained in exchange for new lease liabilities: Finance leases $ 1 $ — Operating leases 79 43

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS The Company assesses both goodwill and indefinite-lived intangible assets for impairment annually during the second quarter or more frequently if events or changes in circumstances indicate the asset might be impaired. The Company conducted its annual goodwill and indefinite-lived intangible assets impairment tests as of April 1, 2021. 2021 Annual Goodwill Impairment Testing The fair values of the Company’s five reporting units were computed using a discounted cash flow model with inputs developed using both internal and market-based data. The discounted cash flow model uses five- to ten- year forecasted cash flows plus a terminal value based on capitalizing the last period’s cash flows using a perpetual growth rate. The Company’s significant assumptions in the discounted cash flow models include, but are not limited to, the discount rates, revenue growth rates (including perpetual growth rates), and operating margin percentages of the reporting unit’s business. These assumptions were developed in consideration of current market conditions. The total forecasted cash flows for each of the reporting units were discounted using rates ranging between 8.0% to 9.5%. Further, the Company reconciled the aggregate fair values of its reporting units to its market capitalization, which included a reasonable control premium based on market conditions. The revenue growth rate assumptions were developed in consideration of future expectations which include, but were not limited to, distribution channel changes, impact from competition, and new product developments for these reporting units. The Company also considered the current and projected market and economic conditions amid the ongoing COVID-19 pandemic for the dental industry both in the U.S. and globally, when determining its assumptions. As a result of the annual tests of goodwill performed as of April 1, 2021, no impairment was identified. The use of estimates and the development of assumptions results in uncertainties around forecasted cash flows. For this reason, in conjunction with the annual test, the Company applied a hypothetical sensitivity analysis to its reporting units. In conjunction with its annual goodwill impairment test, the Company applied a hypothetical sensitivity analysis to each of its reporting units by increasing the discount rate of these reporting units by 100 basis points and, in a separate test, reducing by 10% the fair value of those reporting units. All of the Company’s reporting units passed the hypothetical tests without the fair value being reduced below carrying value, and therefore it was noted that there were currently no reporting units deemed at risk of being impaired based on the sensitivity analysis. During the time subsequent to the annual evaluation, and at December 31, 2021, the Company considered whether any events or changes in circumstances had resulted in the likelihood that the goodwill of any of its reporting units may have been impaired. It is management’s assessment that no such events have occurred. A change in any of the estimates and assumptions used in the annual test, as well as further unfavorable changes in the ongoing COVID-19 pandemic, a decline in the overall markets served by these reporting units, among other factors, could have a negative material impact to the fair value of the reporting units and could result in a future impairment charge. There can be no assurance that the Company’s future goodwill impairment testing will not result in a material charge to earnings. 2021 Annual Indefinite-Lived Intangibles Impairment Testing The Company also assessed the annual impairment of indefinite-lived intangible assets at April 1, 2021, which largely consists of acquired tradenames and trademarks, in conjunction with the annual impairment tests of goodwill. The fair value of acquired tradenames and trademarks is estimated by the use of a relief from royalty method, which values an indefinite-lived intangible asset by estimating the royalties saved through ownership of an asset. Management judgment is necessary to determine key assumptions, including revenue growth rates, perpetual revenue growth rates, royalty rates, and discount rates. The Company utilized discount rates ranging from 8.5% to 10.0%. As a result of the annual impairment test of indefinite-lived intangible assets, no impairment was identified. The Company applied a hypothetical sensitivity analysis. It was noted that if the fair value of each of these indefinite-lived intangibles assets had been hypothetically reduced by 10% or the discount rate had been hypothetically increased by 100 basis points at April 1, 2021, the fair value of these assets would still exceed their book value. Should the Company’s analysis in the future indicate additional unfavorable impacts related to the ongoing COVID-19 pandemic, an increase in discount rates, or a decline in the use of the tradenames and trademarks, any of which could have a negative material impact to the implied fair values and could result in a future impairment to the carrying value of the indefinite-lived intangible assets. There can be no assurance that the Company’s future indefinite-lived intangible asset impairment testing will not result in a material charge to earnings. 2020 Annual Goodwill and Indefinite-Lived Intangibles Impairment and Testing During the three months ended March 31, 2020, the Company recorded an impairment charge of $157 million related to the goodwill associated with the Equipment & Instruments reporting unit. The impairment was a result of changes in forecasted revenues, operating margins, and discount rates due to the negative impacts of the COVID-19 pandemic on customer demand for the Company’s products, which caused a decline in revenue and profitability in the first quarter of 2020. To determine the fair value of each of the reporting units for which a triggering event was concluded to exist as of March 31, 2020, the Company utilized a discounted cash flow model consistent with the valuation approach described above for the annual impairment test, and utilized discount rates for each of the reporting units which ranged between 9.5% to 11.5%. As a result of these models which included updates to the estimates and assumptions resulting from the ongoing COVID-19 pandemic, the Company determined the goodwill associated with the Equipment & Instruments reporting unit was impaired. The impairment charge was recorded as a separate line in the Consolidated Statements of Operations. The Company also concluded in the first quarter of 2020 that due to the negative effects of the COVID-19 pandemic on revenue and profitability, a triggering event also existed for all but two of the Company’s indefinite-lived intangible assets as of March 31, 2020. The Company performed impairment tests for the indefinite-lived intangible assets using an income approach, more specifically a relief from royalty method. In the development of the forecasted cash flows, the Company applied significant judgment to determine key assumptions, including royalty rates, and discount rates, which ranged from 10.0% to 17.5%. The impairment test resulted in an impairment charge of $39 million related to certain tradenames and trademarks related to the Equipment & Instruments reporting unit during the three months ended March 31, 2020. The impairment charge was driven by a decline in forecasted sales as a result of the COVID-19 pandemic as discussed above, as well as an unfavorable change in the discount rates. The impairment charge was recorded in Restructuring and other costs in the Consolidated Statements of Operations. The Company further performed the required annual impairment tests of goodwill and indefinite-lived intangibles at April 30, 2020 consistent with the valuation approaches described above, which did not result in any additional impairment in 2020. 2019 Annual Goodwill and Indefinite-Lived Intangibles Impairment and Testing Effective January 1, 2019, the Company realigned certain businesses between segments resulting in a change from eleven reporting units to five. As a result, the Company transferred goodwill between segments due to these changes. Affected reporting units, including the CAD/CAM and Treatment Center reporting units in the Technologies & Equipment segment, were tested for potential impairment of goodwill before the transfers. No goodwill impairment was identified due to the realignment. The Company further performed the required annual impairment tests of goodwill at April 30, 2019 on all five reporting units. The performance of the Company’s annual impairment test did not result in any impairment of the Company’s goodwill. During the three months ended March 31, 2019, the Company impaired $5 million of product tradenames and trademarks within the Technologies & Equipment segment. The impairment was the result of a change in forecasted sales related to the divestitures of non-strategic product lines. The Company further assessed the annual impairment of the remaining indefinite-lived intangible assets at April 30, 2019, which largely consists of acquired tradenames and trademarks, in conjunction with the annual impairment tests of goodwill. The performance of the Company’s annual impairment test did not result in any impairment of the Company’s indefinite-lived intangible assets. A reconciliation of changes in the Company’s goodwill by reportable segment were as follows: (in millions) Technologies & Equipment Consumables Total Balance at December 31, 2019 Goodwill $ 5,253 $ 881 $ 6,134 Accumulated impairment losses (2,737) — (2,737) Goodwill, net $ 2,516 $ 881 $ 3,397 Acquisition related additions (a) 631 — 631 Impairment (157) — (157) Translation and other 102 13 115 Balance at December 31, 2020 Goodwill $ 5,985 $ 894 $ 6,879 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,092 $ 894 $ 3,986 Acquisition related additions (a) 109 — 109 Translation and other (105) (14) (119) Balance at December 31, 2021 Goodwill $ 5,989 $ 880 $ 6,869 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,096 $ 880 $ 3,976 (a) Refer to Note 6, Business Combinations, for more information regarding recent acquisitions. Identifiable definite-lived and indefinite-lived intangible assets at were as follows: Year Ended December 31, 2021 2020 (in millions) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology and patents $ 1,729 $ (762) $ 967 $ 1,681 $ (677) $ 1,004 Tradenames and trademarks 269 (79) 190 273 (70) 203 Licensing agreements 36 (32) 4 37 (30) 7 Customer relationships 1,091 (545) 546 1,142 (494) 648 Total definite-lived $ 3,125 $ (1,418) $ 1,707 $ 3,133 $ (1,271) $ 1,862 Indefinite-lived tradenames and trademarks 598 — 598 642 — 642 In-process R&D (a) 14 — 14 — — — Total indefinite-lived 612 — 612 642 — 642 Total identifiable intangible assets $ 3,737 $ (1,418) $ 2,319 $ 3,775 $ (1,271) $ 2,504 (a) Intangible assets acquired in a business combination that are in-process and used in research and development (“R&D”) activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed . Amortization expense for identifiable definite-lived intangible assets for the years ended December 31, 2021, 2020 and 2019 was $222 million, $192 million and $190 million, respectively. The annual estimated amortization expense related to these intangible assets for each of the five succeeding calendar years is $214 million, $216 million, $219 million, $224 million and $146 million for 2022, 2023, 2024, 2025 and 2026, respectively. During the second quarter of 2021, the Company purchased certain developed technology rights for an initial payment of $3 million. The purchase consideration also includes contingent payments of $17 million to be made upon reaching certain regulatory and commercial milestones, which were not yet deemed probable at December 31, 2021.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets were as follows: Year Ended December 31, (in millions) 2021 2020 Prepaid expenses $ 89 $ 78 Value-added tax receivable 53 39 Deposits 22 33 Other current assets 84 67 Prepaid expenses and other current assets $ 248 $ 217

ACCRUED LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
ACCRUED LIABILITIES	ACCRUED LIABILITIES Accrued liabilities were as follows: Year Ended December 31, (in millions) 2021 2020 Payroll, commissions, bonuses, other cash compensation and employee benefits $ 172 $ 142 Sales and marketing programs 66 56 Reserve for dealer rebates 209 134 Restructuring costs 11 31 Accrued vacation and holidays 40 41 Professional and legal costs 19 33 Current portion of derivatives 3 32 General insurance 12 12 Warranty liabilities 28 18 Third party royalties 7 11 Deferred income 68 53 Accrued interest 8 13 Accrued property taxes 6 13 Current operating lease liabilities 50 48 Other 61 75 Accrued liabilities $ 760 $ 712

FINANCING ARRANGEMENTS

FINANCING ARRANGEMENTS	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
FINANCING ARRANGEMENTS	FINANCING ARRANGEMENTS Short-Term Debt Short-term debt was as follows: Year Ended December 31, 2021 2020 Principal Interest Principal Interest (in millions except percentages) Balance Rate Balance Rate Corporate commercial paper facility $ 170 0.3 % $ — — % Other short-term borrowings 11 4.8 % 3 1.9 % Add: Current portion of long-term debt 1 296 Total short-term debt $ 182 $ 299 Maximum month-end short-term debt outstanding during the year $ 380 $ 299 Average amount of short-term debt outstanding during the year $ 265 $ 95 Weighted-average interest rate on short-term debt at year-end 0.6 % 1.9 % Short-Term Borrowings The Company has access to a $700 million multi-currency revolving credit facility (“2018 Credit Facility”) through July 28, 2024. The facility is unsecured and contains certain affirmative and negative covenants relating to the operations and financial condition of the Company. The most restrictive of these covenants pertain to asset dispositions and prescribed ratios of indebtedness to total capital and operating income, plus depreciation and amortization to interest expense. The credit facility serves as a back-stop facility for the Company’s commercial paper program. The Company has a $500 million commercial paper facility. At December 31, 2021, the Company had borrowings of $170 million outstanding under this facility. The average balance outstanding for the commercial paper facility during the year ended December 31, 2021 was $16 million. At December 31, 2020, the Company had no outstanding borrowings under this commercial paper facility. The Company also has access to $41 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings of $11 million. On July 2, 2021 the Company pre-paid the fixed rate Senior Notes totaling $296 million that were scheduled to mature on August 16, 2021 using cash and short-term commercial paper. Long-Term Debt Long-term debt was as follows: Year Ended December 31, 2021 2020 Principal Interest Principal Interest (in millions except percentages) Balance Rate Balance Rate Fixed rate senior notes $450 million due August 2021 $ — — % $ 296 4.1 % Private placement notes 70 million euros due October 2024 79 1.0 % 85 1.0 % Private placement notes 25 million Swiss franc due December 2025 27 0.9 % 28 0.9 % Private placement notes 97 million euros due December 2025 110 2.1 % 118 2.1 % Private placement notes 26 million euros due February 2026 30 2.1 % 32 2.1 % Private placement notes 58 million Swiss franc due August 2026 64 1.0 % 65 1.0 % Private placement notes 106 million euros due August 2026 121 2.3 % 129 2.3 % Private placement notes 70 million euros due October 2027 80 1.3 % 85 1.3 % Private placement notes 8 million Swiss franc due December 2027 8 1.0 % 8 1.0 % Private placement notes 15 million euros due December 2027 17 2.2 % 18 2.2 % Private placement notes 140 million Swiss franc due August 2028 153 1.2 % 158 1.2 % Private placement notes 70 million euros due October 2029 79 1.5 % 85 1.5 % Fixed rate senior notes 750 million due June 2030 750 3.3 % 750 3.3 % Private placement notes 70 million euros due October 2030 80 1.6 % 85 1.6 % Private placement notes 45 million euros due February 2031 51 2.5 % 55 2.5 % Private placement notes 65 million Swiss franc due August 2031 71 1.3 % 73 1.3 % Private placement notes 12.6 billion Japanese yen due September 2031 109 1.0 % 122 1.0 % Private placement notes 70 million euros due October 2031 80 1.7 % 85 1.7 % Other borrowings, various currencies and rates 13 7 $ 1,922 $ 2,284 Less: Current portion (included in “Notes payable and current portion of long-term debt” in the Consolidated Balance Sheets) 1 296 Less: Long-term portion of deferred financing costs 8 10 Long-term portion $ 1,913 $ 1,978 At December 31, 2021, the Company had $560 million borrowings available under unused lines of credit, including lines available under its short-term arrangements and revolving credit agreement. The Company’s revolving credit facility, term loans and senior notes contain certain affirmative and negative covenants relating to the Company’s operations and financial condition. At December 31, 2021, the Company was in compliance with all debt covenants. The table below reflects the contractual maturity dates of the various long-term borrowings as follows: (in millions) December 31, 2021 2022 $ 3 2023 11 2024 84 2025 138 2026 213 2027 and beyond 1,473 $ 1,922

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Equity	EQUITY On July 28, 2021, the Board of Directors of the Company approved an increase to $1.0 billion in the value of shares of common stock that may be repurchased under the share repurchase program. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. For the years ended December 31, 2021, 2020 and 2019, the Company repurchased outstanding shares of common stock at a cost of $200 million, $140 million and $260 million, respectively. At December 31, 2021, the Company had authorization to repurchase $890 million in shares of common stock remaining under the share repurchase program. For the years ended December 31, 2021, 2020 and 2019, the Company received proceeds of $51 million, $11 million and $109 million, respectively, primarily as a result of stock options exercised in the amount of 1.1 million, 0.3 million and 2.7 million in each of the years, respectively. It is the Company’s practice to issue shares from treasury stock when options are exercised. Total outstanding shares of common stock and treasury stock were as follows: (in millions) Shares of Common Stock Shares of Treasury Stock Outstanding Shares Balance at December 31, 2018 264.5 (41.5) 223.0 Shares of treasury stock issued — 3.1 3.1 Repurchase of common stock at an average cost of $54.18 — (4.8) (4.8) Balance at December 31, 2019 264.5 (43.2) 221.3 Shares of treasury stock issued — 1.1 1.1 Repurchase of common stock at an average cost of $38.25 — (3.7) (3.7) Balance at December 31, 2020 264.5 (45.8) 218.7 Shares of treasury stock issued — 2.2 2.2 Repurchase of common stock at an average cost of $57.47 — (3.5) (3.5) Balance at December 31, 2021 264.5 (47.1) 217.4

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The components of income (loss) before income taxes were as follows: Year Ended December 31, (in millions) 2021 2020 2019 United States $ 51 $ (91) $ (115) Foreign 494 41 453 Total income (loss) before income taxes $ 545 $ (50) $ 338 The components of the provision (benefit) for income taxes from operations were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Current: U.S. federal $ 1 $ (5) $ (11) U.S. state 4 1 2 Foreign 154 89 131 Total $ 159 $ 85 $ 122 Deferred: U.S. federal $ 10 $ 4 $ (3) U.S. state 2 (1) 1 Foreign (37) (65) (38) Total $ (25) $ (62) $ (40) Total provision for income taxes $ 134 $ 23 $ 82 The reconciliation of the U.S. federal statutory tax rate to the effective rate were as follows: Year Ended December 31, 2021 2020 2019 Statutory U.S. federal income tax rate 21.0 % 21.0 % 21.0 % Effect of: State income taxes, net of federal benefit 0.8 1.1 0.7 Federal benefit of R&D and foreign tax credits (0.9) 18.9 (2.0) US other permanent differences 0.4 (6.1) 0.8 Tax effect of international operations 0.3 10.0 0.9 Global Intangible Low Taxed Income (GILTI) 2.4 (13.0) 3.8 Foreign Derived Intangible Income (FDII) (1.3) 11.8 (0.1) Net effect of tax audit activity 1.6 (8.2) 0.4 Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions 1.9 (0.2) 0.1 Federal tax on unremitted earnings of certain foreign subsidiaries (0.2) (5.4) 0.1 Valuation allowance adjustments (1.7) (15.3) (1.4) Tax effect of impairment of goodwill and intangibles — (60.8) (0.1) Other 0.3 0.2 0.1 Effective income tax rate on operations 24.6 % (46.0 %) 24.3 % The tax effect of significant temporary differences giving rise to deferred tax assets and liabilities were as follows: Year Ended December 31, 2021 2020 (in millions) Deferred Tax Asset Deferred Tax Liability Deferred Tax Asset Deferred Tax Liability Commission and bonus accrual $ 6 $ — $ 8 $ — Employee benefit accruals 51 — 58 — Inventory 16 — 25 — Identifiable intangible assets — 569 — 613 Insurance premium accruals 3 — 3 — Miscellaneous accruals 27 — 24 — Other 17 — 10 — Unrealized losses included in AOCI 47 — 98 — Property, plant and equipment — 47 — 50 Lease right-of-use asset — 47 — 42 Lease right-of-use liability 47 — 42 — Product warranty accruals 1 — 1 — Foreign tax credit and R&D carryforward 49 — 60 — Restructuring and other cost accruals 5 — 9 — Sales and marketing accrual 14 — 7 — Taxes on unremitted earnings of foreign subsidiaries — 5 — 6 Tax loss carryforwards and other tax attributes 275 — 280 — Subtotal $ 558 $ 668 $ 625 $ 711 Valuation allowances (267) — (287) — Total $ 291 $ 668 $ 338 $ 711 Deferred tax assets and liabilities are included in the following Consolidated Balance Sheets line items at December 31 were as follows: (in millions) 2021 2020 Assets Other noncurrent assets $ 14 $ 8 Liabilities Deferred income taxes $ 391 $ 381 The Company has $45 million of foreign tax credit carryforwards at December 31, 2021, of which $36 million will expire in 2025, $3 million will expire in 2027, and $6 million will expire at various times from 2028 through 2031. The Company has tax loss carryforwards related to certain foreign and domestic subsidiaries of approximately $1,278 million at December 31, 2021, of which $1,017 million expires at various times through 2041 and $261 million may be carried forward indefinitely. Included in deferred income tax assets at December 31, 2021 are tax benefits totaling $228 million, before valuation allowances, for the tax loss carryforwards. In addition, the Company has recorded a deferred tax asset of $48 million, related to tax attributes. The Company has recorded $210 million of valuation allowance to offset the tax benefit of net operating losses, $45 million to offset the tax benefit of foreign tax credits, and $12 million of valuation allowance for other deferred tax assets. The Company has recorded these valuation allowances due to the uncertainty that these assets can be realized in the future. The Company has provided $5 million of withholding taxes on certain undistributed earnings of its foreign subsidiaries that the Company anticipates will be repatriated. Tax Contingencies The total amount of gross unrecognized tax benefits at December 31, 2021 is approximately $42 million, of this total, approximately $41 million represents the amount of unrecognized tax benefits that, if recognized, would affect the effective income tax rate. It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date of the Company’s consolidated financial statements. Expiration of statutes of limitation in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $1 million. Of this approximately $1 million represents the amount of unrecognized tax benefits that, if recognized, would affect the effective income tax rate. The total amount of accrued interest and penalties were $8 million and $4 million at December 31, 2021 and 2020, respectively. The Company has consistently classified interest and penalties recognized in its consolidated financial statements as income taxes based on the accounting policy election of the Company. During the years ended December 31, 2021 and 2020, the Company recognized income tax expense of $2 million each year, related to interest and penalties. During the year ended December 31, 2019, the Company recognized income tax benefit of $2 million, related to interest and penalties. The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The significant jurisdictions include the U.S., Germany, Sweden and Switzerland. The Company has substantially concluded all U.S. federal income tax matters for years through 2011. The Company is currently under audit for the tax years 2012, 2013, 2015 and 2016. For further information on the Internal Revenue Service (“IRS”) Audit, see Note 22, Commitments and Contingencies. The tax years 2014 through 2020 are subject to future potential tax audit adjustments. The Company has concluded audits in Germany through the tax year 2013 and is currently under audit for the years 2014 through 2017. The tax years 2018 through 2020 are subject to future potential audit adjustments in Germany. The taxable years that remain open for Sweden are 2013 through 2020. For information related to Sweden, see Note 22, Commitments and Contingencies. The taxable years that remain open for Switzerland are 2011 through 2020. The activity recorded for unrecognized tax benefits were as follows: (in millions) 2021 2020 2019 Unrecognized tax benefits at beginning of period $ 27 $ 24 $ 28 Gross change for prior-period positions 6 1 — Gross change for current year positions 2 1 — Decrease due to settlements and payments — — (4) Decrease due to statute expirations — — — Increase due to effect of foreign currency translation — 1 — Decrease due to effect from foreign currency translation (1) — — Unrecognized tax benefits at end of period $ 34 $ 27 $ 24 U.S. Federal Legislative Changes Undistributed earnings of foreign subsidiaries and related companies that are deemed to be permanently invested amounted to $1,771 million a t December 31, 2021 and $1,807 million at December 31, 2020 . The Tax Cuts and Jobs Act (the “act” or “U.S. tax reform”) imposed U.S. tax on all post-1986 foreign unrepatriated earnings accumulated through December 31, 2017. Unrepatriated earnings generated after December 31, 2017, are now subject to tax in the current year. All undistributed earnings are still subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply. It is not practicable to calculate the unrecognized deferred tax liability on undistributed earnings. For the Global Intangible Low Taxed Income (GILTI) provision of the Act, the Company has made the policy election to record any liability associated with GILTI in the period in which it is incurred. In March 2020, in response to the impact of the COVID-19 pandemic in the U.S. and across the globe, the U.S. Congress passed the Coronavirus Aid, Relief and Economic Security (CARES) Act. In December 2020, the U.S. Congress passed a second relief package, Consolidated Appropriations Act, 2021. The enactment period impacts to the Company were immaterial to income tax expense.

BENEFIT PLANS

BENEFIT PLANS	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
BENEFIT PLANS	BENEFIT PLANS Defined Contribution Plans The Company maintains both U.S. and non-U.S. employee defined contribution plans. The primary U.S. plan, the Dentsply Sirona Inc. 401(k) Savings Plan (the “Plan”), allows eligible employees to contribute a portion of their cash compensation to the plan on a tax-deferred basis, and in most cases, the Company provides a matching contribution. The Plan includes various investment funds. The Company makes a discretionary cash contribution that is initially targeted to be 3% of compensation. Each eligible participant who elects to defer to the Plan will receive a matching contribution of 100% on the first 1% contributed and 50% on the next 5% contributed for a total maximum matching contribution of 3.5%. In addition to the primary U.S. plan, the Company also maintains various other U.S. and non-U.S. defined contribution and non-qualified deferred compensation plans. The annual expenses, net of forfeitures, were $39 million, $36 million and $35 million for the years ended December 31, 2021, 2020, and 2019, respectively. Defined Benefit Plans The Company maintains defined benefit pension plans for certain employees in Austria, France, Germany, Italy, Japan, the Netherlands, Norway, Sweden, Switzerland, Taiwan, and the United States. These plans provide benefits based upon age, years of service and remuneration. Substantially all of the German and Swedish plans are unfunded book reserve plans. Most employees and retirees outside the U.S. are covered by government health plans. The Company predominantly derives its discount rates by applying the specific spot rates along the yield curve to the relevant projected cash flows; or, in markets where there is an absence of a sufficiently deep corporate bond market, it uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate or government bond yield in the respective economic regions of the plan. For the large defined benefits pension plans, the Company uses a spot rate approach for the estimation of the Service Cost and Interest Cost components of benefit cost by applying the specific spot rates along the yield curve to the relevant projected cash flows. Significant changes in the retirement plan benefit obligations for the year ended December 31, 2021 include a $26 million actuarial gain primarily attributable to the increase in discount rates, the effect of which is slightly offset by the change in inflation and salary increase assumptions in some plans. The changes also include a $6 million actuarial gain due to demographic assumption changes and a $16 million actuarial loss due to plan experience different than anticipated. Significant changes in the retirement plan benefit obligations for the year ended December 31, 2020 include a $31 million actuarial loss primarily attributable to the change in discount rates, the effect of which is slightly offset by the change in inflation and salary increase assumptions in some plans. Defined Benefit Pension Plan Assets The primary investment strategy is to ensure that the assets of the plans, along with anticipated future contributions, will be invested in order that the benefit entitlements of employees, pensioners and beneficiaries covered under the plan can be met when due with high probability. Pension plan assets consist mainly of common stock and fixed income investments. The target allocations for defined benefit plan assets are 30% to 65% equity securities, 30% to 65% fixed income securities, 0% to 15% real estate, and 0% to 25% in all other types of investments. Equity securities include investments in companies located both in and outside the U.S. Equity securities in the defined benefit pension plans do not include Company common stock contributed directly by the Company. Fixed income securities include corporate bonds of companies from diversified industries, government bonds, mortgage notes and pledge letters. Other types of investments include investments in mutual funds, insurance contracts, hedge funds and real estate. These plan assets are not recorded in the Company’s Consolidated Balance Sheet as they are held in trust or other off-balance sheet investment vehicles. The defined benefit pension plan assets maintained in Austria, Germany, Norway, the Netherlands, Switzerland and Taiwan all have separate investment policies but generally have an objective to achieve a long-term rate of return in excess of 2% while at the same time mitigating the impact of investment risk associated with investment categories that are expected to yield greater than average returns. In accordance with the investment policies, the plans’ assets were invested in the following investment categories: interest-bearing cash, U.S. and foreign equities, foreign fixed income securities (primarily corporate and government bonds), insurance company contracts, real estate and hedge funds. Reconciliation of changes in the defined benefit obligations, fair value of assets and statement of funded status were as follows: Year Ended December 31, (in millions) 2021 2020 Change in Benefit Obligation Benefit obligation at beginning of year $ 675 $ 578 Service cost 17 16 Interest cost 3 5 Participant contributions 4 4 Actuarial losses (gains) (16) 31 Plan amendments (1) — Acquisitions/Divestitures (2) — Effect of exchange rate changes (41) 59 Plan curtailments and settlements (1) (1) Benefits paid (19) (17) Benefit obligation at end of year $ 619 $ 675 Change in Plan Assets Fair value of plan assets at beginning of year $ 213 $ 185 Actual return on assets 10 9 Plan settlements (1) — Acquisitions/Divestitures (3) — Effect of exchange rate changes (7) 17 Employer contributions 15 15 Participant contributions 4 4 Benefits paid (19) (17) Fair value of plan assets at end of year $ 212 $ 213 Funded status at end of year $ (407) $ (462) The amounts recognized in the accompanying Consolidated Balance Sheets, net of tax effects, were as follows: Location In The Year Ended December 31, (in millions) Consolidated Balance Sheets 2021 2020 Other noncurrent assets, net Other noncurrent assets $ 2 $ — Deferred tax asset Other noncurrent assets 36 49 Total assets $ 38 $ 49 Current liabilities Accrued liabilities (9) (10) Other noncurrent liabilities Other noncurrent liabilities (400) (452) Deferred tax liability Deferred income taxes (1) (1) Total liabilities $ (410) $ (463) Accumulated other comprehensive income Accumulated other comprehensive loss 105 139 Net amount recognized $ (267) $ (275) Amounts recognized in AOCI were as follows: Year Ended December 31, (in millions) 2021 2020 Net actuarial loss $ 144 $ 191 Net prior service cost (4) (4) Before tax AOCI $ 140 $ 187 Less: Deferred taxes 35 48 Net of tax AOCI $ 105 $ 139 Information for pension plans with a projected or accumulated benefit obligation in excess of plan assets were as follows: Year Ended December 31, (in millions) 2021 2020 Projected benefit obligation $ 427 $ 484 Accumulated benefit obligation 403 455 Fair value of plan assets 17 26 Components of net periodic benefit cost were as follows: Year Ended December 31, Location in Consolidated (in millions) 2021 2020 2019 Statements of Operations Service cost $ 7 $ 6 $ 6 Cost of products sold Service cost 10 10 8 Selling, general and administrative expenses Interest cost 3 5 8 Other expense (income), net Expected return on plan assets (4) (4) (5) Other expense (income), net Amortization of prior service credit (1) (1) (1) Other expense (income), net Amortization of net actuarial loss 12 9 6 Other expense (income), net Acquisitions/Divestitures 1 — — Other expense (income), net Curtailment and settlement (gains) loss (1) — 6 Other expense (income), net Net periodic benefit cost $ 27 $ 25 $ 28 Other changes in plan assets and benefit obligations recognized in AOCI were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Net actuarial loss (gain) $ (36) $ 43 $ 53 Amortization (11) (9) (5) Total recognized in AOCI $ (47) $ 34 $ 48 Total recognized in net periodic benefit cost and AOCI $ (20) $ 59 $ 76 Assumptions The weighted average assumptions used to determine benefit obligations for the Company’s plans, principally in foreign locations were as follows: Year Ended December 31, 2021 2020 2019 Interest crediting rate 1.3 % 1.3 % 1.3 % Discount rate 1.1 % 0.6 % 1.0 % Rate of compensation increase 2.6 % 2.4 % 2.5 % The weighted average assumptions used to determine net periodic benefit cost for the Company’s plans, principally in foreign locations were as follows: Year Ended December 31, 2021 2020 2019 Interest crediting rate 1.3 % 1.3 % 1.3 % Discount rate 0.6 % 1.0 % 1.8 % Expected return on plan assets 2.2 % 2.3 % 2.9 % Rate of compensation increase 2.4 % 2.5 % 2.5 % Measurement date 12/31/2021 12/31/2020 12/31/2019 To develop the assumptions for the expected long-term rate of return on assets, the Company considered the current level of expected returns on risk free investments (primarily U.S. government bonds), the historical level of the risk premium associated with the other asset classes in which the assets are invested and the expectations for future returns of each asset class. The expected return for each asset class was then weighted based on the target asset allocations to develop the assumptions for the expected long-term rate of return on assets. Fair Value Measurements of Plan Assets The fair value of the Company’s pension plan assets at December 31, 2021 and 2020 is presented in the table below by asset category. Approximately 78% of the total plan assets are categorized as Level 1, and therefore, the values assigned to these pension assets are based on quoted prices available in active markets. For the other category levels, a description of the valuation is provided in Note 1, Significant Accounting Policies and Restatement, under the “Fair Value Measurement” heading. December 31, 2021 (in millions) Total Level 1 Level 2 Level 3 Assets Category Cash and cash equivalents $ 17 $ 17 $ — $ — Equity securities: International 65 65 — — Fixed income securities: Fixed rate bonds (a) 66 66 — — Other types of investments: Mutual funds (b) 18 18 — — Insurance contracts 34 — — 34 Hedge funds 11 — — 11 Real estate 1 — — 1 Total $ 212 $ 166 $ — $ 46 December 31, 2020 (in millions) Total Level 1 Level 2 Level 3 Assets Category Cash and cash equivalents $ 16 $ 16 $ — $ — Equity securities: International 58 58 — — Fixed income securities: Fixed rate bonds (a) 65 65 — — Other types of investments: Mutual funds (b) 20 20 — — Common trusts (c) 5 — 5 — Insurance contracts 37 — — 37 Hedge funds 12 — — 12 Total $ 213 $ 159 $ 5 $ 49 (a) This category includes fixed income securities invested primarily in Swiss bonds, foreign bonds denominated in Swiss francs, foreign currency bonds, mortgage notes and pledged letters. (b) This category includes mutual funds balanced between moderate-income generation and moderate capital appreciation with investment allocations of approximately 50% equities and 50% fixed income investments. (c) This category includes common/collective funds with investments in approximately 65% equities and 35% in fixed income investments. A reconciliation from December 31, 2020 to December 31, 2021 for the plan assets categorized as Level 3 were as follows: December 31, 2021 (in millions) Insurance Contracts Hedge Funds Real Estate Total Balance at December 31, 2020 $ 37 $ 12 $ — $ 49 Actual return on plan assets: Relating to assets still held at the reporting date (2) 1 1 — Purchases, sales and settlements, net (1) (2) — (3) Transfers in and/or (out) 2 — — 2 Effect of exchange rate changes (2) — — (2) Balance at December 31, 2021 $ 34 $ 11 $ 1 $ 46 December 31, 2020 (in millions) Insurance Contracts Hedge Funds Real Estate Total Balance at December 31, 2019 $ 30 $ 9 $ — $ 39 Actual return on plan assets: Relating to assets still held at the reporting date 3 — — 3 Purchases, sales and settlements, net — 2 — 2 Effect of exchange rate changes 4 1 — 5 Balance at December 31, 2020 $ 37 $ 12 $ — $ 49 Fair values for Level 3 assets are determined as follows: Insurance Contracts: The value of the asset represents the mathematical reserve of the insurance policies and is calculated by the insurance firms using their own assumptions. Hedge Funds: The investments are valued using the net asset value provided by the administrator of the fund, which is based on the fair value of the underlying securities. Real Estate: Investment is stated by its appraised value. Cash Flows In 2022, the Company expects to make employer contributions of $17 million to its defined benefit pension plans. Estimated Future Benefit Payments Total benefits expected to be paid from the plans in the future were as follows: (in millions) Pension Benefits 2022 $ 23 2023 24 2024 24 2025 25 2026 25 2027-2031 127

RESTRUCTURING AND OTHER COSTS

RESTRUCTURING AND OTHER COSTS	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND OTHER COSTS	RESTRUCTURING AND OTHER COSTS During the year ended December 31, 2021, the Company recorded net restructuring and other costs of $20 million, which consists primarily of severance and other restructuring costs of $23 million, offset by adjustments to inventory reserve of $3 million. During the year ended December 31, 2020, the Company recorded restructuring and other costs of $123 million which consists primarily of inventory write-downs of $31 million, accelerated depreciation of $14 million, severance costs of $23 million, indefinite-lived intangible asset impairment of $39 million, and other impairments of $8 million. During the year ended December 31, 2019, the Company recorded restructuring and other costs of $128 million, which consists primarily of inventory write-downs of $20 million, accelerated depreciation of $3 million, severance costs of $37 million, fixed asset impairments of $33 million, and $9 million related to impairments of both definite-lived and indefinite-lived intangible assets. The details of total restructuring and other costs for the years ended 2021, 2020 and 2019 were as follows: Affected Line Item in the Consolidated Statements of Operations Year Ended December 31, (in millions) 2021 2020 2019 Cost of products sold $ (3) $ 44 $ 25 Selling, general, and administrative expenses 6 2 23 Restructuring and other costs 17 77 81 Other income and expenses — — (1) Total restructuring and other costs $ 20 $ 123 $ 128 Restructuring Programs and Accruals In 2018, the Board of Directors of the Company approved a plan to restructure and simplify the Company’s business, which was expanded in 2020 for certain portfolio optimization objectives including the exit of the Company’s traditional orthodontics business as well as portions of its laboratory business. These plans are nearing completion as of the end of 2021 and are expected to result in total charges of approximately $345 million, of which $321 million has been incurred as of December 31, 2021. For the year ended December 31, 2021, the Company made a $3 million adjustment related to inventory reserves and recorded severance costs of $2 million related to these plans. Remaining expenses in 2021 pertain to minor restructuring actions taken during the year. These expenses are included in the above table. The Company’s restructuring accruals at December 31, 2021 were as follows: Severance (in millions) 2019 and Prior Plans 2020 Plans 2021 Plans Total Balance at December 31, 2020 $ 12 $ 17 $ — $ 29 Provisions and adjustments 3 3 13 19 Amounts applied (10) (11) (4) (25) Change in estimates (2) (7) — (9) Balance at December 31, 2021 $ 3 $ 2 $ 9 $ 14 Other Restructuring Costs (in millions) 2019 and Prior Plans 2020 Plans 2021 Plans Total Balance at December 31, 2020 $ 3 $ 2 $ — $ 5 Provisions and adjustments 2 5 3 10 Amounts applied (2) (5) (3) (10) Balance at December 31, 2021 $ 3 $ 1 $ — $ 4 The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows: (in millions) December 31, 2020 Provisions and Adjustments Amounts Applied Change in Estimates December 31, 2021 Technologies & Equipment $ 16 $ 9 $ (14) $ (4) $ 7 Consumables 17 15 (16) (5) 11 All Other 1 5 (5) (1) — Total $ 34 $ 29 $ (35) $ (10) $ 18 The Company’s restructuring accruals at December 31, 2020 were as follows: Severances (in millions) 2018 and Prior Plans 2019 Plans 2020 Plans Total Balance at December 31, 2019 $ 7 $ 20 $ — $ 27 Provisions and adjustments 2 2 28 32 Amounts applied (4) (8) (9) (21) Change in estimates — (7) (2) (9) Balance at December 31, 2020 $ 5 $ 7 $ 17 $ 29 Other Restructuring Costs (in millions) 2018 and Prior Plans 2019 Plans 2020 Plans Total Balance at December 31, 2019 $ 3 $ — $ — $ 3 Provisions and adjustments — 1 3 4 Amounts applied — (1) (1) (2) Balance at December 31, 2020 $ 3 $ — $ 2 $ 5 The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows: (in millions) December 31, 2019 Provisions and Adjustments Amounts Applied Change in Estimates December 31, 2020 Technologies & Equipment $ 19 $ 16 $ (12) $ (7) $ 16 Consumables 11 16 (8) (2) 17 All Other — 4 (3) — 1 Total $ 30 $ 36 $ (23) $ (9) $ 34

FINANCIAL INSTRUMENTS AND DERIV

FINANCIAL INSTRUMENTS AND DERIVATIVES	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
FINANCIAL INSTRUMENTS AND DERIVATIVES	FINANCIAL INSTRUMENTS AND DERIVATIVES Derivative Instruments and Hedging Activities The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and cash flows. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes. The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes, by derivative instrument type at December 31, 2021 and the notional amounts expected to mature during the next 12 months: Aggregate Notional Amount Aggregate Notional Amount Maturing within 12 Months (in millions) Cash Flow Hedges Foreign exchange forward contracts $ 311 $ 235 Total derivative instruments designated as cash flow hedges $ 311 $ 235 Hedges of Net Investments Foreign exchange forward contracts $ 182 $ 91 Cross currency basis swaps 303 — Total derivative instruments designated as hedges of net investments $ 485 $ 91 Fair Value Hedges Foreign exchange forward contracts $ 217 $ 87 Interest rate swaps 250 — Total derivative instruments designated as fair value hedges $ 467 $ 87 Derivative Instruments not Designated as Hedges Foreign exchange forward contracts $ 301 $ 301 Total derivative instruments not designated as hedges $ 301 $ 301 Cash Flow Hedges Foreign Exchange Risk Management The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows and the counterparties to the transactions are typically large international financial institutions. Interest Rate Risk Management The Company enters into interest rate swap contracts to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. On May 26, 2020, the Company paid $31 million to settle the $150 million notional T-Lock contract, which partially hedged the interest rate risk of the $750 million senior unsecured notes. This loss is amortized over the ten-year life of the notes. At December 31, 2021, $25 million of this loss is remaining to be amortized from AOCI in future periods. AOCI Release Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At December 31, 2021, the Company expects to reclassify $1 million of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 5, Comprehensive (Loss) Income. Hedges of Net Investments in Foreign Operations The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of this exposure. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments and are included in AOCI. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows. The fair value of the foreign exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates, cross-currency swap basis rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects. On July 2, 2021, the Company entered into a cross-currency basis swap of a notional amount of $300 million, which matures on June 3, 2030. The cross-currency basis swap is designated as a hedge of net investments. This contract effectively converts a portion of the $750 million bond coupon from 3.3% to 1.7%, which will result in a net reduction of interest expense in 2021. On May 25, 2021, the Company re-established its euro net investment hedge portfolio by entering into eight foreign exchange forward contracts, each with a notional amount of 10 million euro. The contracts have quarterly maturity dates through March 31, 2023. On April 7, 2020, the Company terminated its entire foreign exchange forward contracts net investment hedge portfolio early which resulted in a $48 million cash receipt. The Company elected to enter into this transaction to convert the favorable gain position into additional liquidity. Fair Value Hedges Foreign Exchange Risk Management The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. On January 6, 2021 the Company entered into foreign exchange forward contracts with a notional value of SEK 1.3 billion as a result of an increase in intercompany loans denominated in Swedish kronor. The foreign exchange forwards are designated as fair value hedges. Interest Rate Risk Management On July 1, 2021, the Company entered into variable interest rate swaps with a notional amount of $250 million, which effectively converted a portion of the underlying fixed rate of 3.3% on the $750 million Senior Notes due June 2030 to a variable interest rate. Of the $250 million notional amount, $100 million has a term of five-years maturing on June 1, 2026 and $150 million has a term of nine years maturing on March 1, 2030. Derivative Instruments Not Designated as Hedges The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other expense (income), net in the Consolidated Statements of Operations. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in operating activities in the Consolidated Statements of Cash Flows. Derivative Instrument Activity The amount of gains (losses) recorded in the Company’s Consolidated Balance Sheets and Consolidated Statements of Operations related to all derivative instruments were as follows: Year Ended December 31, 2021 (in millions) Gain (Loss) in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Ineffective Portion Recognized in Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ 3 Cost of products sold $ (3) $ 2 $ — Interest rate swaps — Interest expense, net (4) — — Total for cash flow hedging $ 3 $ (7) $ 2 $ — Hedges of Net Investments Cross currency basis swaps $ 13 Interest expense, net $ — $ — $ 6 Foreign exchange forward contracts 10 Other expense (income), net — 1 — Total for net investment hedging $ 23 $ — $ 1 $ 6 Fair Value Hedges Foreign exchange forward contracts $ (1) Other expense (income), net $ — $ 1 $ 23 Interest rate swap — Interest expense, net — — 1 Total for fair value hedging $ (1) $ — $ 1 $ 24 Year Ended December 31, 2020 (in millions) Gain (Loss) in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Ineffective Portion Recognized in Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ (2) Cost of products sold $ 2 $ 4 $ — Interest rate swaps (16) Interest expense, net (4) — — Total for cash flow hedging $ (18) $ (2) $ 4 $ — Hedges of Net Investments Cross currency basis swaps $ (26) Interest expense, net $ — $ — $ 9 Foreign exchange forward contracts 6 Other expense (income), net — 6 — Total for net investment hedging $ (20) $ — $ 6 $ 9 Fair Value Hedges Foreign exchange forward contracts $ (3) Interest expense, net $ — $ 3 $ — Total for fair value hedging $ (3) $ — $ 3 $ — . Year Ended December 31, 2019 (in millions) Gain (Loss) in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Ineffective Portion Recognized in Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ (6) Cost of products sold $ 1 $ 2 $ — Interest rate swaps (11) Interest expense, net (2) — — Total for cash flow hedging $ (17) $ (1) $ 2 $ — Hedges of Net Investments Cross currency basis swaps $ 9 Interest expense, net $ — $ — $ 8 Foreign exchange forward contracts 9 Other expense (income), net — 22 — Total for net investment hedging $ 18 $ — $ 22 $ 8 Fair Value Hedges Foreign exchange forward contracts $ 3 Interest expense, net $ — $ 3 $ — Total for fair value hedging $ 3 $ — $ 3 $ — Consolidated Statements of Operations Location Gain (Loss) Recognized December 31, (in millions) 2021 2020 2019 Derivative Instruments not Designated as Hedges Foreign exchange forward contracts Other expense (income), net $ (9) $ 7 $ (3) Total for instruments not designated as hedges $ (9) $ 7 $ (3) Consolidated Balance Sheets Location of Derivative Fair Values The fair value and the location of the Company’s derivatives in the Consolidated Balance Sheets were as follows: Year Ended December 31, 2021 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 18 $ 11 $ 2 $ 1 Interest rate swaps 5 — — 9 Cross currency basis swaps 4 — — 7 Total $ 27 $ 11 $ 2 $ 17 Not Designated as Hedges: Foreign exchange forward contracts $ 1 $ — $ 1 $ — Total $ 1 $ — $ 1 $ — Year Ended December 31, 2020 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 5 $ 2 $ 10 $ 3 Cross currency basis swaps — — 20 — Total $ 5 $ 2 $ 30 $ 3 Not Designated as Hedges: Foreign exchange forward contracts $ 3 $ — $ 2 $ — Total $ 3 $ — $ 2 $ — Balance Sheet Offsetting Substantially all of the Company’s derivative contracts are subject to netting arrangements; whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets. Offsetting of financial assets and liabilities under netting arrangements at December 31, 2021 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amounts Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 31 $ — $ 31 $ (9) $ — $ 22 Total assets $ 31 $ — $ 31 $ (9) $ — $ 22 Liabilities Foreign exchange forward contracts $ 4 $ — $ 4 $ (4) $ — $ — Interest rate swaps 4 — 4 (2) — 2 Cross currency basis swaps 4 — 4 (3) — 1 Total liabilities $ 12 $ — $ 12 $ (9) $ — $ 3 Offsetting of financial assets and liabilities under netting arrangements at December 31, 2020 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amounts Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 9 $ — $ 9 $ (9) $ — $ — Cross currency basis swaps — — — — — — Total assets $ 9 $ — $ 9 $ (9) $ — $ — Liabilities Foreign exchange forward contracts $ 15 $ — $ 15 $ — $ — $ 15 Cross currency basis swaps 20 — 20 (7) — 13 Total liabilities $ 35 $ — $ 35 $ (7) $ — $ 28

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	FAIR VALUE MEASUREMENT The estimated fair value and carrying value of the Company’s total long-term debt, including current portion, was $2,239 million and $2,095 million, respectively, at December 31, 2021. At December 31, 2020, the estimated the fair value and carrying value was $2,509 million and $2,281 million, respectively. The fair value of long-term debt is based on recent trade information in the financial markets of the Company’s public debt or is determined by discounting future cash flows using interest rates available at December 31, 2021 to companies with similar credit ratings for issues with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes. The interest rate on the outstanding principal of the $750 million Senior Notes is a fixed rate of 3.3%. The fair value of the Senior Notes is based on interest rates at December 31, 2021. For additional details on interest rates of long-term debt, please see Note 15, Financing Arrangements. Assets and liabilities measured at fair value on a recurring basis The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows: Year Ended December 31, 2021 (in millions) Total Level 1 Level 2 Level 3 Assets Interest rate swaps $ 5 $ — $ 5 $ — Long-term debt 4 — 4 — Cross currency interest rate swaps 4 — 4 — Foreign exchange forward contracts 30 — 30 — Total assets $ 43 $ — $ 43 $ — Liabilities Interest rate swaps $ 9 $ — $ 9 $ — Cross currency basis swaps 7 — 7 — Foreign exchange forward contracts 4 — 4 — Contingent considerations on acquisitions 10 — — 10 Total liabilities $ 30 $ — $ 20 $ 10 Year Ended December 31, 2020 (in millions) Total Level 1 Level 2 Level 3 Assets Foreign exchange forward contracts $ 10 $ — $ 10 $ — Total assets $ 10 $ — $ 10 $ — Liabilities Cross currency interest rate swaps $ 20 $ — $ 20 $ — Foreign exchange forward contracts 15 — 15 — Contingent considerations on acquisitions 5 — — 5 Total liabilities $ 40 $ — $ 35 $ 5 Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks. The Company utilizes interest rates swaps and foreign exchange forward contracts that are considered cash flow hedges. In addition, the Company at times employs certain cross currency interest rate swaps and forward exchange contracts that are considered hedges of net investment in foreign operations. Both types of designated derivative instruments are further discussed in Note 20, Financial Instruments and Derivatives. Assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) The Company’s Level 3 liabilities at December 31, 2021 are related to earn-out obligations from acquisitions and licensing arrangements. The following table presents a reconciliation of the Company’s Level 3 holdings measured at fair value on a recurring basis using unobservable inputs: (in millions) Level 3 Balance, December 31, 2019 $ 9 Issuance of new contingent consideration — Loss (gain) in Other expense (income), net — Payments (4) Balance, December 31, 2020 $ 5 Issuance of contingent consideration from business acquisition (a) 9 Loss (gain) in Other expense (income), net — Payments (4) Balance, December 31, 2021 $ 10 (a) Refer to Note 6, “Business Combinations” for more information regarding recent acquisitions There were no additional purchases or transfers of Level 3 financial instruments in 2021 and 2020.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Contingencies On January 25, 2018, Futuredontics, Inc., a former wholly-owned subsidiary of the Company, received service of a purported class action lawsuit brought by Henry Olivares and other similarly situated individuals in the Superior Court of the State of California for the County of Los Angeles. In January 2019, an amended complaint was filed adding another named plaintiff, Rachael Clarke, and various claims. The plaintiff class alleges several violations of the California wage and hours laws, including, but not limited to, failure to provide rest and meal breaks and the failure to pay overtime. The parties have engaged in written and other discovery. On February 5, 2019, Plaintiff Calethia Holt (represented by the same counsel as Mr. Olivares and Ms. Clarke) filed a separate representative action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. On April 5, 2019, Plaintiff Kendra Cato filed a similar action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has agreed to resolve all three actions (Olivares, Holt, and Cato). The court in Cato approved the settlement in that case, the settlement payment has been made, and the court dismissed the lawsuit. The parties to Olivares and Holt are in the process of seeking court approval of that settlement. The expected settlement amount, which is immaterial to the financial statements, has been recorded as an accrued liability within the Company’s consolidated balance sheet as of December 31, 2021. On June 7, 2018, and August 9, 2018, two putative class action suits were filed, and later consolidated, in the Supreme Court of the State of New York, County of New York claiming that the Company and certain individual defendants, violated U.S. securities laws (the “State Court Action”) by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. (“Sirona”) with DENTSPLY International Inc. (the “Merger”). The amended complaint alleges that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products and that three distributors of the Company’s products had been engaging in anticompetitive conduct. The plaintiffs seek to recover damages on behalf of a class of former Sirona shareholders who exchanged their shares for shares of the Company’s stock in the Merger. On September 26, 2019, the Court granted the Company’s motion to dismiss all claims and a judgment dismissing the case was subsequently entered. On February 4, 2020, the Court denied plaintiffs’ post-judgment motion to vacate or modify the judgment and to grant them leave to amend their complaint. The plaintiffs appealed the dismissal and the denial of the post-judgment motion to the Supreme Court of the State of New York, Appellate Division, First Department, and the Company cross-appealed select rulings in the Court’s decision dismissing the action. The plaintiffs’ appeals and the Company’s cross-appeal were consolidated and argued on January 12, 2021. On February 2, 2021, the Appellate Division issued its decision upholding the dismissal of the State Court Action with prejudice on statute of limitations grounds. The Plaintiffs did not appeal the Appellate Division decision. On December 19, 2018, a related putative class action was filed in the U.S. District Court for the Eastern District of New York against the Company and certain individual defendants (the “Federal Class Action”). The plaintiff makes similar allegations and asserts the same claims as those asserted in the State Court Action. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between February 20, 2014, and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of (a) all purchasers of the Company’s stock during the period February 20, 2014 through August 7, 2018 and (b) former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company’s stock in the Merger. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021. Briefing on the motion to dismiss was fully submitted on May 21, 2021, and that motion is currently pending before the Court. The Company intends to defend itself vigorously in these actions. As a result of an audit by the IRS for the fiscal years 2012 through 2013, on February 11, 2019, the IRS issued to the Company a “30-day letter” and a Revenue Agent’s Report (“RAR”), relating to the Company’s worthless stock deduction in 2013 in the amount of $546 million. The RAR disallows the deduction and, after adjusting the Company’s net operating loss carryforward, asserts that the Company is entitled to a refund of $5 million for 2012, has no tax liability for 2013, and owes a deficiency of $17 million in tax for 2014, excluding interest. In accordance with ASC 740, the Company recorded the tax benefit associated with the worthless stock deduction in the Company’s 2012 financial statements. In March 2019, the Company submitted a formal protest disputing on multiple grounds the proposed taxes. The Company and its advisors discussed its position with the IRS Appeals Office Team on October 28, 2020 and, on November 13, 2020, submitted a supplemental response to questions raised by the Appeals Team. The Company’s position continues to be reviewed by the IRS Appeals Office team. The Company believes the IRS’ position is without merit and believes that it is more likely-than-not the Company’s position will be sustained upon further review by the IRS Appeals Office Team. The Company has not accrued a liability relating to the proposed tax adjustments. However, the outcome of this dispute involves a number of uncertainties, including those inherent in the valuation of various assets at the time of the worthless stock deduction, and those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. If determined adversely, the dispute would result in a current period charge to earnings and could have a material adverse effect in the consolidated results of operations, financial position, and liquidity of the Company. The Swedish Tax Agency has disallowed certain of the Company’s interest expense deductions for the tax years from 2013 to 2018. If such interest expense deductions were disallowed, the Company would be subject to an additional $44 million in tax expense. The Company has appealed the disallowance to the Swedish Administrative Court. With respect to such deductions taken in the tax years from 2013 to 2014, the Court ruled against the Company on July 5, 2017. On August 7, 2017, the Company appealed the unfavorable decision of the Swedish Administrative Court. On November 5, 2018, the Company delivered its final argument to the Administrative Court of Appeals at a hearing. The European Union Commission has taken the view that Sweden’s interest deduction limitation rules are incompatible with European Union law and supporting legal opinions, and therefore the Company has not paid the tax or made provision in its financial statements for such potential expense. This view has now been confirmed by the European Union Court of Justice in a preliminary ruling requested by the Swedish Supreme Administrative Court. Subsequently, the Swedish Tax Authority has conceded in pending court proceedings that the Company should be granted further interest expense deductions, but still claims that interest expense deductions incurring a maximum additional tax expense of $11 million should be disallowed on grounds not relating to European Union law. The Company intends to vigorously defend its position and pursue related appeals. In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity. While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses. Commitments Purchase Commitments The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At December 31, 2021, non-cancelable purchase commitments are as follows: (in millions) 2022 $ 161 2023 73 2024 38 2025 41 2026 42 Thereafter — Total $ 355 Off-Balance Sheet Arrangements As of December 31, 2021, we had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above. Indemnification In the normal course of business to facilitate sale of our products and services, we indemnify certain parties: customers, vendors, lessors, and other parties with respect to certain matters, including, but not limited to, services to be provided by us and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and our executive officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim. It is not possible to make a reasonable estimate of the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material effect on our results of operations, cash flows or financial position. As of December 31, 2021, we did not have any material indemnification claims that were probable or reasonably possible. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period. Other Commitments At December 31, 2021, we were obligated under various operating lease agreements. Please refer to Note 11, Leases, for additional details. At December 31, 2021, we were obligated under various defined benefit pension plans in the U.S. and other countries that cover employees who meet eligibility requirements. Please refer to Note 18, Benefit Plans, for additional details.

CORRECTION OF PREVIOUSLY ISSUED

CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION	12 Months Ended
	Dec. 31, 2021
Accounting Changes and Error Corrections [Abstract]
Correction of Previously Issued Quarterly Information	CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION The following tables present the effect of correcting the Company’s previously issued quarterly financial statements for the accounting errors described in Note 1, Significant Accounting Policies and Restatement: CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,027 $ (1) $ 1,026 $ 874 $ 7 $ 881 Cost of products sold 448 (1) 447 406 — 406 Gross profit 579 — 579 468 7 475 Selling, general, and administrative expenses 385 1 386 359 (2) 357 Research and development expenses 37 3 40 34 2 36 Goodwill impairment — — — 157 — 157 Restructuring and other costs 3 — 3 43 (1) 42 Operating income (loss) 154 (4) 150 (125) 8 (117) Other income and expenses: Interest expense, net 14 — 14 7 (1) 6 Other expense (income), net (9) — (9) (2) 1 (1) Income (loss) before income taxes 149 (4) 145 (130) 8 (122) Provision for income taxes 32 1 33 10 2 12 Net income (loss) 117 (5) 112 (140) 6 (134) Less: Net income (loss) attributable to noncontrolling interest — — — — — — Net income (loss) attributable to Dentsply Sirona $ 117 $ (5) $ 112 $ (140) $ 6 $ (134) Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 0.53 $ (0.02) $ 0.51 $ (0.63) $ 0.02 $ (0.61) Diluted $ 0.53 $ (0.02) $ 0.51 $ (0.63) $ 0.02 $ (0.61) CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,067 $ (5) $ 1,062 $ 491 $ 8 $ 499 Cost of products sold 469 (2) 467 315 2 317 Gross profit 598 (3) 595 176 6 182 Selling, general, and administrative expenses 398 (5) 393 261 (2) 259 Research and development expenses 40 3 43 18 2 20 Restructuring and other costs 5 — 5 1 1 2 Operating income (loss) 155 (1) 154 (104) 5 (99) Other income and expenses: Interest expense, net 16 (1) 15 11 — 11 Other expense (income), net 5 3 8 5 (1) 4 Income (loss) before income taxes 134 (3) 131 (120) 6 (114) Provision (benefit) for income taxes 35 — 35 (24) 2 (22) Net income (loss) 99 (3) 96 (96) 4 (92) Less: Net income (loss) attributable to noncontrolling interest — — — (1) — (1) Net income (loss) attributable to Dentsply Sirona $ 99 $ (3) $ 96 $ (95) $ 4 $ (91) Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 0.45 $ (0.01) $ 0.44 $ (0.44) $ 0.02 $ (0.42) Diluted $ 0.45 $ (0.02) $ 0.43 $ (0.44) $ 0.02 $ (0.42) CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised Net sales $ 1,069 $ (29) $ 1,040 $ 895 $ (12) $ 883 Cost of products sold 478 (7) 471 453 (2) 451 Gross profit 591 (22) 569 442 (10) 432 Selling, general, and administrative expenses 394 1 395 315 (2) 313 Research and development expenses 35 4 39 27 2 29 Restructuring and other costs 3 — 3 18 — 18 Operating income 159 (27) 132 82 (10) 72 Interest expense, net 13 1 14 14 — 14 Other expense (income), net 8 (3) 5 1 — 1 Income before income taxes 138 (25) 113 67 (10) 57 Provision for income taxes 35 (6) 29 13 (4) 9 Net income 103 (19) 84 54 (6) 48 Net income attributable to Dentsply Sirona $ 103 $ (19) $ 84 $ 53 $ (6) $ 47 Net income per common share attributable to Dentsply Sirona: Basic $ 0.47 $ (0.08) $ 0.39 $ 0.25 $ (0.03) $ 0.22 Diluted $ 0.47 $ (0.09) $ 0.38 $ 0.25 $ (0.03) $ 0.22 CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,088 $ 15 $ 1,103 $ 1,082 $ (6) $ 1,076 Cost of products sold 495 4 499 511 (2) 509 Gross profit 593 11 604 571 (4) 567 Selling, general, and administrative expenses 374 3 377 377 (4) 373 Research and development expenses 59 (10) 49 44 (6) 38 Restructuring and other costs 6 — 6 15 — 15 Operating income 154 18 172 135 6 141 Other income and expenses: Interest expense, net 12 — 12 15 — 15 Other expense (income), net 4 — 4 (3) — (3) Income before income taxes 138 18 156 123 6 129 Provision for income taxes 36 1 37 24 — 24 Net income 102 17 119 99 6 105 Less: Net income attributable to noncontrolling interest — — — — — — Net income attributable to Dentsply Sirona $ 102 $ 17 $ 119 $ 99 $ 6 $ 105 Net income per common share attributable to Dentsply Sirona: Basic $ 0.47 $ 0.08 $ 0.55 $ 0.45 $ 0.03 $ 0.48 Diluted $ 0.47 $ 0.07 $ 0.54 $ 0.45 $ 0.03 $ 0.48 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 117 $ (5) $ 112 $ (140) $ 6 $ (134) Total comprehensive income 27 (5) 22 (252) 6 (246) Comprehensive income attributable to Dentsply Sirona $ 27 $ (5) $ 22 $ (252) $ 6 $ (246) CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 99 $ (3) $ 96 $ (96) $ 4 $ (92) Total comprehensive income 142 (3) 139 (28) 4 (24) Comprehensive income attributable to Dentsply Sirona $ 142 $ (3) $ 139 $ (28) $ 4 $ (24) CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised Net income $ 103 $ (19) $ 84 $ 54 $ (6) $ 48 Total comprehensive income 47 (19) 28 121 (6) 115 Comprehensive income attributable to Dentsply Sirona $ 47 $ (19) $ 28 $ 121 $ (6) $ 115 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 102 $ 17 $ 119 $ 99 $ 6 $ 105 Total comprehensive income 75 17 92 213 8 221 Comprehensive income attributable to Dentsply Sirona $ 75 $ 17 $ 92 $ 213 $ 8 $ 221 The correcting of these accounting errors on the Company’s previously issued Consolidated Statement of Cash Flows resulted in no changes to cash used in or provided by Operating, Investing and Financing activities for the quarterly periods of the year ended December 31, 2021. For the three months ended March 31, 2020, six months ended June 30, 2020 and nine months ended September 30, 2020 cash provided by operating activities and used in financing activities were increased by $6 million, $12 million, and $13 million, respectively.
QUARTERLY FINANCIAL INFORMATION (UNAUDITED)	2021 Net Sales Gross Profit Operating Income (Loss) Net (Loss) Income attributable to Dentsply Sirona Net (Loss) Income per Common Share - Basic Net (Loss) Income per Common Share - Diluted Cash Dividends Declared per Common Share First Quarter As previously issued $ 1,027 $ 579 $ 154 $ 117 $ 0.53 $ 0.53 $ 0.1000 Adjustment (1) — (4) (5) (0.02) (0.02) — As revised $ 1,026 $ 579 $ 150 $ 112 $ 0.51 $ 0.51 $ 0.1000 Second Quarter As previously issued $ 1,067 $ 598 $ 155 $ 99 $ 0.45 $ 0.45 $ 0.1100 Adjustment (5) (3) (1) (3) (0.01) (0.02) — As revised $ 1,062 $ 595 $ 154 $ 96 $ 0.44 $ 0.43 $ 0.1100 Third Quarter As previously issued $ 1,069 $ 591 $ 159 $ 103 $ 0.47 $ 0.47 $ 0.1100 Adjustment (29) (22) (27) (19) (0.08) (0.09) — As restated $ 1,040 $ 569 $ 132 $ 84 $ 0.39 $ 0.38 $ 0.1100 Fourth Quarter As previously issued $ 1,088 $ 593 $ 154 $ 102 $ 0.47 $ 0.47 $ 0.1100 Adjustment 15 11 18 17 0.08 0.07 — As restated $ 1,103 $ 604 $ 172 $ 119 $ 0.55 $ 0.54 $ 0.1100 Rounding, As previously issued — — — — 0.01 (0.01) — Rounding: Adjustment — — — — (0.02) 0.02 — Rounding, As revised — — — — (0.01) 0.01 — Total Year As previously issued $ 4,251 $ 2,361 $ 622 $ 421 $ 1.93 $ 1.91 $ 0.4300 Adjustment (20) (14) (14) (10) (0.05) (0.04) — As revised $ 4,231 $ 2,347 $ 608 $ 411 $ 1.88 $ 1.87 $ 0.4300 2020 Net Sales Gross Profit Operating Income (Loss) Net (Loss) Income attributable to Dentsply Sirona Net (Loss) Income per Common Share - Basic Net (Loss) Income per Common Share - Diluted Cash Dividends Declared per Common Share First Quarter As previously issued $ 874 $ 468 $ (125) $ (140) $ (0.63) $ (0.63) $ 0.1000 Adjustment 7 7 8 6 0.02 0.02 — As revised $ 881 $ 475 $ (117) $ (134) $ (0.61) $ (0.61) $ 0.1000 Second Quarter As previously issued $ 491 $ 176 $ (104) $ (95) $ (0.44) $ (0.44) $ 0.1000 Adjustment 8 6 5 4 0.02 0.02 — As revised $ 499 $ 182 $ (99) $ (91) $ (0.42) $ (0.42) $ 0.1000 Third Quarter As previously issued $ 895 $ 442 $ 82 $ 53 $ 0.25 $ 0.25 $ 0.1000 Adjustment (12) (10) (10) (6) (0.03) (0.03) — As revised $ 883 $ 432 $ 72 $ 47 $ 0.22 $ 0.22 $ 0.1000 Fourth Quarter As previously issued $ 1,082 $ 571 $ 135 $ 99 $ 0.45 $ 0.45 $ 0.1000 Adjustment (6) (4) 6 6 0.03 0.03 — As revised $ 1,076 $ 567 $ 141 $ 105 $ 0.48 $ 0.48 $ 0.1000 Rounding, As previously issued — — — — (0.01) (0.01) — Rounding, Adjustment — — — — 0.01 0.01 — Total Year As previously issued $ 3,342 $ 1,657 $ (12) $ (83) $ (0.38) $ (0.38) $ 0.4000 Adjustment (3) (1) 9 10 0.05 0.05 — As revised $ 3,339 $ 1,656 $ (3) $ (73) $ (0.33) $ (0.33) $ 0.4000

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II DENTSPLY SIRONA INC. AND SUBSIDIARIES VALUATION AND QUALIFYING ACCOUNTS FOR THE YEARS ENDED DECEMBER 31, 2021, 2020, and 2019 Additions Description Balance at Beginning of Period Charged (Credited) To Costs And Expenses Charged to Other Accounts Write-offs Net of Recoveries Translation Adjustment Balance at End of Period (in millions) Allowance for doubtful accounts: For the Year Ended December 31, 2019 $ 25 $ 10 $ 1 $ (6) $ (1) $ 29 2020 29 1 (2) (12) 2 18 2021 18 2 (3) (2) (2) 13 Inventory valuation reserve: For the Year Ended December 31, 2019 $ 93 $ 8 $ — $ (16) $ — $ 85 2020 85 62 — (33) 3 117 2021 117 17 — (41) (7) 86 Deferred tax asset valuation allowance: For the Year Ended December 31, 2019 $ 288 $ 8 $ — $ (6) $ (2) $ 288 2020 288 (5) — (2) 6 287 2021 287 (10) — (3) (7) 267

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ materially from those estimates. Specifically, for the year ended December 31, 2021, some of these estimates and assumptions continue to be based on an ongoing evaluation of expected future impacts from the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly have a negative material impact on the Company’s financial condition, liquidity, or results of operations in future periods is highly uncertain and difficult to predict. More specifically, the demand for the Company’s products has been, and continues to be, affected by social distancing guidelines, dental practice safety protocols which reduce patient traffic, and some lingering patient reluctance to seek dental care. The Company’s 2020 results were materially impacted by the preventative measures implemented at the outset of the pandemic, including the closure or reduced operations of dental practices. During 2021, demand for the Company’s products has largely recovered, although impacts from the pandemic continue to be experienced as evidenced by the more recent shortages and higher prices of raw materials such as electronic components, higher related transportation costs, and labor shortages. In the current year, the Company has experienced supply chain constraints, which has impacted its ability to timely produce and deliver certain products, and has also resulted in increases in shipping rates. To address these issues, the Company has taken steps to mitigate the impact of these trends, including continued emphasis on cost reduction and supply chain efficiencies. However, uncertainties remain regarding how long these impacts will continue, whether customer demand will fully return to pre-COVID-19 levels upon lifting of remaining government restrictions, or whether future variants of the virus may have an adverse impact on demand in affected markets.
Principles of Presentation	The consolidated financial statements include the results of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. The consolidated financial statements include corrections of previously issued statements which are presented below for annual periods and in Note 23 for quarterly periods. Additi onally, research and development (“R&D”) expenses for the years ended December 31, 2020 and 2019 have been separately presented on the Consolidated Statement of Operations to conform to the current year presentation.
Cash and Cash Equivalents	Cash and cash equivalents include deposits with banks as well as highly liquid time deposits with original maturities of ninety days or less.
Short-term Investments	Short-term investments are highly liquid time deposits with original maturities greater than ninety days and with remaining maturities of one year or less.
Accounts Receivable	The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction. Payment terms are typically 30 days in the U.S. but may be longer in international markets. In general, contracts containing significant financing components are not material to the Company’s financial statements. The Company establishes an allowance for doubtful accounts based on an estimate of current expected credit losses resulting from the inability of its customers to make required payments. The allowance is determined based on a combination of factors, including the length of time that the receivable is past due, history of write-offs, and the Company’s knowledge of circumstances relating to specific customers’ ability to meet their financial obligations. Provision for doubtful accounts are included in Selling, general and administrative expenses in the Consolidated Statements of Operations. For customers on credit terms, the Company performs ongoing credit evaluation of those customers’ financial condition and generally does not require collateral from them.
Inventories	Inventories are stated at the lower of cost and net realizable value. The cost of inventories is based upon the First In First Out Method (“FIFO”) or average cost methods, except for $3 million and $5 million of inventories that was determined by the last-in, first-out (“LIFO”) method as of December 31, 2020 and 2019, respectively. During the current fiscal year 2021, the method of accounting for these inventories was changed from LIFO to FIFO. This change in accounting is preferable as the value of inventory for which cost was previously determined using a LIFO cost flow assumption has declined from prior years due to changes in the business, and it also allows for a more consistent methodology being utilized across the Company, and provides improved comparability with industry peers. This change in accounting principle was effected during the second quarter, and resulted in an increase in inventories of $4 million and a corresponding reduction to Cost of products sold. The impact of this change was not material to the Company’s financial position as of December 31, 2020, the Company’s results of operations for any previously reported prior year nor is the cumulative effect of the change material to the results of operations for the year ended December 31, 2021. Therefore, prior year amounts have not been retrospectively adjusted. The Company establishes reserves for inventory estimated to be excess, obsolete or unmarketable based upon assumptions about future demand, market conditions, and expiration of products.
Valuation of Goodwill and Indefinite-Lived Intangible Assets	Effective 2021 and prospectively, the Company is performing its required annual goodwill impairment test as of April 1 rather than as of April 30 which was the Company’s previous practice. The Company believes this change is preferable as it more closely aligns with the timing of the Company’s strategic business planning process. This change did not result in any delay, acceleration or avoidance of impairment. Furthermore, a retrospective application to prior periods is impracticable as the Company is unable to objectively determine, without the use of hindsight, the assumptions which would be used in earlier periods. The following information outlines the Company’s significant accounting policies on long-lived assets by type. Goodwill Goodwill is the excess of the purchase price over the fair value of identifiable net assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. The Company conducts an impairment test as of April 1 of each year, or more frequently if events or circumstances indicate that the carrying value of goodwill may be impaired. This impairment assessment includes an evaluation of reporting units, which the Company has determined are either an operating segment or one level below its operating segments, as determined in accordance with ASC 350. The Company performs impairment tests by comparing the fair value of each reporting unit to its carrying amount to determine if there is a potential impairment. If the carrying value of a reporting unit with goodwill exceeds its fair value, an impairment charge is recognized for the excess amount. To determine the fair value of the Company’s reporting units, the Company uses a discounted cash flow model as its valuation technique to measure the fair value for its reporting units. The discounted cash flow model uses five- to ten-year forecasted cash flows plus a terminal value based on capitalizing the last period’s cash flows using a perpetual growth rate. The Company’s significant assumptions in the discounted cash flow models include, but are not limited to, the discount rates, revenue growth rates, perpetual revenue growth rates, and operating margin percentages of the reporting unit’s business. The Company considers the current market conditions when determining its assumptions. Lastly, the Company reconciles the aggregate fair values of its reporting units to its market capitalization, which include a reasonable control premium based on market conditions. Additional information related to the testing for goodwill impairment including results of the annual test performed at April 1, 2021 is provided in Note 12, Goodwill and Intangible Assets. Indefinite-Lived Intangible Assets Indefinite-lived intangible assets consists primarily of tradenames and trademarks and in-process research and development acquired during business combinations, and these are not subject to amortization. Valuations of indefinite life intangibles assets acquired are based on information and assumptions available at the time of their acquisition, using income and market approaches to determine fair value. The Company conducts an impairment test as of April 1 of each year, or more frequently if events or circumstances indicate that the carrying value of indefinite-lived intangible assets may be impaired. Potential impairment is identified by comparing the fair value of an intangible asset to its carrying value. For most indefinite-lived intangible assets, the Company performs impairment tests using an income approach, more specifically a relief from royalty method. In the development of the forecasted cash flows, the Company applies significant judgment to determine key assumptions, including revenue growth rates, perpetual revenue growth rates, royalty rates, and discount rates. For certain indefinite-lived intangible assets, the Company performs a qualitative assessment. If the carrying value exceeds the fair value, an impairment loss in the amount equal to the excess is recognized. Additional information related to the testing for indefinite-lived intangible asset impairment including results of the annual test performed at April 1, 2021 is provided in Note 12, Goodwill and Intangible Assets. Definite-Lived Intangible Assets Definite-lived intangible assets primarily consist of patents, tradenames, trademarks, licensing agreements, developed technology, and customer relationships. Valuation of definite-lived intangibles assets acquired in business combinations are based on information and assumptions available at the time of acquisition, using income and market model approaches to determine fair value. Identifiable definite-lived intangible assets are amortized on a basis that best reflects how their economic benefits are utilized over the life of the asset or on a straight-line basis if not materially different from actual utilization. The useful life is the period over which the asset is expected to contribute to the future cash flows of the Company. The Company uses the following useful lives for its definite-lived intangible assets: Definite-lived Intangible Asset Type Useful Life Patents Up to date patent expires Tradenames and trademarks Up to 20 years Licensing agreements Up to 20 years Customer relationships Up to 15 years Developed technology Up to 15 years When the expected useful life of an intangible is not known, the Company will estimate its useful life based on similar asset or asset groups, any legal, regulatory, or contractual provision that limits the useful life, the effect of economic factors, including obsolescence, demand, competition, and the level of maintenance expenditures required to obtain the expected future economic benefit from the asset. These assets are reviewed for impairment whenever events or circumstances suggest that the carrying amount of the asset may not be recoverable. The Company closely monitors all intangible assets, including those related to new and existing technologies, for indicators of impairment as these assets have more risk of becoming impaired. Impairment is based upon an initial evaluation of the identifiable undiscounted cash flows. If the initial evaluation identifies a potential impairment, a fair value of the asset is determined by using a discounted cash flows valuation. If impaired, the resulting charge reflects the excess of the asset’s carrying cost over its fair value.
Property, Plant and Equipment	Property, plant and equipment are stated at cost, net of accumulated depreciation. Assets acquired through acquisitions are recorded at fair value . The Company capitalizes costs incurred in the development or acquisition of software, whether for internal or external use. The Company expenses costs incurred in the preliminary project planning stage. E xcept for leasehold improvements, depreciation and amortization is computed by the straight-line method over the assets’ estimated useful lives: Property, Plant, and Equipment Assets Type Useful Life Buildings 40 years Machinery and Equipment 4 to 15 years Capitalized Software 2 to 10 years Leasehold Improvements Shorter of the estimated useful life or the term of the lease Maintenance and repairs are expensed as incurred; replacements and major improvements are capitalized. If events or circumstances exist which suggest that the carrying amount of the asset group may not be recoverable, the identifiable undiscounted cash flows of the asset group are compared to the carrying value of the asset. If the carrying value is in excess of the identifiable undiscounted cash flows, the excess of the asset group’s carrying cost over its fair value is recorded as an impairment charge.
Leases	In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) with subsequent amendments (collectively, “ASC 842”). The Company adopted the new leasing standards on January 1, 2019 using the modified retrospective approach transition method. The Company leases real estate, automobiles and equipment under various operating and finance leases. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the implicit rate is not readily determinable in most of the Company’s lease agreements, the Company uses its estimated secured incremental borrowing rate, based on the information available, at commencement of the lease to determine the present value of lease payments. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Beginning January 1, 2019, any new real estate and equipment operating lease agreements with lease and non-lease components, were accounted for as a single lease component; auto leases were accounted for as separate lease components. The Company determines if an arrangement is a lease or contains a lease at inception. The Company’s leases have remaining lease terms of approximately 1 year to 10 years. Many of the Company’s real estate and equipment leases have one or more options to renew, with terms that can extend primarily from 1 year to 3 years, which are not included in the initial lease term until deemed probable of renewal. The Company does not have lease agreements with residual value guarantees, sale-and-leaseback terms, or material restrictive covenants. The Company does not have any material sublease arrangements.
Derivative Financial Instruments	The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, and assets and liabilities denominated in foreign currencies. Additionally, the Company manages exposures to changes in interest rates by utilizing interest rate swaps that have the effect of converting floating rate debt to fixed rate, or vice versa. The Company records all derivative instruments at fair value and changes in fair value are recorded each period in the consolidated statements of operations or accumulated other comprehensive income (“AOCI”). The Company classifies derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less. The Company has elected to classify the cash flow from derivative instruments in the same category as the cash flows from the items being hedged. Should the Company enter into a derivative instrument that included an other-than-insignificant financing element then all cash flows will be classified as financing activities in the Consolidated Statements of Cash Flows as required by US GAAP. See Note 20, Financial Instruments for additional information on derivative instruments.
Pension and Other Postemployment Benefits	Some of the employees of the Company and its subsidiaries are covered by government or Company-sponsored defined benefit plans and defined contribution plans. Additionally, certain union and salaried employee groups in the United States are covered by postemployment healthcare plans. Projected benefit obligations and net periodic costs for Company-sponsored defined benefit and postemployment benefit plans are based on an annual actuarial valuation that includes assessment of key assumptions relating to expected return on plan assets, discount rates, employee compensation increase rates and health care cost trends. Expected return on plan assets, discount rates and health care cost trend assumptions are particularly important when determining the Company’s benefit obligations and net periodic benefit costs associated with postemployment benefits. Changes in these assumptions can impact the Company’s earnings. In determining the cost of postemployment benefits, certain assumptions are established annually to reflect market conditions and plan experience to appropriately reflect the expected costs as determined by actuaries. These assumptions include medical inflation trend rates, discount rates, employee turnover and mortality rates. The Company predominantly uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate bond yields in the respective economic regions of the plans. The expected return on plan assets is the weighted average long-term expected return based upon asset allocations and historic average returns for the markets where the assets are invested, principally in foreign locations. The Company reports the funded status of its defined benefit pension and other postemployment benefit plans on its consolidated balance sheets as a net liability or asset.
Accruals for Self-Insured Losses	The Company maintains insurance for certain risks, including workers’ compensation, and is self-insured for employee related healthcare benefits. The Company accrues for the expected costs associated with these risks by considering historical claims experience, demographic factors, severity factors and other relevant information. Costs are recognized in the period the claim is incurred, and the financial statement accruals include an estimate of claims incurred but not yet reported. The Company has stop-loss coverage to limit its exposure to any significant exposure on a per claim basis.
Litigation	The Company and its subsidiaries, from time to time, are parties to lawsuits arising from operations. The Company records liabilities when a loss is probable and can be reasonably estimated. If these estimates are in the form of ranges, the Company records the liabilities at the most likely outcome within the range. If no point within the range represents a better estimate of the probable loss, then the low point in the range is accrued. The ranges established by management are based on analysis made by internal and external legal counsel who considers the best information known at the time. If the Company determines that a contingency is reasonably possible, it considers the same information to estimate the possible exposure and discloses any material potential liability. These loss contingencies are monitored regularly for a change in fact or circumstance that would require an accrual adjustment. Legal costs related to these lawsuits are expensed as incurred.
Foreign Currency Translation	The local currency of foreign operations, except for those in highly inflationary economies, generally are considered to be their functional currency. Assets and liabilities of foreign subsidiaries are translated at foreign exchange rates on the balance sheet date; revenue and expenses are translated at the monthly average foreign exchange rates. The effects of these translation adjustments are reported within AOCI in the Consolidated Balance Sheets. During the year ended December 31, 2021, the Company had translation loss of $225 million and a gain of $46 million on its loans designated as hedges of net investments. During the year ended December 31, 2020, the Company had translation gains of $235 million and losses of $54 million on its loans designated as hedges of net investments. Foreign currency gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved are included within Other expense (income), net in the Consolidated Statements of Operations.
Revenue Recognition	Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services in accordance with ASC 606-10, Revenues from Contracts with Customers . Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of products and services to its customers, which for products generally occurs when title and risk of loss transfers to the customer, and for services generally occurs as the customer receives and consumes the benefit. Sales, value-added, and other taxes collected concurrent with revenue-producing activities are excluded from revenue. Certain of our contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately may require significant judgment. The Company generally uses an observable price, typically average selling price, to determine the stand-alone selling price for separate performance obligations. The Company determines the stand-alone selling price, based on Company geographic sales locations’ database of pricing and discounting practices for the specific product or service when sold separately, and utilizes this data to arrive at average selling prices by product. In cases where an average selling price is not observable, the Company determines the stand-alone selling price using relevant information and applies suitable estimation methods including, but not limited to, the cost plus a margin approach. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each distinct performance obligation. The Company exercises judgment in estimating variable consideration, which primarily includes volume discounts, sales rebates, and product returns. The Company adjusts the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed. The Company estimates volume discounts by evaluating specific inputs and assumptions, including the individual customer’s historical and estimated future product purchases. Discounts are deducted from revenue at the time of sale or when the discount is offered, whichever is later. In estimating sales rebates, the Company evaluates inputs such as customer-specific trends, terms of the customers’ contracted rebate program, historical experience, and the forecasted performance of a customer and their expected level of achievement within the rebate programs. The accruals for these rebate programs are updated as actual results and updated forecasts impact the estimated achievement for customers within the rebate programs. When the Company gives customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are not material. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. For most of its products, the Company transfers control and recognizes revenue when products are shipped from the Company’s manufacturing facility or warehouse to the customer. For contracts with customers that contain destination shipping terms, revenue is not recognized until the goods are delivered to the agreed upon destination. As such, the Company’s performance obligations related to product sales are satisfied at a point in time as this is when the customer obtains the use of and substantially all of the benefit of the product. The Company recognizes revenue from support and maintenance contracts, extended warranties, and other certain contract performance obligations over time based on the period of the contracts or as the services are performed, as the customer simultaneously receives and consumes the benefits provided by the Company’s performance of the services. In general, the total amount of revenue recognized over time is not material to the Company’s financial statements. Depending on the terms of its contracts, the Company may defer the recognition of a portion of revenue on a relative stand-alone selling price basis when certain performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. The Company has elected to account for shipping and handling activities as a fulfillment cost within the cost of products sold, and records shipping and handling costs collected from customers in net sales. The Company has adopted one practical expedient: relief from considering the existence of a significant financing component when the payment for the good or service is expected to be one year or less.
Cost of Products Sold	Cost of products sold represents costs directly related to the manufacture and distribution of the Company’s products, and include costs of raw materials, packaging, direct labor, overhead, shipping and handling, warehousing and the depreciation of manufacturing, warehousing and distribution facilities and amortization of intangible assets. Overhead and related expenses include salaries, wages, employee benefits, utilities, lease costs, maintenance and property taxes.
Warranties	The Company provides manufacturer’s warranties on certain equipment products. Estimated warranty costs are accrued when sales are made to customers. Estimates for warranty costs are based primarily on historical warranty claim experience. Warranty costs are included in Cost of products sold in the Consolidated Statements of Operations.
Selling, General and Administrative Expenses	Selling, general and administrative expenses (“SG&A”) represent indirect costs associated with generating revenues and in managing the business of the Company. Such costs include advertising and marketing expenses, salaries, employee benefits, incentive compensation, travel, office expenses, lease costs, amortization of capitalized software developed for internal use, and depreciation of administrative facilities. Advertising cost are expensed as incurred.
Research and Development Costs	Research and development (“R&D”) costs primarily include costs associated with developing products, including software. These costs include internal labor costs, material costs, consulting expenses, and certain overheads, such as facilities and information technology costs. In addition, the Company contracts with outside vendors to conduct R&D activities. All costs incurred prior to feasibility of technology are expensed. The Company capitalizes the costs of equipment that have general R&D uses and expenses any equipment that is solely for specific R&D projects. The depreciation expense related to capitalized equipment, including any software directly supporting R&D activities is included in the Company’s R&D costs. Software development costs related to software to be sold, leased, or otherwise marketed incurred prior to the attainment of technological feasibility are considered R&D and are expensed as incurred. Once technological feasibility is established, the cost of software developed for external use is capitalized until the product is available for general release to customers. Amortization of these costs are included in Cost of products sold over the estimated life of the products.
Stock Compensation	Stock-based compensation is measured at the grant date at fair value, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity awards). The compensation cost is only recognized for the portion of the awards that are expected to vest. Stock options granted become exercisable as determined by the grant agreement and expire ten years after the date of grant under these plans. Restricted Stock Units (“RSU”) vest as determined by the grant agreement and are subject to a service condition, which requires grantees to remain employed by the Company during the period following the date of grant. Under the terms of the RSUs, the vesting period is referred to as the restricted period. In addition to the service condition, certain granted RSUs are subject to performance requirements that can vary between the first year and up to the final year of the RSU award. If targeted performance is not met the RSU granted is adjusted to reflect the achievement level. Upon the expiration of the applicable restricted period and the satisfaction of all conditions imposed, the restrictions on RSUs will lapse, and shares of common stock will be issued as payment for each vested RSU. Upon death, disability or qualified retirement all awards become immediately exercisable for up to one year. Awards are expensed as compensation over their respective vesting periods or to the eligible retirement date if shorter. The Company records forfeitures on stock-based compensation as the participant terminates rather than estimating forfeitures. During 2019, the Company granted certain performance-based RSUs issued under the 2016 Omnibus Incentive Plan to provide performance targets for the Company’s previously disclosed three year restructuring program announced in November 2018. The adjusted operating income margin performance target approximates the adjusted operating income margin targets previously disclosed by the Company as part of its effort to support revenue growth and margin expansion. The performance period began on January 1, 2019 and concludes on December 31, 2022. Under this program the Company could issue up to 3 million shares of common stock if all performance targets are met within the period. See Note 16 Equity for more information.
Income Taxes	The Company’s tax expense includes U.S. and international income taxes plus the provision for U.S. taxes on undistributed earnings of international subsidiaries not deemed to be permanently invested. Tax credits and other incentives reduce tax expense in the year the credits are claimed. Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. Deferred tax assets are recognized if it is more likely than not that the assets will be realized in future years. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely. The Company applies a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company recognizes in the consolidated financial statements the impact of a tax position if that position is more likely than not of being sustained upon examination by the taxing authorities based on the technical merits of the position. The Company’s tax positions are subject to ongoing examinations by the tax authorities. The Company operates within multiple taxing jurisdictions throughout the world and in the normal course of business is examined by taxing authorities in those jurisdictions. Adjustments to the uncertain tax positions are recorded when taxing authority examinations are completed, statutes of limitation are closed, changes in tax laws occur or as new information comes to light with regard to the technical merits of the tax position.
Earnings Per Share	Basic earnings per share are calculated by dividing net earnings attributable to Company’s shareholders by the weighted average number of shares outstanding for the period. Diluted earnings per share is calculated by dividing net earnings attributable to Company’s shareholders by the weighted average number of shares outstanding for the period, adjusted for the effect of an assumed exercise of all dilutive options outstanding at the end of the period, unless the impact of including these options is anti-dilutive.
Business Acquisitions	The Company acquires businesses as well as partial interests in businesses. Acquired businesses are accounted for using the acquisition method of accounting which requires the Company to record assets acquired and liabilities assumed at their respective fair values with the excess of the purchase price over estimated fair values recorded as goodwill. The Company obtains information during due diligence and through other sources to establish respective fair values. Examples of factors and information that the Company uses to determine the fair values include: tangible and intangible asset valuations and appraisals, and evaluations of existing contingencies, liabilities, and product line information. If the initial valuation for an acquisition is incomplete by the end of the reporting period in which the acquisition occurred, the Company will record provisional estimates in the financial statements. The provisional estimates will be finalized as soon as information becomes available, but not later than one year from the acquisition date. As part of purchase accounting for acquisitions, the Company values identified intangible assets using an income approach. Technology know-how is valued using an excess earnings method. Tradename and trademark assets are valued using a relief-from-royalty method. Non-compete agreements are valued using a with-and-without method. The Company applies judgment in estimating the fair value of intangible assets acquired, which involves the use of estimates and assumptions with respect to revenue growth rates, EBITDA margin percentages, royalty rate, technology obsolescence factors, useful lives of the assets and discount rates used in computing present values. In addition, the estimates of useful lives of these acquired intangibles are used to calculate depreciation and amortization expense. For additional information related to accounting for acquisitions, see Note 6, Business Combinations.
Investments in Unconsolidated Affiliates	Investments in non-consolidated affiliates, joint ventures and partnerships where the Company maintains significant influence over an entity, but does not have control are accounted for using the equity method. The Company records the carrying value of these investments within Other noncurrent assets in the Consolidated Balance Sheets, and records the Company’s proportional share of the investees’ net earnings or losses within Other expense (income). Investments in which the Company does not exercise significant influence are recorded at cost, and assessed for any other-than-temporary impairment when events or changes in circumstances indicate the carrying amount of the investment might not be recoverable.
Noncontrolling Interests	The Company reports noncontrolling interest (“NCI”) in a subsidiary as a separate component of Equity in the Consolidated Balance Sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the Consolidated Statements of Operations, and in the Consolidated Statements of Comprehensive Income.
Segment Reporting	The Company has numerous operating businesses covering a wide range of products and geographic regions, primarily serving the professional dental market and to a lesser extent the consumable medical device market. The Company has two reportable segments and a description of the activities within these segments is included in Note 7, Segment and Geographic Information.
Fair Value Measurement	Recurring Basis The Company records certain financial assets and liabilities at fair value in accordance with the accounting guidance, which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date in current markets. The accounting guidance establishes a hierarchical disclosure framework associated with the level of pricing observability utilized in measuring financial instruments at fair value. The three broad levels defined by the fair value hierarchy are as follows: Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reported date. Level 2 - Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reported date. These financial instruments include derivative instruments whose fair value have been derived using a model where inputs to the model are directly observable in the market or can be derived principally from, or corroborated by observable market data. Level 3 - Instruments that have little to no pricing observability as of the reported date. These financial instruments do not have two-way markets and are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment or estimation. The degree of judgment utilized in measuring the fair value of certain financial assets and liabilities generally correlates to the level of pricing observability. Pricing observability is impacted by a number of factors, including the type of financial instrument. Financial assets and liabilities with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of pricing observability and a lesser degree of judgment utilized in measuring fair value. Conversely, financial assets and liabilities rarely traded or not quoted will generally have less, or no pricing observability and a higher degree of judgment utilized in measuring fair value. The Company primarily applies the market approach for recurring fair value measurements and endeavors to utilize the best available information. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Additionally, the Company considers its credit risks and its counterparties’ credit risks when determining the fair values of its financial assets and liabilities. The Company records its derivatives and contingent considerations on a recurring fair value basis. The Company believes the carrying amounts of cash and cash equivalents, accounts receivable (net of allowance for doubtful accounts), prepaid expenses and other current assets, accounts payable, accrued liabilities, income taxes payable and notes payable approximate fair value due to the short-term nature of these instruments. The Company has presented the required disclosures in Note 21, Fair Value Measurement. Non-Recurring Basis When events or circumstances require an asset or liability to be measured at fair valued that otherwise is generally recorded based on another valuation method, such as, net realizable value, the Company will utilize the valuation techniques described above. The Company records its business combinations and impairments on a non-recurring basis.
Recently Adopted Accounting Pronouncements and Accounting Standards Not Yet Adopted	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13 “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” This newly issued accounting standard changes the recognition and measurement of credit losses, including trade accounts receivable. Under current accounting standards, a loss is recognized when loss becomes probable of occurring. The new standard broadens the information that an entity must consider when developing expected credit loss estimates. The amendments in this update are effective for the fiscal years and interim periods ending after December 15, 2019. Early adoption is permitted. The amendments in this update should be applied on a prospective basis for all periods presented with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company adopted this accounting standard on January 1, 2020. The adoption of this standard did not materially impact the Company’s consolidated financial statements or related disclosures. In August 2018, the FASB issued ASU No. 2018-14 “Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans.” This newly issued accounting standard changes disclosure requirements for defined benefit plans, including removal and modification of existing disclosures. The amendments in this update are effective for the fiscal years ending after December 15, 2020. Early adoption is permitted. The amendments in this update should be applied on a retrospective basis for all periods presented. The Company adopted this accounting standard on January 1, 2020. The adoption of this standard did not materially impact the Company’s disclosures. In December 2019, the FASB issued ASU No. 2019-12 “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” This newly issued accounting standard simplifies key provisions for accounting for income taxes, as part of the FASB’s initiative to reduce complexity in accounting standards. The amendments eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments also clarify and simplify other aspects of the accounting for income taxes. The amendments in this update are effective for interim and fiscal period beginning after December 31, 2020. The Company adopted this accounting standard on January 1, 2020. The adoption of this standard did not materially impact the Company’s consolidated financial statements or related disclosures. Accounting Pronouncements Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04 “Reference Rate Reform (Topic 828), Facilitation of the Effects of Reference Rate Reform on Financial Reporting”, which was subsequently amended by ASU No. 2021-01 “Reference Rate Reform (Topic 848): Scope” in January 2021. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate (“LIBOR”) or another rate expected to be discontinued due to the reference rate reform. This standard is permitted to be adopted any time through December 31, 2022, and does not apply to contract modifications made or hedging relationships entered into or evaluated after December 31, 2022. The Company does not expect this standard to have a material impact on its consolidated financial statements and related disclosures. In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers , as if it had originated the contracts. The current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value differs from the current approach. This standard is effective for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following tables present the effect of correcting these accounting errors on the Company’s previously issued financial statements: CONSOLIDATED STATEMENTS OF OPERATIONS Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions, except per share amounts) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Net sales $ 4,251 $ (20) $ 4,231 $ 3,342 $ (3) $ 3,339 $ 4,029 $ (7) $ 4,022 Cost of products sold 1,890 (6) 1,884 1,685 (2) 1,683 1,864 (6) 1,858 Gross profit 2,361 (14) 2,347 1,657 (1) 1,656 2,165 (1) 2,164 Selling, general, and administrative expenses 1,551 — 1,551 1,312 (10) 1,302 1,580 7 1,587 Research and development expenses 171 — 171 123 — 123 143 — 143 Goodwill impairment — — — 157 — 157 — — — Restructuring and other costs 17 — 17 77 — 77 81 — 81 Operating income (loss) 622 (14) 608 (12) 9 (3) 361 (8) 353 Other income and expenses: Interest expense, net 55 — 55 47 (1) 46 28 (1) 27 Other expense (income), net 8 — 8 1 — 1 (12) — (12) Income (loss) before income taxes 559 (14) 545 (60) 10 (50) 345 (7) 338 Provision for income taxes 138 (4) 134 23 — 23 82 — 82 Net income (loss) 421 (10) 411 (83) 10 (73) 263 (7) 256 Less: Net income (loss) attributable to noncontrolling interests — — — — — — — — — Net income (loss) attributable to Dentsply Sirona $ 421 $ (10) $ 411 $ (83) $ 10 $ (73) $ 263 $ (7) $ 256 Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 1.93 $ (0.05) $ 1.88 $ (0.38) $ 0.05 $ (0.33) $ 1.18 $ (0.03) $ 1.15 Diluted $ 1.91 $ (0.04) $ 1.87 $ (0.38) $ 0.05 $ (0.33) $ 1.17 $ (0.03) $ 1.14 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Net income (loss) $ 421 (10) $ 411 $ (83) 10 $ (73) $ 263 (7) $ 256 Pension liability adjustments 26 — 26 (13) — (13) (36) 10 (26) Total other comprehensive (loss) income (130) — (130) 137 2 139 (120) 10 (110) Total comprehensive income 291 (10) 281 54 12 66 143 3 146 Comprehensive income attributable to Dentsply Sirona 293 (10) 283 53 12 65 142 3 145 CONSOLIDATED BALANCE SHEETS December 31, 2021 December 31, 2020 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Accounts and notes receivable-trade, net $ 747 $ 3 $ 750 $ 673 $ (6) $ 667 Inventories, net 504 11 515 466 10 476 Prepaid expenses and other current assets 247 1 248 214 3 217 Total Current Assets 1,837 15 1,852 1,791 7 1,798 Operating lease right-of-use assets, net 193 5 198 176 — 176 Other noncurrent assets 122 (1) 121 94 1 95 Total Assets 9,220 19 9,239 9,342 8 9,350 Accounts payable 268 (6) 262 305 (3) 302 Accrued liabilities 679 81 760 653 59 712 Income taxes payable 57 — 57 60 (1) 59 Total Current Liabilities 1,186 75 1,261 1,317 55 1,372 Operating lease liabilities 145 4 149 130 — 130 Deferred income taxes 408 (17) 391 393 (12) 381 Total Liabilities 4,177 65 4,242 4,372 43 4,415 Retained earnings 1,560 (46) 1,514 1,233 (35) 1,198 Total Dentsply Sirona Equity 5,042 (46) 4,996 4,967 (35) 4,932 Total Equity 5,043 (46) 4,997 4,970 (35) 4,935 Total Liabilities and Equity 9,220 19 9,239 9,342 8 9,350 CONSOLIDATED STATEMENT OF CASH FLOWS Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Cash flows from operating activities: Net income (loss) $ 421 $ (10) $ 411 $ (83) $ 10 $ (73) $ 263 $ (7) $ 256 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Deferred income taxes (20) (5) (25) (64) 2 (62) (37) (3) (40) Other non-cash (income) expense 34 — 34 2 1 3 (6) 12 6 Changes in operating assets and liabilities, net of acquisitions: Accounts and notes receivable-trade, net (109) (8) (117) 126 5 131 (91) 1 (90) Inventories, net (63) (1) (64) 124 (1) 123 14 (3) 11 Prepaid expenses and other current assets, net (35) 3 (32) 42 (3) 39 13 (1) 12 Accounts payable (46) (3) (49) (23) (5) (28) 26 1 27 Accrued liabilities 78 22 100 (17) 7 (10) 45 14 59 Income taxes 17 — 17 (39) (2) (41) (16) 2 (14) Other noncurrent liabilities 10 2 12 (15) — (15) (2) (10) (12) Net cash provided by operating activities 657 — 657 635 14 649 633 6 639 Cash flows from financing activities: Other financing activities, net (36) — (36) (12) (14) (26) (34) (6) (40) Net cash (used in) provided by financing activities (379) — (379) 490 (14) 476 (466) (6) (472) The following tables present the effect of correcting the Company’s previously issued quarterly financial statements for the accounting errors described in Note 1, Significant Accounting Policies and Restatement: CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,027 $ (1) $ 1,026 $ 874 $ 7 $ 881 Cost of products sold 448 (1) 447 406 — 406 Gross profit 579 — 579 468 7 475 Selling, general, and administrative expenses 385 1 386 359 (2) 357 Research and development expenses 37 3 40 34 2 36 Goodwill impairment — — — 157 — 157 Restructuring and other costs 3 — 3 43 (1) 42 Operating income (loss) 154 (4) 150 (125) 8 (117) Other income and expenses: Interest expense, net 14 — 14 7 (1) 6 Other expense (income), net (9) — (9) (2) 1 (1) Income (loss) before income taxes 149 (4) 145 (130) 8 (122) Provision for income taxes 32 1 33 10 2 12 Net income (loss) 117 (5) 112 (140) 6 (134) Less: Net income (loss) attributable to noncontrolling interest — — — — — — Net income (loss) attributable to Dentsply Sirona $ 117 $ (5) $ 112 $ (140) $ 6 $ (134) Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 0.53 $ (0.02) $ 0.51 $ (0.63) $ 0.02 $ (0.61) Diluted $ 0.53 $ (0.02) $ 0.51 $ (0.63) $ 0.02 $ (0.61) CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,067 $ (5) $ 1,062 $ 491 $ 8 $ 499 Cost of products sold 469 (2) 467 315 2 317 Gross profit 598 (3) 595 176 6 182 Selling, general, and administrative expenses 398 (5) 393 261 (2) 259 Research and development expenses 40 3 43 18 2 20 Restructuring and other costs 5 — 5 1 1 2 Operating income (loss) 155 (1) 154 (104) 5 (99) Other income and expenses: Interest expense, net 16 (1) 15 11 — 11 Other expense (income), net 5 3 8 5 (1) 4 Income (loss) before income taxes 134 (3) 131 (120) 6 (114) Provision (benefit) for income taxes 35 — 35 (24) 2 (22) Net income (loss) 99 (3) 96 (96) 4 (92) Less: Net income (loss) attributable to noncontrolling interest — — — (1) — (1) Net income (loss) attributable to Dentsply Sirona $ 99 $ (3) $ 96 $ (95) $ 4 $ (91) Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 0.45 $ (0.01) $ 0.44 $ (0.44) $ 0.02 $ (0.42) Diluted $ 0.45 $ (0.02) $ 0.43 $ (0.44) $ 0.02 $ (0.42) CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised Net sales $ 1,069 $ (29) $ 1,040 $ 895 $ (12) $ 883 Cost of products sold 478 (7) 471 453 (2) 451 Gross profit 591 (22) 569 442 (10) 432 Selling, general, and administrative expenses 394 1 395 315 (2) 313 Research and development expenses 35 4 39 27 2 29 Restructuring and other costs 3 — 3 18 — 18 Operating income 159 (27) 132 82 (10) 72 Interest expense, net 13 1 14 14 — 14 Other expense (income), net 8 (3) 5 1 — 1 Income before income taxes 138 (25) 113 67 (10) 57 Provision for income taxes 35 (6) 29 13 (4) 9 Net income 103 (19) 84 54 (6) 48 Net income attributable to Dentsply Sirona $ 103 $ (19) $ 84 $ 53 $ (6) $ 47 Net income per common share attributable to Dentsply Sirona: Basic $ 0.47 $ (0.08) $ 0.39 $ 0.25 $ (0.03) $ 0.22 Diluted $ 0.47 $ (0.09) $ 0.38 $ 0.25 $ (0.03) $ 0.22 CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,088 $ 15 $ 1,103 $ 1,082 $ (6) $ 1,076 Cost of products sold 495 4 499 511 (2) 509 Gross profit 593 11 604 571 (4) 567 Selling, general, and administrative expenses 374 3 377 377 (4) 373 Research and development expenses 59 (10) 49 44 (6) 38 Restructuring and other costs 6 — 6 15 — 15 Operating income 154 18 172 135 6 141 Other income and expenses: Interest expense, net 12 — 12 15 — 15 Other expense (income), net 4 — 4 (3) — (3) Income before income taxes 138 18 156 123 6 129 Provision for income taxes 36 1 37 24 — 24 Net income 102 17 119 99 6 105 Less: Net income attributable to noncontrolling interest — — — — — — Net income attributable to Dentsply Sirona $ 102 $ 17 $ 119 $ 99 $ 6 $ 105 Net income per common share attributable to Dentsply Sirona: Basic $ 0.47 $ 0.08 $ 0.55 $ 0.45 $ 0.03 $ 0.48 Diluted $ 0.47 $ 0.07 $ 0.54 $ 0.45 $ 0.03 $ 0.48 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 117 $ (5) $ 112 $ (140) $ 6 $ (134) Total comprehensive income 27 (5) 22 (252) 6 (246) Comprehensive income attributable to Dentsply Sirona $ 27 $ (5) $ 22 $ (252) $ 6 $ (246) CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 99 $ (3) $ 96 $ (96) $ 4 $ (92) Total comprehensive income 142 (3) 139 (28) 4 (24) Comprehensive income attributable to Dentsply Sirona $ 142 $ (3) $ 139 $ (28) $ 4 $ (24) CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised Net income $ 103 $ (19) $ 84 $ 54 $ (6) $ 48 Total comprehensive income 47 (19) 28 121 (6) 115 Comprehensive income attributable to Dentsply Sirona $ 47 $ (19) $ 28 $ 121 $ (6) $ 115 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 102 $ 17 $ 119 $ 99 $ 6 $ 105 Total comprehensive income 75 17 92 213 8 221 Comprehensive income attributable to Dentsply Sirona $ 75 $ 17 $ 92 $ 213 $ 8 $ 221
Schedule of Intangible Assets	The Company uses the following useful lives for its definite-lived intangible assets: Definite-lived Intangible Asset Type Useful Life Patents Up to date patent expires Tradenames and trademarks Up to 20 years Licensing agreements Up to 20 years Customer relationships Up to 15 years Developed technology Up to 15 years
Property, Plant and Equipment	E xcept for leasehold improvements, depreciation and amortization is computed by the straight-line method over the assets’ estimated useful lives: Property, Plant, and Equipment Assets Type Useful Life Buildings 40 years Machinery and Equipment 4 to 15 years Capitalized Software 2 to 10 years Leasehold Improvements Shorter of the estimated useful life or the term of the lease Property, plant and equipment, net, were as follows: Year Ended December 31, (in millions) 2021 2020 Land $ 51 $ 54 Buildings and improvements 561 595 Machinery and equipment 982 1,075 Capitalized Software 353 339 Construction in progress 134 120 $ 2,081 $ 2,183 Less: Accumulated depreciation and amortization 1,308 1,392 Property, plant and equipment, net $ 773 $ 791
Schedule of Warranty Expense and Accrual	The Company’s warranty expense and warranty accrual were as follows: December 31, (in millions) 2021 2020 2019 Warranty Expense $ 44 $ 27 $ 30 Warranty Accrual 28 18 18

REVENUE (Tables)

REVENUE (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Net sales disaggregated by product category were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Equipment & Instruments $ 728 $ 577 $ 686 CAD/CAM 574 455 523 Orthodontics 273 160 190 Implants 626 475 592 Healthcare 303 287 280 Technology & Equipment segment net sales $ 2,504 $ 1,954 $ 2,271 Endodontic & Restorative $ 1,261 $ 961 $ 1,203 Other Consumables 466 424 548 Consumables segment net sales $ 1,727 $ 1,385 $ 1,751 Total net sales $ 4,231 $ 3,339 $ 4,022
Revenue from External Customers by Geographic Areas	Net sales disaggregated by geographic region were as follows: Year Ended December 31, (in millions) 2021 2020 2019 United States $ 1,480 $ 1,115 $ 1,374 Europe 1,675 1,381 1,609 Rest of World 1,076 843 1,039 Total net sales $ 4,231 $ 3,339 $ 4,022

STOCK COMPENSATION (Tables)

STOCK COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Cost by Plan	The amounts of stock compensation expense recorded in the Company’s Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019 were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Cost of products sold $ 3 $ 1 $ 2 Selling, general, and administrative expense 44 44 61 Research and development expense 2 1 2 Total stock based compensation expense $ 49 $ 46 $ 65 Related deferred income tax benefit $ 6 $ 5 $ 8
Schedule of Assumptions Used to Determine Compensation Cost for the Company's Non-qualified Stock Options Issued	The Company uses the Black-Scholes option-pricing model to estimate the fair value of each option awarded. The average assumptions used to determine compensation cost for the Company’s NQSOs issued were as follows: Year Ended December 31, 2021 2020 2019 Weighted average fair value per share $ 15.90 $ 10.03 $ 12.20 Expected dividend yield 0.68 % 0.84 % 0.71 % Risk-free interest rate 0.79 % 0.77 % 2.36 % Expected volatility 31.5 % 24.0 % 22.6 % Expected life (years) 5.08 5.49 6.00
Schedule of Non-qualified Stock Option Transactions	The NQSO transactions for the year ended December 31, 2021 were as follows: Outstanding Exercisable (in millions, except per share amounts) Shares Weighted Average Exercise Price Aggregate Intrinsic Value Shares Weighted Average Exercise Price Aggregate Intrinsic Value December 31, 2020 4.0 $ 50.01 $ 17 2.7 $ 50.28 $ 12 Granted 0.5 58.85 Exercised (1.1) 46.81 Forfeited (0.2) 53.03 December 31, 2021 3.2 $ 52.44 $ 15 2.2 $ 52.05 $ 11
Schedule of Information about Non-qualified Stock Options Outstanding	Information about NQSOs outstanding for the year ended December 31, 2021 were as follows: Outstanding Exercisable Number Outstanding at December 31, 2021 Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable at December 31, 2021 Weighted Average Exercise Price Range of Exercise Prices (in millions, except per share amounts and life) 30.01 - 40.00 0.1 1.4 $ 37.29 0.1 $ 37.29 40.01 - 50.00 1.4 5.9 47.31 0.8 46.73 50.01 - 60.00 1.4 6.0 56.32 0.9 55.05 60.01 - 70.00 0.3 4.3 62.37 0.4 62.24 3.2 2.2
Schedule of the Unvested RSU Transactions	The unvested RSU transactions for the year ended December 31, 2021 were as follows: Unvested Restricted Stock Units Shares Weighted Average Grant Date Fair Value (in millions, except per share amounts) Unvested at December 31, 2020 4.2 $ 47.29 Granted 1.0 63.61 Vested (1.5) 45.08 Forfeited (0.6) 50.01 Unvested at December 31, 2021 3.1 $ 53.52

EARNINGS PER COMMON SHARE (Tabl

EARNINGS PER COMMON SHARE (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Earnings Per Common Share	The computation of basic and diluted earnings (loss) per common share for the years ended December 31 were as follows: Basic Earnings (Loss) Per Common Share (in millions, except per share amounts) 2021 2020 2019 Net income (loss) attributable to Dentsply Sirona $ 411 $ (73) $ 256 Weighted average common shares outstanding 218.4 219.2 223.1 Earnings (loss) per common share - basic $ 1.88 $ (0.33) $ 1.15 Diluted Earnings (Loss) Per Common Share (in millions, except per share amounts) 2021 2020 2019 Net income (loss) attributable to Dentsply Sirona $ 411 $ (73) $ 256 Weighted average common shares outstanding 218.4 219.2 223.1 Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards 1.8 — 1.3 Total weighted average diluted shares outstanding 220.2 219.2 224.4 Earnings (loss) per common share - diluted $ 1.87 $ (0.33) $ 1.14

COMPREHENSIVE (LOSS) INCOME (Ta

COMPREHENSIVE (LOSS) INCOME (Tables)	12 Months Ended
	Dec. 31, 2021
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in AOCI, net of tax, by component for the years ended December 31, 2021 and 2020 were as follows: (in millions) Foreign Currency Translation Gain (Loss) Gain and (Loss) on Cash Flow Hedges Gain and (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2020 $ (187) $ (25) $ (119) $ (133) $ (464) Other comprehensive (loss) income before reclassifications and tax impact (156) 3 22 26 (105) Tax expense (23) (1) (6) (8) (38) Other comprehensive (loss) income, net of tax, before reclassifications $ (179) $ 2 $ 16 $ 18 $ (143) Amounts reclassified from accumulated other comprehensive income, net of tax — 7 — 8 15 Net (decrease) increase in other comprehensive income (179) 9 16 26 (128) Balance, net of tax, at December 31, 2021 $ (366) $ (16) $ (103) $ (107) $ (592) (in millions) Foreign Currency Translation Gain (Loss) Gain and (Loss) on Cash Flow Hedges Gain and (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2019 $ (370) $ (11) $ (101) $ (120) $ (602) Other comprehensive income (loss) before reclassifications and tax impact 153 (17) (23) (26) 87 Tax benefit 30 1 5 7 43 Other comprehensive income (loss), net of tax, before reclassifications $ 183 $ (16) $ (18) $ (19) $ 130 Amounts reclassified from accumulated other comprehensive income, net of tax — 2 — 6 8 Net increase (decrease) in other comprehensive income 183 (14) (18) (13) 138 Balance, net of tax, at December 31, 2020 $ (187) $ (25) $ (119) $ (133) $ (464)
Reclassification out of Accumulated Other Comprehensive Income	Reclassification out of AOCI to the Consolidated Statements of Operations for the years ended December 31, 2021, 2020, and 2019 were as follows: Amounts Reclassified from AOCI Affected Line Item in the Consolidated Statements of Operations Year Ended December 31, (in millions) 2021 2020 2019 Loss on derivative financial instruments: Interest rate swaps $ (4) $ (4) $ (2) Interest expense, net Foreign exchange forward contracts (3) 2 1 Cost of products sold Net loss before tax $ (7) $ (2) $ (1) Tax impact — — — Provision for income taxes Net loss after tax $ (7) $ (2) $ (1) Amortization of defined benefit pension and other postemployment benefit items: Amortization of prior service benefits $ 1 $ 1 $ 1 (a) Amortization of net actuarial losses (12) (9) (6) (a) Net loss before tax $ (11) $ (8) $ (5) Tax impact 3 2 1 Provision for income taxes Net loss after tax $ (8) $ (6) $ (4) Total reclassifications for the period $ (15) $ (8) $ (5) (a) These AOCI components are included in the computation of net periodic benefit cost for the years ended December 31, 2021, 2020, and 2019, respectively.

BUSINESS COMBINATIONS (Tables)

BUSINESS COMBINATIONS (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Intangible Assets Acquired	Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) In-process R&D $ 3 Indefinite Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 10 Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 15 In-process R&D 10 Indefinite Total $ 76 Intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Non-compete agreements $ 16 5 Technology know-how 210 10 Tradenames and trademarks 190 20 Total $ 416
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The preliminary fair values of the assets acquired and liabilities assumed in connection with the Propel Orthodontics acquisition were as follows: (in millions) Other current assets $ 4 Intangible assets 66 Current liabilities (1) Net assets acquired 69 Goodwill 63 Purchase consideration $ 132 The fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows: (in millions) Cash and cash equivalents $ 2 Other current assets 2 Intangible assets 76 Current liabilities (2) Other long-term assets (liabilities), net (14) Net assets acquired 64 Goodwill 39 Purchase consideration $ 103 The fair values of the assets acquired and liabilities assumed in connection with the Byte acquisition for the year ended December 31, 2020 were as follows: (in millions) Cash and cash equivalents $ 14 Current assets 16 Intangible assets 416 Current liabilities (28) Net assets acquired 418 Goodwill 627 Purchase consideration $ 1,045

SEGMENT AND GEOGRAPHIC INFORM_2

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Schedule of Net Sales	The Company’s segment information for the years ended December 31 was as follows: Net Sales Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment $ 2,504 $ 1,954 $ 2,271 Consumables 1,727 1,385 1,751 Total net sales $ 4,231 $ 3,339 $ 4,022
Schedule of Depreciation and Amortization	Depreciation and Amortization Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment $ 280 $ 261 $ 258 Consumables 52 61 54 All Other (a) 15 12 11 Total $ 347 $ 334 $ 323 (a) Includes amounts recorded at Corporate headquarters.
Schedule of Segment Operating Income (Loss)	Segment Adjusted Operating Income Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment (a) $ 543 $ 382 $ 460 Consumables (a) 539 316 447 Segment adjusted operating income $ 1,082 $ 698 $ 907 Reconciling items (income) expense: All other (a) (b) 229 269 277 Goodwill impairment — 157 — Restructuring and other costs 17 77 81 Interest expense, net 55 46 27 Other expense (income), net 8 1 (12) Amortization of intangible assets 222 192 189 Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations 6 6 7 Income (loss) before income taxes $ 545 $ (50) $ 338 (a) $38 million of charges related to discontinuance of product lines, incurred in 2019, which were previously reported in adjusted operating income for the reportable segments, have been reclassified to the “All other” category to conform to current year presentation and our internal reporting to our Chief Operating Decision Maker package (“CODM”). These amounts are not material to the measure of segment results for the years presented. (b) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations.
Schedule of Capital Expenditures	Capital Expenditures Year Ended December 31, (in millions) 2021 2020 2019 Technologies & Equipment $ 100 $ 50 $ 73 Consumables 37 26 34 All Other (a) 22 11 16 Total $ 159 $ 87 $ 123 (a) Includes capital expenditures of Corporate headquarters.
Schedule of Assets	Assets Year Ended December 31, (in millions) 2021 2020 Technologies & Equipment $ 6,902 $ 7,014 Consumables 2,123 2,170 All Other (a) 214 166 Total $ 9,239 $ 9,350 (a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations.
Schedule of Revenue and Long Lived Assets by Geographic Location	The following tables set forth information about the Company’s significant operations by geographic areas, for the years ended December 31, 2021, 2020, and 2019. Net Sales reported below represent revenues from external customers in those respective countries based on the destination of shipments. Year Ended December 31, (in millions) 2021 2020 2019 Net sales United States $ 1,484 $ 1,116 $ 1,377 Germany 482 432 472 Other Foreign 2,265 1,791 2,173 Total net sales $ 4,231 $ 3,339 $ 4,022 Property, plant and equipment, net, represents those long-lived assets held by the operating businesses located in the respective geographic areas. Year Ended December 31, (in millions) 2021 2020 2019 Property, plant, and equipment, net United States $ 166 $ 145 $ 168 Germany 309 337 327 Sweden 107 110 99 Other Foreign 191 199 208 Total property, plant, and equipment, net $ 773 $ 791 $ 802
Schedules of Concentration of Risk, by Risk Factor	Customers that accounted for 10% or more of net sales and accounts receivable for the years ended December 31, 2020 and 2019 were as follows: Year Ended December 31, 2020 2019 % of net sales % of accounts receivable % of net sales % of accounts receivable Henry Schein, Inc. 14 % N/A 13 % 12 % Patterson Companies, Inc. 10 % 18 % N/A 17 %

OTHER EXPENSE (INCOME) , NET (T

OTHER EXPENSE (INCOME) , NET (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Schedule of Other Expense (Income)	Other expense (income), net, were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Foreign exchange transaction (gain) loss $ (6) $ (13) $ (27) Other expense (income), net 14 14 15 Total other expense (income), net $ 8 $ 1 $ (12)

INVENTORIES, NET (Tables)

INVENTORIES, NET (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories, Net	Inventories, net were as follows: Year Ended December 31, (in millions) 2021 2020 Raw materials and supplies $ 139 $ 134 Work-in-process 72 68 Finished Goods 304 274 Inventories, net $ 515 $ 476

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	E xcept for leasehold improvements, depreciation and amortization is computed by the straight-line method over the assets’ estimated useful lives: Property, Plant, and Equipment Assets Type Useful Life Buildings 40 years Machinery and Equipment 4 to 15 years Capitalized Software 2 to 10 years Leasehold Improvements Shorter of the estimated useful life or the term of the lease Property, plant and equipment, net, were as follows: Year Ended December 31, (in millions) 2021 2020 Land $ 51 $ 54 Buildings and improvements 561 595 Machinery and equipment 982 1,075 Capitalized Software 353 339 Construction in progress 134 120 $ 2,081 $ 2,183 Less: Accumulated depreciation and amortization 1,308 1,392 Property, plant and equipment, net $ 773 $ 791

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Assets and Liabilities, Leases	The net present value of finance and operating lease right-of-use assets and liabilities were as follows: Year Ended December 31, (in millions, except percentages) Location in the Consolidated Balance Sheets 2021 2020 Assets Finance leases Property, plant, and equipment, net $ 2 $ 1 Operating leases Operating lease right-of-use assets, net 198 176 Total right-of-use assets $ 200 $ 177 Liabilities Current liabilities Finance leases Notes payable and current portion of long-term debt $ 1 $ — Operating leases Accrued liabilities 50 48 Noncurrent liabilities Finance leases Long-term debt 1 1 Operating leases Operating lease liabilities 149 130 Total lease liabilities $ 201 $ 179 Supplemental information: Weighted-average discount rate Finance leases 3.2 % 3.7 % Operating leases 3.3 % 3.0 % Weighted-average remaining lease term in years Finance leases 4.3 6.5 Operating leases 5.3 5.2
Schedule of Lease Costs	The lease cost recognized in the Consolidated Statements of Operations for the year ended December 31, 2021 and 2020 were as follows: (in millions) 2021 2020 Operating lease cost $ 67 $ 57 Short-term lease cost 1 1 Variable lease cost 10 9 Total lease cost $ 78 $ 67 The supplemental cash flow information for the year ended December 31, 2021 and 2020 were as follows: (in millions) 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows paid for operating leases $ 65 $ 56 Right-of-use assets obtained in exchange for new lease liabilities: Finance leases $ 1 $ — Operating leases 79 43
Schedule of Finance Lease Maturity	The contractual maturity dates of the remaining lease liabilities for the year ended December 31, 2021 were as follows: (in millions) Finance Leases Operating Leases Total 2022 $ 1 $ 58 $ 59 2023 1 46 47 2024 — 36 36 2025 — 24 24 2026 — 18 18 2027 and beyond — 38 38 Total lease payments $ 2 $ 220 $ 222 Less imputed interest — 21 21 Present value of lease liabilities $ 2 $ 199 $ 201
Schedule of Operating Lease Maturity	The contractual maturity dates of the remaining lease liabilities for the year ended December 31, 2021 were as follows: (in millions) Finance Leases Operating Leases Total 2022 $ 1 $ 58 $ 59 2023 1 46 47 2024 — 36 36 2025 — 24 24 2026 — 18 18 2027 and beyond — 38 38 Total lease payments $ 2 $ 220 $ 222 Less imputed interest — 21 21 Present value of lease liabilities $ 2 $ 199 $ 201

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Reconciliation of Changes in the Company's Goodwill	A reconciliation of changes in the Company’s goodwill by reportable segment were as follows: (in millions) Technologies & Equipment Consumables Total Balance at December 31, 2019 Goodwill $ 5,253 $ 881 $ 6,134 Accumulated impairment losses (2,737) — (2,737) Goodwill, net $ 2,516 $ 881 $ 3,397 Acquisition related additions (a) 631 — 631 Impairment (157) — (157) Translation and other 102 13 115 Balance at December 31, 2020 Goodwill $ 5,985 $ 894 $ 6,879 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,092 $ 894 $ 3,986 Acquisition related additions (a) 109 — 109 Translation and other (105) (14) (119) Balance at December 31, 2021 Goodwill $ 5,989 $ 880 $ 6,869 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,096 $ 880 $ 3,976 (a) Refer to Note 6, Business Combinations, for more information regarding recent acquisitions.
Schedule of Identifiable Definite-Lived Intangible Assets	Identifiable definite-lived and indefinite-lived intangible assets at were as follows: Year Ended December 31, 2021 2020 (in millions) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology and patents $ 1,729 $ (762) $ 967 $ 1,681 $ (677) $ 1,004 Tradenames and trademarks 269 (79) 190 273 (70) 203 Licensing agreements 36 (32) 4 37 (30) 7 Customer relationships 1,091 (545) 546 1,142 (494) 648 Total definite-lived $ 3,125 $ (1,418) $ 1,707 $ 3,133 $ (1,271) $ 1,862 Indefinite-lived tradenames and trademarks 598 — 598 642 — 642 In-process R&D (a) 14 — 14 — — — Total indefinite-lived 612 — 612 642 — 642 Total identifiable intangible assets $ 3,737 $ (1,418) $ 2,319 $ 3,775 $ (1,271) $ 2,504 (a) Intangible assets acquired in a business combination that are in-process and used in research and development (“R&D”) activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed .
Schedule of Indefinite-Lived Intangible Assets	Identifiable definite-lived and indefinite-lived intangible assets at were as follows: Year Ended December 31, 2021 2020 (in millions) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology and patents $ 1,729 $ (762) $ 967 $ 1,681 $ (677) $ 1,004 Tradenames and trademarks 269 (79) 190 273 (70) 203 Licensing agreements 36 (32) 4 37 (30) 7 Customer relationships 1,091 (545) 546 1,142 (494) 648 Total definite-lived $ 3,125 $ (1,418) $ 1,707 $ 3,133 $ (1,271) $ 1,862 Indefinite-lived tradenames and trademarks 598 — 598 642 — 642 In-process R&D (a) 14 — 14 — — — Total indefinite-lived 612 — 612 642 — 642 Total identifiable intangible assets $ 3,737 $ (1,418) $ 2,319 $ 3,775 $ (1,271) $ 2,504 (a) Intangible assets acquired in a business combination that are in-process and used in research and development (“R&D”) activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed .

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure	Prepaid expenses and other current assets were as follows: Year Ended December 31, (in millions) 2021 2020 Prepaid expenses $ 89 $ 78 Value-added tax receivable 53 39 Deposits 22 33 Other current assets 84 67 Prepaid expenses and other current assets $ 248 $ 217

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities were as follows: Year Ended December 31, (in millions) 2021 2020 Payroll, commissions, bonuses, other cash compensation and employee benefits $ 172 $ 142 Sales and marketing programs 66 56 Reserve for dealer rebates 209 134 Restructuring costs 11 31 Accrued vacation and holidays 40 41 Professional and legal costs 19 33 Current portion of derivatives 3 32 General insurance 12 12 Warranty liabilities 28 18 Third party royalties 7 11 Deferred income 68 53 Accrued interest 8 13 Accrued property taxes 6 13 Current operating lease liabilities 50 48 Other 61 75 Accrued liabilities $ 760 $ 712

FINANCING ARRANGEMENTS (Tables)

FINANCING ARRANGEMENTS (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Short-Term Debt	Short-term debt was as follows: Year Ended December 31, 2021 2020 Principal Interest Principal Interest (in millions except percentages) Balance Rate Balance Rate Corporate commercial paper facility $ 170 0.3 % $ — — % Other short-term borrowings 11 4.8 % 3 1.9 % Add: Current portion of long-term debt 1 296 Total short-term debt $ 182 $ 299 Maximum month-end short-term debt outstanding during the year $ 380 $ 299 Average amount of short-term debt outstanding during the year $ 265 $ 95 Weighted-average interest rate on short-term debt at year-end 0.6 % 1.9 %
Schedule of Long-term Debt	Long-term debt was as follows: Year Ended December 31, 2021 2020 Principal Interest Principal Interest (in millions except percentages) Balance Rate Balance Rate Fixed rate senior notes $450 million due August 2021 $ — — % $ 296 4.1 % Private placement notes 70 million euros due October 2024 79 1.0 % 85 1.0 % Private placement notes 25 million Swiss franc due December 2025 27 0.9 % 28 0.9 % Private placement notes 97 million euros due December 2025 110 2.1 % 118 2.1 % Private placement notes 26 million euros due February 2026 30 2.1 % 32 2.1 % Private placement notes 58 million Swiss franc due August 2026 64 1.0 % 65 1.0 % Private placement notes 106 million euros due August 2026 121 2.3 % 129 2.3 % Private placement notes 70 million euros due October 2027 80 1.3 % 85 1.3 % Private placement notes 8 million Swiss franc due December 2027 8 1.0 % 8 1.0 % Private placement notes 15 million euros due December 2027 17 2.2 % 18 2.2 % Private placement notes 140 million Swiss franc due August 2028 153 1.2 % 158 1.2 % Private placement notes 70 million euros due October 2029 79 1.5 % 85 1.5 % Fixed rate senior notes 750 million due June 2030 750 3.3 % 750 3.3 % Private placement notes 70 million euros due October 2030 80 1.6 % 85 1.6 % Private placement notes 45 million euros due February 2031 51 2.5 % 55 2.5 % Private placement notes 65 million Swiss franc due August 2031 71 1.3 % 73 1.3 % Private placement notes 12.6 billion Japanese yen due September 2031 109 1.0 % 122 1.0 % Private placement notes 70 million euros due October 2031 80 1.7 % 85 1.7 % Other borrowings, various currencies and rates 13 7 $ 1,922 $ 2,284 Less: Current portion (included in “Notes payable and current portion of long-term debt” in the Consolidated Balance Sheets) 1 296 Less: Long-term portion of deferred financing costs 8 10 Long-term portion $ 1,913 $ 1,978
Schedule of Maturities of Long-term Debt	The table below reflects the contractual maturity dates of the various long-term borrowings as follows: (in millions) December 31, 2021 2022 $ 3 2023 11 2024 84 2025 138 2026 213 2027 and beyond 1,473 $ 1,922

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Total Outstanding Shares	Total outstanding shares of common stock and treasury stock were as follows: (in millions) Shares of Common Stock Shares of Treasury Stock Outstanding Shares Balance at December 31, 2018 264.5 (41.5) 223.0 Shares of treasury stock issued — 3.1 3.1 Repurchase of common stock at an average cost of $54.18 — (4.8) (4.8) Balance at December 31, 2019 264.5 (43.2) 221.3 Shares of treasury stock issued — 1.1 1.1 Repurchase of common stock at an average cost of $38.25 — (3.7) (3.7) Balance at December 31, 2020 264.5 (45.8) 218.7 Shares of treasury stock issued — 2.2 2.2 Repurchase of common stock at an average cost of $57.47 — (3.5) (3.5) Balance at December 31, 2021 264.5 (47.1) 217.4

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Components of Income Before Income Taxes from Operations	The components of income (loss) before income taxes were as follows: Year Ended December 31, (in millions) 2021 2020 2019 United States $ 51 $ (91) $ (115) Foreign 494 41 453 Total income (loss) before income taxes $ 545 $ (50) $ 338
Schedule of Components of the Provision for Income Taxes from Operations	The components of the provision (benefit) for income taxes from operations were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Current: U.S. federal $ 1 $ (5) $ (11) U.S. state 4 1 2 Foreign 154 89 131 Total $ 159 $ 85 $ 122 Deferred: U.S. federal $ 10 $ 4 $ (3) U.S. state 2 (1) 1 Foreign (37) (65) (38) Total $ (25) $ (62) $ (40) Total provision for income taxes $ 134 $ 23 $ 82
Schedule of Reconciliation of the U.S. Federal Statutory Tax Rate to the Effective Rate	The reconciliation of the U.S. federal statutory tax rate to the effective rate were as follows: Year Ended December 31, 2021 2020 2019 Statutory U.S. federal income tax rate 21.0 % 21.0 % 21.0 % Effect of: State income taxes, net of federal benefit 0.8 1.1 0.7 Federal benefit of R&D and foreign tax credits (0.9) 18.9 (2.0) US other permanent differences 0.4 (6.1) 0.8 Tax effect of international operations 0.3 10.0 0.9 Global Intangible Low Taxed Income (GILTI) 2.4 (13.0) 3.8 Foreign Derived Intangible Income (FDII) (1.3) 11.8 (0.1) Net effect of tax audit activity 1.6 (8.2) 0.4 Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions 1.9 (0.2) 0.1 Federal tax on unremitted earnings of certain foreign subsidiaries (0.2) (5.4) 0.1 Valuation allowance adjustments (1.7) (15.3) (1.4) Tax effect of impairment of goodwill and intangibles — (60.8) (0.1) Other 0.3 0.2 0.1 Effective income tax rate on operations 24.6 % (46.0 %) 24.3 %
Schedule of Tax Effect of Significant Temporary Differences Giving Rise to Deferred Tax Assets and Liabilities	The tax effect of significant temporary differences giving rise to deferred tax assets and liabilities were as follows: Year Ended December 31, 2021 2020 (in millions) Deferred Tax Asset Deferred Tax Liability Deferred Tax Asset Deferred Tax Liability Commission and bonus accrual $ 6 $ — $ 8 $ — Employee benefit accruals 51 — 58 — Inventory 16 — 25 — Identifiable intangible assets — 569 — 613 Insurance premium accruals 3 — 3 — Miscellaneous accruals 27 — 24 — Other 17 — 10 — Unrealized losses included in AOCI 47 — 98 — Property, plant and equipment — 47 — 50 Lease right-of-use asset — 47 — 42 Lease right-of-use liability 47 — 42 — Product warranty accruals 1 — 1 — Foreign tax credit and R&D carryforward 49 — 60 — Restructuring and other cost accruals 5 — 9 — Sales and marketing accrual 14 — 7 — Taxes on unremitted earnings of foreign subsidiaries — 5 — 6 Tax loss carryforwards and other tax attributes 275 — 280 — Subtotal $ 558 $ 668 $ 625 $ 711 Valuation allowances (267) — (287) — Total $ 291 $ 668 $ 338 $ 711
Schedule of Deferred Tax Assets and Liabilities Included in the Consolidated Balance Sheet	Deferred tax assets and liabilities are included in the following Consolidated Balance Sheets line items at December 31 were as follows: (in millions) 2021 2020 Assets Other noncurrent assets $ 14 $ 8 Liabilities Deferred income taxes $ 391 $ 381
Schedule of Unrecognized Tax Benefits	The activity recorded for unrecognized tax benefits were as follows: (in millions) 2021 2020 2019 Unrecognized tax benefits at beginning of period $ 27 $ 24 $ 28 Gross change for prior-period positions 6 1 — Gross change for current year positions 2 1 — Decrease due to settlements and payments — — (4) Decrease due to statute expirations — — — Increase due to effect of foreign currency translation — 1 — Decrease due to effect from foreign currency translation (1) — — Unrecognized tax benefits at end of period $ 34 $ 27 $ 24

BENEFIT PLANS (Tables)

BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Schedule of Reconciliations of Changes in the Defined Benefit and Postretirement Healthcare Plans' Benefit Obligations, Fair Value of Assets and Statement of Funded Status	Reconciliation of changes in the defined benefit obligations, fair value of assets and statement of funded status were as follows: Year Ended December 31, (in millions) 2021 2020 Change in Benefit Obligation Benefit obligation at beginning of year $ 675 $ 578 Service cost 17 16 Interest cost 3 5 Participant contributions 4 4 Actuarial losses (gains) (16) 31 Plan amendments (1) — Acquisitions/Divestitures (2) — Effect of exchange rate changes (41) 59 Plan curtailments and settlements (1) (1) Benefits paid (19) (17) Benefit obligation at end of year $ 619 $ 675 Change in Plan Assets Fair value of plan assets at beginning of year $ 213 $ 185 Actual return on assets 10 9 Plan settlements (1) — Acquisitions/Divestitures (3) — Effect of exchange rate changes (7) 17 Employer contributions 15 15 Participant contributions 4 4 Benefits paid (19) (17) Fair value of plan assets at end of year $ 212 $ 213 Funded status at end of year $ (407) $ (462)
Schedule of Amounts Recognized in the Accompanying Consolidated Balance Sheets, Net of Tax Effects	The amounts recognized in the accompanying Consolidated Balance Sheets, net of tax effects, were as follows: Location In The Year Ended December 31, (in millions) Consolidated Balance Sheets 2021 2020 Other noncurrent assets, net Other noncurrent assets $ 2 $ — Deferred tax asset Other noncurrent assets 36 49 Total assets $ 38 $ 49 Current liabilities Accrued liabilities (9) (10) Other noncurrent liabilities Other noncurrent liabilities (400) (452) Deferred tax liability Deferred income taxes (1) (1) Total liabilities $ (410) $ (463) Accumulated other comprehensive income Accumulated other comprehensive loss 105 139 Net amount recognized $ (267) $ (275)
Schedule of Amounts Recognized in Accumulated Other Comprehensive Income	Amounts recognized in AOCI were as follows: Year Ended December 31, (in millions) 2021 2020 Net actuarial loss $ 144 $ 191 Net prior service cost (4) (4) Before tax AOCI $ 140 $ 187 Less: Deferred taxes 35 48 Net of tax AOCI $ 105 $ 139
Schedule of Information for Pension Plans with an Accumulated Benefit Obligation in Excess of Plan Assets	Information for pension plans with a projected or accumulated benefit obligation in excess of plan assets were as follows: Year Ended December 31, (in millions) 2021 2020 Projected benefit obligation $ 427 $ 484 Accumulated benefit obligation 403 455 Fair value of plan assets 17 26
Schedule of Components of Net Periodic Benefit Cost	Components of net periodic benefit cost were as follows: Year Ended December 31, Location in Consolidated (in millions) 2021 2020 2019 Statements of Operations Service cost $ 7 $ 6 $ 6 Cost of products sold Service cost 10 10 8 Selling, general and administrative expenses Interest cost 3 5 8 Other expense (income), net Expected return on plan assets (4) (4) (5) Other expense (income), net Amortization of prior service credit (1) (1) (1) Other expense (income), net Amortization of net actuarial loss 12 9 6 Other expense (income), net Acquisitions/Divestitures 1 — — Other expense (income), net Curtailment and settlement (gains) loss (1) — 6 Other expense (income), net Net periodic benefit cost $ 27 $ 25 $ 28
Schedule of Other Changes in Plan Assets and Benefit Obligations Recognized in AOCI	Other changes in plan assets and benefit obligations recognized in AOCI were as follows: Year Ended December 31, (in millions) 2021 2020 2019 Net actuarial loss (gain) $ (36) $ 43 $ 53 Amortization (11) (9) (5) Total recognized in AOCI $ (47) $ 34 $ 48 Total recognized in net periodic benefit cost and AOCI $ (20) $ 59 $ 76
Schedule of Weighted Average Assumptions Used to Determine Benefit Obligations, Principally in Foreign Locations	The weighted average assumptions used to determine benefit obligations for the Company’s plans, principally in foreign locations were as follows: Year Ended December 31, 2021 2020 2019 Interest crediting rate 1.3 % 1.3 % 1.3 % Discount rate 1.1 % 0.6 % 1.0 % Rate of compensation increase 2.6 % 2.4 % 2.5 %
Schedule of Weighted Average Assumptions Used to Determine Net Periodic Benefit Cost	The weighted average assumptions used to determine net periodic benefit cost for the Company’s plans, principally in foreign locations were as follows: Year Ended December 31, 2021 2020 2019 Interest crediting rate 1.3 % 1.3 % 1.3 % Discount rate 0.6 % 1.0 % 1.8 % Expected return on plan assets 2.2 % 2.3 % 2.9 % Rate of compensation increase 2.4 % 2.5 % 2.5 % Measurement date 12/31/2021 12/31/2020 12/31/2019
Schedule of Fair Value Measurements of Plan Assets	The fair value of the Company’s pension plan assets at December 31, 2021 and 2020 is presented in the table below by asset category. Approximately 78% of the total plan assets are categorized as Level 1, and therefore, the values assigned to these pension assets are based on quoted prices available in active markets. For the other category levels, a description of the valuation is provided in Note 1, Significant Accounting Policies and Restatement, under the “Fair Value Measurement” heading. December 31, 2021 (in millions) Total Level 1 Level 2 Level 3 Assets Category Cash and cash equivalents $ 17 $ 17 $ — $ — Equity securities: International 65 65 — — Fixed income securities: Fixed rate bonds (a) 66 66 — — Other types of investments: Mutual funds (b) 18 18 — — Insurance contracts 34 — — 34 Hedge funds 11 — — 11 Real estate 1 — — 1 Total $ 212 $ 166 $ — $ 46 December 31, 2020 (in millions) Total Level 1 Level 2 Level 3 Assets Category Cash and cash equivalents $ 16 $ 16 $ — $ — Equity securities: International 58 58 — — Fixed income securities: Fixed rate bonds (a) 65 65 — — Other types of investments: Mutual funds (b) 20 20 — — Common trusts (c) 5 — 5 — Insurance contracts 37 — — 37 Hedge funds 12 — — 12 Total $ 213 $ 159 $ 5 $ 49 (a) This category includes fixed income securities invested primarily in Swiss bonds, foreign bonds denominated in Swiss francs, foreign currency bonds, mortgage notes and pledged letters. (b) This category includes mutual funds balanced between moderate-income generation and moderate capital appreciation with investment allocations of approximately 50% equities and 50% fixed income investments. (c) This category includes common/collective funds with investments in approximately 65% equities and 35% in fixed income investments.
Schedule of Reconciliation for the Plans Assets Categorized as Level 3	A reconciliation from December 31, 2020 to December 31, 2021 for the plan assets categorized as Level 3 were as follows: December 31, 2021 (in millions) Insurance Contracts Hedge Funds Real Estate Total Balance at December 31, 2020 $ 37 $ 12 $ — $ 49 Actual return on plan assets: Relating to assets still held at the reporting date (2) 1 1 — Purchases, sales and settlements, net (1) (2) — (3) Transfers in and/or (out) 2 — — 2 Effect of exchange rate changes (2) — — (2) Balance at December 31, 2021 $ 34 $ 11 $ 1 $ 46 December 31, 2020 (in millions) Insurance Contracts Hedge Funds Real Estate Total Balance at December 31, 2019 $ 30 $ 9 $ — $ 39 Actual return on plan assets: Relating to assets still held at the reporting date 3 — — 3 Purchases, sales and settlements, net — 2 — 2 Effect of exchange rate changes 4 1 — 5 Balance at December 31, 2020 $ 37 $ 12 $ — $ 49
Schedule of Estimated Future Benefit Payments	Estimated Future Benefit Payments Total benefits expected to be paid from the plans in the future were as follows: (in millions) Pension Benefits 2022 $ 23 2023 24 2024 24 2025 25 2026 25 2027-2031 127

RESTRUCTURING AND OTHER COSTS (

RESTRUCTURING AND OTHER COSTS (Tables)	12 Months Ended
	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The details of total restructuring and other costs for the years ended 2021, 2020 and 2019 were as follows: Affected Line Item in the Consolidated Statements of Operations Year Ended December 31, (in millions) 2021 2020 2019 Cost of products sold $ (3) $ 44 $ 25 Selling, general, and administrative expenses 6 2 23 Restructuring and other costs 17 77 81 Other income and expenses — — (1) Total restructuring and other costs $ 20 $ 123 $ 128
Schedule of Restructuring Accruals	The Company’s restructuring accruals at December 31, 2021 were as follows: Severance (in millions) 2019 and Prior Plans 2020 Plans 2021 Plans Total Balance at December 31, 2020 $ 12 $ 17 $ — $ 29 Provisions and adjustments 3 3 13 19 Amounts applied (10) (11) (4) (25) Change in estimates (2) (7) — (9) Balance at December 31, 2021 $ 3 $ 2 $ 9 $ 14 Other Restructuring Costs (in millions) 2019 and Prior Plans 2020 Plans 2021 Plans Total Balance at December 31, 2020 $ 3 $ 2 $ — $ 5 Provisions and adjustments 2 5 3 10 Amounts applied (2) (5) (3) (10) Balance at December 31, 2021 $ 3 $ 1 $ — $ 4 The Company’s restructuring accruals at December 31, 2020 were as follows: Severances (in millions) 2018 and Prior Plans 2019 Plans 2020 Plans Total Balance at December 31, 2019 $ 7 $ 20 $ — $ 27 Provisions and adjustments 2 2 28 32 Amounts applied (4) (8) (9) (21) Change in estimates — (7) (2) (9) Balance at December 31, 2020 $ 5 $ 7 $ 17 $ 29 Other Restructuring Costs (in millions) 2018 and Prior Plans 2019 Plans 2020 Plans Total Balance at December 31, 2019 $ 3 $ — $ — $ 3 Provisions and adjustments — 1 3 4 Amounts applied — (1) (1) (2) Balance at December 31, 2020 $ 3 $ — $ 2 $ 5
Schedule of Cumulative Amounts for the Provisions and Adjustments and Amounts Applied for All the Plans by Segment	The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows: (in millions) December 31, 2020 Provisions and Adjustments Amounts Applied Change in Estimates December 31, 2021 Technologies & Equipment $ 16 $ 9 $ (14) $ (4) $ 7 Consumables 17 15 (16) (5) 11 All Other 1 5 (5) (1) — Total $ 34 $ 29 $ (35) $ (10) $ 18 The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows: (in millions) December 31, 2019 Provisions and Adjustments Amounts Applied Change in Estimates December 31, 2020 Technologies & Equipment $ 19 $ 16 $ (12) $ (7) $ 16 Consumables 11 16 (8) (2) 17 All Other — 4 (3) — 1 Total $ 30 $ 36 $ (23) $ (9) $ 34

FINANCIAL INSTRUMENTS AND DER_2

FINANCIAL INSTRUMENTS AND DERIVATIVES (Tables)	12 Months Ended
	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes, by derivative instrument type at December 31, 2021 and the notional amounts expected to mature during the next 12 months: Aggregate Notional Amount Aggregate Notional Amount Maturing within 12 Months (in millions) Cash Flow Hedges Foreign exchange forward contracts $ 311 $ 235 Total derivative instruments designated as cash flow hedges $ 311 $ 235 Hedges of Net Investments Foreign exchange forward contracts $ 182 $ 91 Cross currency basis swaps 303 — Total derivative instruments designated as hedges of net investments $ 485 $ 91 Fair Value Hedges Foreign exchange forward contracts $ 217 $ 87 Interest rate swaps 250 — Total derivative instruments designated as fair value hedges $ 467 $ 87 Derivative Instruments not Designated as Hedges Foreign exchange forward contracts $ 301 $ 301 Total derivative instruments not designated as hedges $ 301 $ 301
Schedule of Derivative Instruments	The amount of gains (losses) recorded in the Company’s Consolidated Balance Sheets and Consolidated Statements of Operations related to all derivative instruments were as follows: Year Ended December 31, 2021 (in millions) Gain (Loss) in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Ineffective Portion Recognized in Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ 3 Cost of products sold $ (3) $ 2 $ — Interest rate swaps — Interest expense, net (4) — — Total for cash flow hedging $ 3 $ (7) $ 2 $ — Hedges of Net Investments Cross currency basis swaps $ 13 Interest expense, net $ — $ — $ 6 Foreign exchange forward contracts 10 Other expense (income), net — 1 — Total for net investment hedging $ 23 $ — $ 1 $ 6 Fair Value Hedges Foreign exchange forward contracts $ (1) Other expense (income), net $ — $ 1 $ 23 Interest rate swap — Interest expense, net — — 1 Total for fair value hedging $ (1) $ — $ 1 $ 24 Year Ended December 31, 2020 (in millions) Gain (Loss) in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Ineffective Portion Recognized in Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ (2) Cost of products sold $ 2 $ 4 $ — Interest rate swaps (16) Interest expense, net (4) — — Total for cash flow hedging $ (18) $ (2) $ 4 $ — Hedges of Net Investments Cross currency basis swaps $ (26) Interest expense, net $ — $ — $ 9 Foreign exchange forward contracts 6 Other expense (income), net — 6 — Total for net investment hedging $ (20) $ — $ 6 $ 9 Fair Value Hedges Foreign exchange forward contracts $ (3) Interest expense, net $ — $ 3 $ — Total for fair value hedging $ (3) $ — $ 3 $ — . Year Ended December 31, 2019 (in millions) Gain (Loss) in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Ineffective Portion Recognized in Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ (6) Cost of products sold $ 1 $ 2 $ — Interest rate swaps (11) Interest expense, net (2) — — Total for cash flow hedging $ (17) $ (1) $ 2 $ — Hedges of Net Investments Cross currency basis swaps $ 9 Interest expense, net $ — $ — $ 8 Foreign exchange forward contracts 9 Other expense (income), net — 22 — Total for net investment hedging $ 18 $ — $ 22 $ 8 Fair Value Hedges Foreign exchange forward contracts $ 3 Interest expense, net $ — $ 3 $ — Total for fair value hedging $ 3 $ — $ 3 $ — Consolidated Statements of Operations Location Gain (Loss) Recognized December 31, (in millions) 2021 2020 2019 Derivative Instruments not Designated as Hedges Foreign exchange forward contracts Other expense (income), net $ (9) $ 7 $ (3) Total for instruments not designated as hedges $ (9) $ 7 $ (3)
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The fair value and the location of the Company’s derivatives in the Consolidated Balance Sheets were as follows: Year Ended December 31, 2021 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 18 $ 11 $ 2 $ 1 Interest rate swaps 5 — — 9 Cross currency basis swaps 4 — — 7 Total $ 27 $ 11 $ 2 $ 17 Not Designated as Hedges: Foreign exchange forward contracts $ 1 $ — $ 1 $ — Total $ 1 $ — $ 1 $ — Year Ended December 31, 2020 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 5 $ 2 $ 10 $ 3 Cross currency basis swaps — — 20 — Total $ 5 $ 2 $ 30 $ 3 Not Designated as Hedges: Foreign exchange forward contracts $ 3 $ — $ 2 $ — Total $ 3 $ — $ 2 $ —
Offsetting Derivative Assets and Liabilities	Offsetting of financial assets and liabilities under netting arrangements at December 31, 2021 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amounts Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 31 $ — $ 31 $ (9) $ — $ 22 Total assets $ 31 $ — $ 31 $ (9) $ — $ 22 Liabilities Foreign exchange forward contracts $ 4 $ — $ 4 $ (4) $ — $ — Interest rate swaps 4 — 4 (2) — 2 Cross currency basis swaps 4 — 4 (3) — 1 Total liabilities $ 12 $ — $ 12 $ (9) $ — $ 3 Offsetting of financial assets and liabilities under netting arrangements at December 31, 2020 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amounts Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 9 $ — $ 9 $ (9) $ — $ — Cross currency basis swaps — — — — — — Total assets $ 9 $ — $ 9 $ (9) $ — $ — Liabilities Foreign exchange forward contracts $ 15 $ — $ 15 $ — $ — $ 15 Cross currency basis swaps 20 — 20 (7) — 13 Total liabilities $ 35 $ — $ 35 $ (7) $ — $ 28

FAIR VALUE MEASUREMENT (Tables)

FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities that are Recorded at Fair Value and Classified Based on the Lowest Level of Input	The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows: Year Ended December 31, 2021 (in millions) Total Level 1 Level 2 Level 3 Assets Interest rate swaps $ 5 $ — $ 5 $ — Long-term debt 4 — 4 — Cross currency interest rate swaps 4 — 4 — Foreign exchange forward contracts 30 — 30 — Total assets $ 43 $ — $ 43 $ — Liabilities Interest rate swaps $ 9 $ — $ 9 $ — Cross currency basis swaps 7 — 7 — Foreign exchange forward contracts 4 — 4 — Contingent considerations on acquisitions 10 — — 10 Total liabilities $ 30 $ — $ 20 $ 10 Year Ended December 31, 2020 (in millions) Total Level 1 Level 2 Level 3 Assets Foreign exchange forward contracts $ 10 $ — $ 10 $ — Total assets $ 10 $ — $ 10 $ — Liabilities Cross currency interest rate swaps $ 20 $ — $ 20 $ — Foreign exchange forward contracts 15 — 15 — Contingent considerations on acquisitions 5 — — 5 Total liabilities $ 40 $ — $ 35 $ 5
Schedule of Reconciliation of the Company's Assets Measured at Fair Value on a Recurring Basis Using Unobservable Inputs (Level 3)	The following table presents a reconciliation of the Company’s Level 3 holdings measured at fair value on a recurring basis using unobservable inputs: (in millions) Level 3 Balance, December 31, 2019 $ 9 Issuance of new contingent consideration — Loss (gain) in Other expense (income), net — Payments (4) Balance, December 31, 2020 $ 5 Issuance of contingent consideration from business acquisition (a) 9 Loss (gain) in Other expense (income), net — Payments (4) Balance, December 31, 2021 $ 10 (a) Refer to Note 6, “Business Combinations” for more information regarding recent acquisitions

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment	The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At December 31, 2021, non-cancelable purchase commitments are as follows: (in millions) 2022 $ 161 2023 73 2024 38 2025 41 2026 42 Thereafter — Total $ 355

CORRECTION OF PREVIOUSLY ISSU_2

CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following tables present the effect of correcting these accounting errors on the Company’s previously issued financial statements: CONSOLIDATED STATEMENTS OF OPERATIONS Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions, except per share amounts) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Net sales $ 4,251 $ (20) $ 4,231 $ 3,342 $ (3) $ 3,339 $ 4,029 $ (7) $ 4,022 Cost of products sold 1,890 (6) 1,884 1,685 (2) 1,683 1,864 (6) 1,858 Gross profit 2,361 (14) 2,347 1,657 (1) 1,656 2,165 (1) 2,164 Selling, general, and administrative expenses 1,551 — 1,551 1,312 (10) 1,302 1,580 7 1,587 Research and development expenses 171 — 171 123 — 123 143 — 143 Goodwill impairment — — — 157 — 157 — — — Restructuring and other costs 17 — 17 77 — 77 81 — 81 Operating income (loss) 622 (14) 608 (12) 9 (3) 361 (8) 353 Other income and expenses: Interest expense, net 55 — 55 47 (1) 46 28 (1) 27 Other expense (income), net 8 — 8 1 — 1 (12) — (12) Income (loss) before income taxes 559 (14) 545 (60) 10 (50) 345 (7) 338 Provision for income taxes 138 (4) 134 23 — 23 82 — 82 Net income (loss) 421 (10) 411 (83) 10 (73) 263 (7) 256 Less: Net income (loss) attributable to noncontrolling interests — — — — — — — — — Net income (loss) attributable to Dentsply Sirona $ 421 $ (10) $ 411 $ (83) $ 10 $ (73) $ 263 $ (7) $ 256 Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 1.93 $ (0.05) $ 1.88 $ (0.38) $ 0.05 $ (0.33) $ 1.18 $ (0.03) $ 1.15 Diluted $ 1.91 $ (0.04) $ 1.87 $ (0.38) $ 0.05 $ (0.33) $ 1.17 $ (0.03) $ 1.14 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Net income (loss) $ 421 (10) $ 411 $ (83) 10 $ (73) $ 263 (7) $ 256 Pension liability adjustments 26 — 26 (13) — (13) (36) 10 (26) Total other comprehensive (loss) income (130) — (130) 137 2 139 (120) 10 (110) Total comprehensive income 291 (10) 281 54 12 66 143 3 146 Comprehensive income attributable to Dentsply Sirona 293 (10) 283 53 12 65 142 3 145 CONSOLIDATED BALANCE SHEETS December 31, 2021 December 31, 2020 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Accounts and notes receivable-trade, net $ 747 $ 3 $ 750 $ 673 $ (6) $ 667 Inventories, net 504 11 515 466 10 476 Prepaid expenses and other current assets 247 1 248 214 3 217 Total Current Assets 1,837 15 1,852 1,791 7 1,798 Operating lease right-of-use assets, net 193 5 198 176 — 176 Other noncurrent assets 122 (1) 121 94 1 95 Total Assets 9,220 19 9,239 9,342 8 9,350 Accounts payable 268 (6) 262 305 (3) 302 Accrued liabilities 679 81 760 653 59 712 Income taxes payable 57 — 57 60 (1) 59 Total Current Liabilities 1,186 75 1,261 1,317 55 1,372 Operating lease liabilities 145 4 149 130 — 130 Deferred income taxes 408 (17) 391 393 (12) 381 Total Liabilities 4,177 65 4,242 4,372 43 4,415 Retained earnings 1,560 (46) 1,514 1,233 (35) 1,198 Total Dentsply Sirona Equity 5,042 (46) 4,996 4,967 (35) 4,932 Total Equity 5,043 (46) 4,997 4,970 (35) 4,935 Total Liabilities and Equity 9,220 19 9,239 9,342 8 9,350 CONSOLIDATED STATEMENT OF CASH FLOWS Year Ended December 31, 2021 Year Ended December 31, 2020 Year Ended December 31, 2019 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised As Previously Issued Adjustment As Revised Cash flows from operating activities: Net income (loss) $ 421 $ (10) $ 411 $ (83) $ 10 $ (73) $ 263 $ (7) $ 256 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Deferred income taxes (20) (5) (25) (64) 2 (62) (37) (3) (40) Other non-cash (income) expense 34 — 34 2 1 3 (6) 12 6 Changes in operating assets and liabilities, net of acquisitions: Accounts and notes receivable-trade, net (109) (8) (117) 126 5 131 (91) 1 (90) Inventories, net (63) (1) (64) 124 (1) 123 14 (3) 11 Prepaid expenses and other current assets, net (35) 3 (32) 42 (3) 39 13 (1) 12 Accounts payable (46) (3) (49) (23) (5) (28) 26 1 27 Accrued liabilities 78 22 100 (17) 7 (10) 45 14 59 Income taxes 17 — 17 (39) (2) (41) (16) 2 (14) Other noncurrent liabilities 10 2 12 (15) — (15) (2) (10) (12) Net cash provided by operating activities 657 — 657 635 14 649 633 6 639 Cash flows from financing activities: Other financing activities, net (36) — (36) (12) (14) (26) (34) (6) (40) Net cash (used in) provided by financing activities (379) — (379) 490 (14) 476 (466) (6) (472) The following tables present the effect of correcting the Company’s previously issued quarterly financial statements for the accounting errors described in Note 1, Significant Accounting Policies and Restatement: CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,027 $ (1) $ 1,026 $ 874 $ 7 $ 881 Cost of products sold 448 (1) 447 406 — 406 Gross profit 579 — 579 468 7 475 Selling, general, and administrative expenses 385 1 386 359 (2) 357 Research and development expenses 37 3 40 34 2 36 Goodwill impairment — — — 157 — 157 Restructuring and other costs 3 — 3 43 (1) 42 Operating income (loss) 154 (4) 150 (125) 8 (117) Other income and expenses: Interest expense, net 14 — 14 7 (1) 6 Other expense (income), net (9) — (9) (2) 1 (1) Income (loss) before income taxes 149 (4) 145 (130) 8 (122) Provision for income taxes 32 1 33 10 2 12 Net income (loss) 117 (5) 112 (140) 6 (134) Less: Net income (loss) attributable to noncontrolling interest — — — — — — Net income (loss) attributable to Dentsply Sirona $ 117 $ (5) $ 112 $ (140) $ 6 $ (134) Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 0.53 $ (0.02) $ 0.51 $ (0.63) $ 0.02 $ (0.61) Diluted $ 0.53 $ (0.02) $ 0.51 $ (0.63) $ 0.02 $ (0.61) CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,067 $ (5) $ 1,062 $ 491 $ 8 $ 499 Cost of products sold 469 (2) 467 315 2 317 Gross profit 598 (3) 595 176 6 182 Selling, general, and administrative expenses 398 (5) 393 261 (2) 259 Research and development expenses 40 3 43 18 2 20 Restructuring and other costs 5 — 5 1 1 2 Operating income (loss) 155 (1) 154 (104) 5 (99) Other income and expenses: Interest expense, net 16 (1) 15 11 — 11 Other expense (income), net 5 3 8 5 (1) 4 Income (loss) before income taxes 134 (3) 131 (120) 6 (114) Provision (benefit) for income taxes 35 — 35 (24) 2 (22) Net income (loss) 99 (3) 96 (96) 4 (92) Less: Net income (loss) attributable to noncontrolling interest — — — (1) — (1) Net income (loss) attributable to Dentsply Sirona $ 99 $ (3) $ 96 $ (95) $ 4 $ (91) Net income (loss) per common share attributable to Dentsply Sirona: Basic $ 0.45 $ (0.01) $ 0.44 $ (0.44) $ 0.02 $ (0.42) Diluted $ 0.45 $ (0.02) $ 0.43 $ (0.44) $ 0.02 $ (0.42) CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised Net sales $ 1,069 $ (29) $ 1,040 $ 895 $ (12) $ 883 Cost of products sold 478 (7) 471 453 (2) 451 Gross profit 591 (22) 569 442 (10) 432 Selling, general, and administrative expenses 394 1 395 315 (2) 313 Research and development expenses 35 4 39 27 2 29 Restructuring and other costs 3 — 3 18 — 18 Operating income 159 (27) 132 82 (10) 72 Interest expense, net 13 1 14 14 — 14 Other expense (income), net 8 (3) 5 1 — 1 Income before income taxes 138 (25) 113 67 (10) 57 Provision for income taxes 35 (6) 29 13 (4) 9 Net income 103 (19) 84 54 (6) 48 Net income attributable to Dentsply Sirona $ 103 $ (19) $ 84 $ 53 $ (6) $ 47 Net income per common share attributable to Dentsply Sirona: Basic $ 0.47 $ (0.08) $ 0.39 $ 0.25 $ (0.03) $ 0.22 Diluted $ 0.47 $ (0.09) $ 0.38 $ 0.25 $ (0.03) $ 0.22 CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 (in millions, except per share amounts) As Previously Issued Adjustment As As Previously Issued Adjustment As Net sales $ 1,088 $ 15 $ 1,103 $ 1,082 $ (6) $ 1,076 Cost of products sold 495 4 499 511 (2) 509 Gross profit 593 11 604 571 (4) 567 Selling, general, and administrative expenses 374 3 377 377 (4) 373 Research and development expenses 59 (10) 49 44 (6) 38 Restructuring and other costs 6 — 6 15 — 15 Operating income 154 18 172 135 6 141 Other income and expenses: Interest expense, net 12 — 12 15 — 15 Other expense (income), net 4 — 4 (3) — (3) Income before income taxes 138 18 156 123 6 129 Provision for income taxes 36 1 37 24 — 24 Net income 102 17 119 99 6 105 Less: Net income attributable to noncontrolling interest — — — — — — Net income attributable to Dentsply Sirona $ 102 $ 17 $ 119 $ 99 $ 6 $ 105 Net income per common share attributable to Dentsply Sirona: Basic $ 0.47 $ 0.08 $ 0.55 $ 0.45 $ 0.03 $ 0.48 Diluted $ 0.47 $ 0.07 $ 0.54 $ 0.45 $ 0.03 $ 0.48 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 117 $ (5) $ 112 $ (140) $ 6 $ (134) Total comprehensive income 27 (5) 22 (252) 6 (246) Comprehensive income attributable to Dentsply Sirona $ 27 $ (5) $ 22 $ (252) $ 6 $ (246) CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 99 $ (3) $ 96 $ (96) $ 4 $ (92) Total comprehensive income 142 (3) 139 (28) 4 (24) Comprehensive income attributable to Dentsply Sirona $ 142 $ (3) $ 139 $ (28) $ 4 $ (24) CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 (in millions) As Previously Issued Adjustment As Restated As Previously Issued Adjustment As Revised Net income $ 103 $ (19) $ 84 $ 54 $ (6) $ 48 Total comprehensive income 47 (19) 28 121 (6) 115 Comprehensive income attributable to Dentsply Sirona $ 47 $ (19) $ 28 $ 121 $ (6) $ 115 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 (in millions) As Previously Issued Adjustment As As Previously Issued Adjustment As Net income (loss) $ 102 $ 17 $ 119 $ 99 $ 6 $ 105 Total comprehensive income 75 17 92 213 8 221 Comprehensive income attributable to Dentsply Sirona $ 75 $ 17 $ 92 $ 213 $ 8 $ 221
Schedule of Quarterly Financial Information	2021 Net Sales Gross Profit Operating Income (Loss) Net (Loss) Income attributable to Dentsply Sirona Net (Loss) Income per Common Share - Basic Net (Loss) Income per Common Share - Diluted Cash Dividends Declared per Common Share First Quarter As previously issued $ 1,027 $ 579 $ 154 $ 117 $ 0.53 $ 0.53 $ 0.1000 Adjustment (1) — (4) (5) (0.02) (0.02) — As revised $ 1,026 $ 579 $ 150 $ 112 $ 0.51 $ 0.51 $ 0.1000 Second Quarter As previously issued $ 1,067 $ 598 $ 155 $ 99 $ 0.45 $ 0.45 $ 0.1100 Adjustment (5) (3) (1) (3) (0.01) (0.02) — As revised $ 1,062 $ 595 $ 154 $ 96 $ 0.44 $ 0.43 $ 0.1100 Third Quarter As previously issued $ 1,069 $ 591 $ 159 $ 103 $ 0.47 $ 0.47 $ 0.1100 Adjustment (29) (22) (27) (19) (0.08) (0.09) — As restated $ 1,040 $ 569 $ 132 $ 84 $ 0.39 $ 0.38 $ 0.1100 Fourth Quarter As previously issued $ 1,088 $ 593 $ 154 $ 102 $ 0.47 $ 0.47 $ 0.1100 Adjustment 15 11 18 17 0.08 0.07 — As restated $ 1,103 $ 604 $ 172 $ 119 $ 0.55 $ 0.54 $ 0.1100 Rounding, As previously issued — — — — 0.01 (0.01) — Rounding: Adjustment — — — — (0.02) 0.02 — Rounding, As revised — — — — (0.01) 0.01 — Total Year As previously issued $ 4,251 $ 2,361 $ 622 $ 421 $ 1.93 $ 1.91 $ 0.4300 Adjustment (20) (14) (14) (10) (0.05) (0.04) — As revised $ 4,231 $ 2,347 $ 608 $ 411 $ 1.88 $ 1.87 $ 0.4300 2020 Net Sales Gross Profit Operating Income (Loss) Net (Loss) Income attributable to Dentsply Sirona Net (Loss) Income per Common Share - Basic Net (Loss) Income per Common Share - Diluted Cash Dividends Declared per Common Share First Quarter As previously issued $ 874 $ 468 $ (125) $ (140) $ (0.63) $ (0.63) $ 0.1000 Adjustment 7 7 8 6 0.02 0.02 — As revised $ 881 $ 475 $ (117) $ (134) $ (0.61) $ (0.61) $ 0.1000 Second Quarter As previously issued $ 491 $ 176 $ (104) $ (95) $ (0.44) $ (0.44) $ 0.1000 Adjustment 8 6 5 4 0.02 0.02 — As revised $ 499 $ 182 $ (99) $ (91) $ (0.42) $ (0.42) $ 0.1000 Third Quarter As previously issued $ 895 $ 442 $ 82 $ 53 $ 0.25 $ 0.25 $ 0.1000 Adjustment (12) (10) (10) (6) (0.03) (0.03) — As revised $ 883 $ 432 $ 72 $ 47 $ 0.22 $ 0.22 $ 0.1000 Fourth Quarter As previously issued $ 1,082 $ 571 $ 135 $ 99 $ 0.45 $ 0.45 $ 0.1000 Adjustment (6) (4) 6 6 0.03 0.03 — As revised $ 1,076 $ 567 $ 141 $ 105 $ 0.48 $ 0.48 $ 0.1000 Rounding, As previously issued — — — — (0.01) (0.01) — Rounding, Adjustment — — — — 0.01 0.01 — Total Year As previously issued $ 3,342 $ 1,657 $ (12) $ (83) $ (0.38) $ (0.38) $ 0.4000 Adjustment (3) (1) 9 10 0.05 0.05 — As revised $ 3,339 $ 1,656 $ (3) $ (73) $ (0.33) $ (0.33) $ 0.4000

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021 USD ($) country	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) segment country shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Significant Accounting Policies [Line Items]
Company years in innovation and service									134 years
Number of countries in which entity operates | country	150								150
Net sales	$ (1,103)	$ (1,040)	$ (1,062)	$ (1,026)	$ (1,076)	$ (883)	$ (499)	$ (881)	$ (4,231)	$ (3,339)	$ (4,022)
Total Equity	4,997				4,935				4,997	4,935	5,048	$ 5,083
Cost of inventories determined by LIFO method					3					3	5
Increase in inventory	4								4
Foreign currency translation gain (loss)									(181)	184	(83)
Foreign exchange transaction gain (loss)									$ 6	13	27
Shares issued, shares, share-based payment arrangement, after forfeiture (in shares) | shares									3
Equity in net loss of unconsolidated affiliated company									$ 10	1
Number of reportable segments | segment									2
Adjustment
Significant Accounting Policies [Line Items]
Net sales	(15)	$ 29	$ 5	$ 1	6	$ 12	$ (8)	$ (7)	$ 20	3	7
Total Equity	(46)				(35)				$ (46)	(35)
Building
Significant Accounting Policies [Line Items]
Useful life (in years)									40 years
Restricted Stock Units (RSUs)
Significant Accounting Policies [Line Items]
Exercisable period following death, disability or qualified retirement									1 year
Employee Stock Option
Significant Accounting Policies [Line Items]
Award expiration period									10 years
Gain and (Loss) on Cash Flow Hedges | Hedges of Net Investments
Significant Accounting Policies [Line Items]
Total Equity	46				(54)				$ 46	(54)
Foreign currency translation gain (loss)									(225)	235
Retained Earnings
Significant Accounting Policies [Line Items]
Total Equity	1,514				1,198				$ 1,514	1,198	1,359	1,188
Minimum
Significant Accounting Policies [Line Items]
Lease, remaining lease term									1 year
Lessee, lease, renewal term									1 year
Minimum | Machinery and equipment
Significant Accounting Policies [Line Items]
Useful life (in years)									4 years
Minimum | Capitalized Software
Significant Accounting Policies [Line Items]
Useful life (in years)									2 years
Maximum
Significant Accounting Policies [Line Items]
Lease, remaining lease term									10 years
Lessee, lease, renewal term									3 years
Maximum | Machinery and equipment
Significant Accounting Policies [Line Items]
Useful life (in years)									15 years
Maximum | Capitalized Software
Significant Accounting Policies [Line Items]
Useful life (in years)									10 years
Allowance for doubtful accounts
Significant Accounting Policies [Line Items]
Allowance for Sirona opening balance	$ 13				$ 18				$ 13	18	29	$ 25
Allowance for doubtful accounts receivable, write-offs									2	12
Additions - charged (credited) to costs and expenses									$ 2	$ 1	$ 10

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES - Corrections to the Consolidated Statements Of Operations (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 1,103,000,000	$ 1,040,000,000	$ 1,062,000,000	$ 1,026,000,000	$ 1,076,000,000	$ 883,000,000	$ 499,000,000	$ 881,000,000	$ 4,231,000,000	$ 3,339,000,000	$ 4,022,000,000
Cost of products sold	499,000,000	471,000,000	467,000,000	447,000,000	509,000,000	451,000,000	317,000,000	406,000,000	1,884,000,000	1,683,000,000	1,858,000,000
Gross profit	604,000,000	569,000,000	595,000,000	579,000,000	567,000,000	432,000,000	182,000,000	475,000,000	2,347,000,000	1,656,000,000	2,164,000,000
Selling, general, and administrative expenses	377,000,000	395,000,000	393,000,000	386,000,000	373,000,000	313,000,000	259,000,000	357,000,000	1,551,000,000	1,302,000,000	1,587,000,000
Research and development expenses	49,000,000	39,000,000	43,000,000	40,000,000	38,000,000	29,000,000	20,000,000	36,000,000	171,000,000	123,000,000	143,000,000
Goodwill impairment				0				157,000,000	0	157,000,000	0
Restructuring and other costs - non-cash	6,000,000	3,000,000	5,000,000	3,000,000	15,000,000	18,000,000	2,000,000	42,000,000	17,000,000	77,000,000	81,000,000
Operating income	172,000,000	132,000,000	154,000,000	150,000,000	141,000,000	72,000,000	(99,000,000)	(117,000,000)	608,000,000	(3,000,000)	353,000,000
Interest expense, net	12,000,000	14,000,000	15,000,000	14,000,000	15,000,000	14,000,000	11,000,000	6,000,000	55,000,000	46,000,000	27,000,000
Other expense (income), net	4,000,000	5,000,000	8,000,000	(9,000,000)	(3,000,000)	1,000,000	4,000,000	(1,000,000)	8,000,000	1,000,000	(12,000,000)
Income (loss) before income taxes	156,000,000	113,000,000	131,000,000	145,000,000	129,000,000	57,000,000	(114,000,000)	(122,000,000)	545,000,000	(50,000,000)	338,000,000
Provision for income taxes	37,000,000	29,000,000	35,000,000	33,000,000	24,000,000	9,000,000	(22,000,000)	12,000,000	134,000,000	23,000,000	82,000,000
Net income (loss)	119,000,000	84,000,000	96,000,000	112,000,000	105,000,000	48,000,000	(92,000,000)	(134,000,000)	411,000,000	(73,000,000)	256,000,000
Less: Net income (loss) attributable to noncontrolling interests	0		0	0	0		(1,000,000)	0	0	0	0
Net income attributable to Dentsply Sirona	$ 119,000,000	$ 84,000,000	$ 96,000,000	$ 112,000,000	$ 105,000,000	$ 47,000,000	$ (91,000,000)	$ (134,000,000)	$ 411,000,000	$ (73,000,000)	$ 256,000,000
Net income (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ 0.55	$ 0.39	$ 0.44	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.88	$ (0.33)	$ 1.15
Diluted (in dollars per share)	$ 0.54	$ 0.38	$ 0.43	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.87	$ (0.33)	$ 1.14
As Previously Issued
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 1,088,000,000	$ 1,069,000,000	$ 1,067,000,000	$ 1,027,000,000	$ 1,082,000,000	$ 895,000,000	$ 491,000,000	$ 874,000,000	$ 4,251,000,000	$ 3,342,000,000	$ 4,029,000,000
Cost of products sold	495,000,000	478,000,000	469,000,000	448,000,000	511,000,000	453,000,000	315,000,000	406,000,000	1,890,000,000	1,685,000,000	1,864,000,000
Gross profit	593,000,000	591,000,000	598,000,000	579,000,000	571,000,000	442,000,000	176,000,000	468,000,000	2,361,000,000	1,657,000,000	2,165,000,000
Selling, general, and administrative expenses	374,000,000	394,000,000	398,000,000	385,000,000	377,000,000	315,000,000	261,000,000	359,000,000	1,551,000,000	1,312,000,000	1,580,000,000
Research and development expenses	59,000,000	35,000,000	40,000,000	37,000,000	44,000,000	27,000,000	18,000,000	34,000,000	171,000,000	123,000,000	143,000,000
Goodwill impairment				0				157,000,000	0	157,000,000	0
Restructuring and other costs - non-cash	6,000,000	3,000,000	5,000,000	3,000,000	15,000,000	18,000,000	1,000,000	43,000,000	17,000,000	77,000,000	81,000,000
Operating income	154,000,000	159,000,000	155,000,000	154,000,000	135,000,000	82,000,000	(104,000,000)	(125,000,000)	622,000,000	(12,000,000)	361,000,000
Interest expense, net	12,000,000	13,000,000	16,000,000	14,000,000	15,000,000	14,000,000	11,000,000	7,000,000	55,000,000	47,000,000	28,000,000
Other expense (income), net	4,000,000	8,000,000	5,000,000	(9,000,000)	(3,000,000)	1,000,000	5,000,000	(2,000,000)	8,000,000	1,000,000	(12,000,000)
Income (loss) before income taxes	138,000,000	138,000,000	134,000,000	149,000,000	123,000,000	67,000,000	(120,000,000)	(130,000,000)	559,000,000	(60,000,000)	345,000,000
Provision for income taxes	36,000,000	35,000,000	35,000,000	32,000,000	24,000,000	13,000,000	(24,000,000)	10,000,000	138,000,000	23,000,000	82,000,000
Net income (loss)	102,000,000	103,000,000	99,000,000	117,000,000	99,000,000	54,000,000	(96,000,000)	(140,000,000)	421,000,000	(83,000,000)	263,000,000
Less: Net income (loss) attributable to noncontrolling interests	0		0	0	0		(1,000,000)	0	0	0	0
Net income attributable to Dentsply Sirona	$ 102,000,000	$ 103,000,000	$ 99,000,000	$ 117,000,000	$ 99,000,000	$ 53,000,000	$ (95,000,000)	$ (140,000,000)	$ 421,000,000	$ (83,000,000)	$ 263,000,000
Net income (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ 0.47	$ 0.47	$ 0.45	$ 0.53	$ 0.45	$ 0.25	$ (0.44)	$ (0.63)	$ 1.93	$ (0.38)	$ 1.18
Diluted (in dollars per share)	$ 0.47	$ 0.47	$ 0.45	$ 0.53	$ 0.45	$ 0.25	$ (0.44)	$ (0.63)	$ 1.91	$ (0.38)	$ 1.17
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 15,000,000	$ (29,000,000)	$ (5,000,000)	$ (1,000,000)	$ (6,000,000)	$ (12,000,000)	$ 8,000,000	$ 7,000,000	$ (20,000,000)	$ (3,000,000)	$ (7,000,000)
Cost of products sold	4,000,000	(7,000,000)	(2,000,000)	(1,000,000)	(2,000,000)	(2,000,000)	2,000,000	0	(6,000,000)	(2,000,000)	(6,000,000)
Gross profit	11,000,000	(22,000,000)	(3,000,000)	0	(4,000,000)	(10,000,000)	6,000,000	7,000,000	(14,000,000)	(1,000,000)	(1,000,000)
Selling, general, and administrative expenses	3,000,000	1,000,000	(5,000,000)	1,000,000	(4,000,000)	(2,000,000)	(2,000,000)	(2,000,000)	0	(10,000,000)	7,000,000
Research and development expenses	(10,000,000)	4,000,000	3,000,000	3,000,000	(6,000,000)	2,000,000	2,000,000	2,000,000	0	0	0
Goodwill impairment				0				0	0	0	0
Restructuring and other costs - non-cash	0	0	0	0	0	0	1,000,000	(1,000,000)	0	0	0
Operating income	18,000,000	(27,000,000)	(1,000,000)	(4,000,000)	6,000,000	(10,000,000)	5,000,000	8,000,000	(14,000,000)	9,000,000	(8,000,000)
Interest expense, net	0	1,000,000	(1,000,000)	0	0	0	0	(1,000,000)	0	(1,000,000)	(1,000,000)
Other expense (income), net	0	(3,000,000)	3,000,000	0	0	0	(1,000,000)	1,000,000	0	0	0
Income (loss) before income taxes	18,000,000	(25,000,000)	(3,000,000)	(4,000,000)	6,000,000	(10,000,000)	6,000,000	8,000,000	(14,000,000)	10,000,000	(7,000,000)
Provision for income taxes	1,000,000	(6,000,000)	0	1,000,000	0	(4,000,000)	2,000,000	2,000,000	(4,000,000)	0	0
Net income (loss)	17,000,000	(19,000,000)	(3,000,000)	(5,000,000)	6,000,000	(6,000,000)	4,000,000	6,000,000	(10,000,000)	10,000,000	(7,000,000)
Less: Net income (loss) attributable to noncontrolling interests	0		0	0	0		0	0	0	0	0
Net income attributable to Dentsply Sirona	$ 17,000,000	$ (19,000,000)	$ (3,000,000)	$ (5,000,000)	$ 6,000,000	$ (6,000,000)	$ 4,000,000	$ 6,000,000	$ (10,000,000)	$ 10,000,000	$ (7,000,000)
Net income (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ 0.08	$ (0.08)	$ (0.01)	$ (0.02)	$ 0.03	$ (0.03)	$ 0.02	$ 0.02	$ (0.05)	$ 0.05	$ (0.03)
Diluted (in dollars per share)	$ 0.07	$ (0.09)	$ (0.02)	$ (0.02)	$ 0.03	$ (0.03)	$ 0.02	$ 0.02	$ (0.04)	$ 0.05	$ (0.03)

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES - Corrections to the Consolidated Statements Of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)	$ 119	$ 84	$ 96	$ 112	$ 105	$ 48	$ (92)	$ (134)	$ 411	$ (73)	$ 256
Pension liability adjustments									26	(13)	(26)
Other comprehensive income									(130)	139	(110)
Total comprehensive income	92	28	139	22	221	115	(24)	(246)	281	66	146
Comprehensive income attributable to Dentsply Sirona	92	28	139	22	221	115	(24)	(246)	283	65	145
As Previously Issued
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)	102	103	99	117	99	54	(96)	(140)	421	(83)	263
Pension liability adjustments									26	(13)	(36)
Other comprehensive income									(130)	137	(120)
Total comprehensive income	75	47	142	27	213	121	(28)	(252)	291	54	143
Comprehensive income attributable to Dentsply Sirona	75	47	142	27	213	121	(28)	(252)	293	53	142
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)	17	(19)	(3)	(5)	6	(6)	4	6	(10)	10	(7)
Pension liability adjustments									0	0	10
Other comprehensive income									0	2	10
Total comprehensive income	17	(19)	(3)	(5)	8	(6)	4	6	(10)	12	3
Comprehensive income attributable to Dentsply Sirona	$ 17	$ (19)	$ (3)	$ (5)	$ 8	$ (6)	$ 4	$ 6	$ (10)	$ 12	$ 3

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES - Corrections to the Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts and notes receivable-trade, net	$ 750	$ 667
Inventories, net	515	476
Prepaid expenses and other current assets	248	217
Total Current Assets	1,852	1,798
Operating lease right-of-use assets, net	198	176
Other noncurrent assets	121	95
Total Assets	9,239	9,350
Accounts payable	262	302
Accrued liabilities	760	712
Income taxes payable	57	59
Total Current Liabilities	1,261	1,372
Operating lease liabilities	149	130
Deferred income taxes	391	381
Total Liabilities	4,242	4,415
Retained earnings	1,514	1,198
Total Dentsply Sirona Equity	4,996	4,932
Total Equity	4,997	4,935	$ 5,048	$ 5,083
Total Liabilities and Equity	9,239	9,350
As Previously Issued
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts and notes receivable-trade, net	747	673
Inventories, net	504	466
Prepaid expenses and other current assets	247	214
Total Current Assets	1,837	1,791
Operating lease right-of-use assets, net	193	176
Other noncurrent assets	122	94
Total Assets	9,220	9,342
Accounts payable	268	305
Accrued liabilities	679	653
Income taxes payable	57	60
Total Current Liabilities	1,186	1,317
Operating lease liabilities	145	130
Deferred income taxes	408	393
Total Liabilities	4,177	4,372
Retained earnings	1,560	1,233
Total Dentsply Sirona Equity	5,042	4,967
Total Equity	5,043	4,970
Total Liabilities and Equity	9,220	9,342
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts and notes receivable-trade, net	3	(6)
Inventories, net	11	10
Prepaid expenses and other current assets	1	3
Total Current Assets	15	7
Operating lease right-of-use assets, net	5	0
Other noncurrent assets	(1)	1
Total Assets	19	8
Accounts payable	(6)	(3)
Accrued liabilities	81	59
Income taxes payable	0	(1)
Total Current Liabilities	75	55
Operating lease liabilities	4	0
Deferred income taxes	(17)	(12)
Total Liabilities	65	43
Retained earnings	(46)	(35)		$ 38
Total Dentsply Sirona Equity	(46)	(35)
Total Equity	(46)	(35)
Total Liabilities and Equity	$ 19	$ 8

SIGNIFICANT ACCOUNTING POLICI_8

SIGNIFICANT ACCOUNTING POLICIES - Corrections to the Consolidated Statement Of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended								6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 119	$ 84	$ 96	$ 112	$ 105	$ 48	$ (92)	$ (134)			$ 411	$ (73)	$ 256
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred income taxes											(25)	(62)	(40)
Other non-cash (income) expense											34	3	6
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net											(117)	131	(90)
Inventories, net											(64)	123	11
Prepaid expenses and other current assets, net											(32)	39	12
Accounts payable											(49)	(28)	27
Accrued liabilities											100	(10)	59
Income taxes											17	(41)	(14)
Other noncurrent liabilities											12	(15)	(12)
Net cash provided by operating activities	0	0	0	0							657	649	639
Cash flows from financing activities:
Other financing activities, net											(36)	(26)	(40)
Net cash (used in) provided by financing activities	0	0	0	0							(379)	476	(472)
As Previously Issued
Cash flows from operating activities:
Net income (loss)	102	103	99	117	99	54	(96)	(140)			421	(83)	263
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred income taxes											(20)	(64)	(37)
Other non-cash (income) expense											34	2	(6)
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net											(109)	126	(91)
Inventories, net											(63)	124	14
Prepaid expenses and other current assets, net											(35)	42	13
Accounts payable											(46)	(23)	26
Accrued liabilities											78	(17)	45
Income taxes											17	(39)	(16)
Other noncurrent liabilities											10	(15)	(2)
Net cash provided by operating activities											657	635	633
Cash flows from financing activities:
Other financing activities, net											(36)	(12)	(34)
Net cash (used in) provided by financing activities											(379)	490	(466)
Adjustment
Cash flows from operating activities:
Net income (loss)	$ 17	$ (19)	$ (3)	$ (5)	$ 6	$ (6)	$ 4	6			(10)	10	(7)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred income taxes											(5)	2	(3)
Other non-cash (income) expense											0	1	12
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net											(8)	5	1
Inventories, net											(1)	(1)	(3)
Prepaid expenses and other current assets, net											3	(3)	(1)
Accounts payable											(3)	(5)	1
Accrued liabilities											22	7	14
Income taxes											0	(2)	2
Other noncurrent liabilities											2	0	(10)
Net cash provided by operating activities								6	$ 12	$ 13	0	14	6
Cash flows from financing activities:
Other financing activities, net											0	(14)	(6)
Net cash (used in) provided by financing activities								$ 6	$ 12	$ 13	$ 0	$ (14)	$ (6)

SIGNIFICANT ACCOUNTING POLICI_9

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Intangible Assets (Details) - Maximum	12 Months Ended
	Dec. 31, 2021
Tradenames and trademarks
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	20 years
Licensing agreements
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	20 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	15 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life (in years)	15 years

SIGNIFICANT ACCOUNTING POLIC_10

SIGNIFICANT ACCOUNTING POLICIES - Schedule of Warranties (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Warranty Expense	$ 44	$ 27	$ 30
Warranty Accrual	$ 28	$ 18	$ 18

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Total net sales	$ 1,103	$ 1,040	$ 1,062	$ 1,026	$ 1,076	$ 883	$ 499	$ 881	$ 4,231	$ 3,339	$ 4,022
Deferred income	$ 68				$ 53				68	53
United States | Geographical Basis, Country of Sales
Disaggregation of Revenue [Line Items]
Total net sales									1,480	1,115	1,374
Europe | Geographical Basis, Country of Sales
Disaggregation of Revenue [Line Items]
Total net sales									1,675	1,381	1,609
Rest of World | Geographical Basis, Country of Sales
Disaggregation of Revenue [Line Items]
Total net sales									1,076	843	1,039
Technology & Equipment segment
Disaggregation of Revenue [Line Items]
Total net sales									2,504	1,954	2,271
Technology & Equipment segment | Equipment & Instruments
Disaggregation of Revenue [Line Items]
Total net sales									728	577	686
Technology & Equipment segment | CAD/CAM
Disaggregation of Revenue [Line Items]
Total net sales									574	455	523
Technology & Equipment segment | Orthodontics
Disaggregation of Revenue [Line Items]
Total net sales									273	160	190
Technology & Equipment segment | Implants
Disaggregation of Revenue [Line Items]
Total net sales									626	475	592
Technology & Equipment segment | Healthcare
Disaggregation of Revenue [Line Items]
Total net sales									303	287	280
Consumables segment
Disaggregation of Revenue [Line Items]
Total net sales									1,727	1,385	1,751
Consumables segment | Endodontic & Restorative
Disaggregation of Revenue [Line Items]
Total net sales									1,261	961	1,203
Consumables segment | Other Consumables
Disaggregation of Revenue [Line Items]
Total net sales									$ 466	$ 424	$ 548

STOCK COMPENSATION - ADDITIONAL

STOCK COMPENSATION - ADDITIONAL INFORMATION (Details) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2016 shares
Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]
Conversion ratio for RSUs and restricted stock	3.09
Intrinsic value of options exercised | $	$ 16	$ 3	$ 37
Total fair value of share vested during the period | $	$ 76	$ 54	$ 44
Weighted average remaining contractual life (in years)	5 years 7 months 6 days
Weighted average remaining contractual term of exercisable options (in years)	4 years 2 months 12 days
Equity Incentive Plan 2016
Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]
Authorized grants under the plan (in shares) | shares				25
Number of shares available for grant (in shares) | shares	20
Tax Year 2016 | Key Employee
Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]
Cap on restricted stock or RSU (in shares) | shares	1
Nonqualified Plan
Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]
Number of unvested stock options (in shares) | shares	1
Unamortized compensation costs | $	$ 9
Weighted average period for cost recognition	1 year 9 months 18 days
Restricted Stock Units (RSUs)
Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]
Unamortized compensation costs | $	$ 42
Weighted average period for cost recognition	2 years

STOCK COMPENSATION - SUMMARY ST

STOCK COMPENSATION - SUMMARY STOCK COMPENSATION EXPENSE (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	$ 49	$ 46	$ 65
Related deferred income tax benefit	6	5	8
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	3	1	2
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	44	44	61
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	$ 2	$ 1	$ 2

STOCK COMPENSATION - ASSUMPTION

STOCK COMPENSATION - ASSUMPTIONS USED TO DETERMINE COMPENSATION COST FOR THE COMPANY'S NON-QUALIFIED STOCK OPTIONS ISSUED (Details) - Nonqualified Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value per share (in dollars per share)	$ 15.9	$ 10.03	$ 12.2
Expected dividend yield	0.68%	0.84%	0.71%
Risk-free interest rate	0.79%	0.77%	2.36%
Expected volatility	31.50%	24%	22.60%
Expected life (years)	5 years 29 days	5 years 5 months 26 days	6 years

STOCK COMPENSATION - NON-QUALIF

STOCK COMPENSATION - NON-QUALIFIED STOCK OPTION TRANSACTIONS (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Shares
Exercised (in shares)	(1.1)	(0.3)	(2.7)
Nonqualified Stock Options
Shares
Beginning balance (in shares)	4
Granted (in shares)	0.5
Exercised (in shares)	(1.1)
Forfeited (in shares)	(0.2)
Ending balance (in shares)	3.2	4
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 50.01
Granted (in dollars per share)	58.85
Exercised (in dollars per share)	46.81
Forfeited (in dollars per share)	53.03
Ending balance (in dollars per share)	$ 52.44	$ 50.01
Aggregate Intrinsic Value
Balance	$ 15	$ 17
Exercisable
Shares at year end (in shares)	2.2	2.7
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 52.05	$ 50.28
Aggregate Intrinsic Value	$ 11	$ 12

STOCK COMPENSATION - INFORMATIO

STOCK COMPENSATION - INFORMATION ABOUT NON-QUALIFIED STOCK OPTIONS OUTSTANDING (Details) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Contractual Life (in years)	5 years 7 months 6 days
Nonqualified Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Outstanding (in shares)	3.2	4
Weighted Average Exercise Price (in dollars per share)	$ 52.44	$ 50.01
Number Exercisable (in shares)	2.2	2.7
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 52.05	$ 50.28
Nonqualified Stock Options | Exercise Prices: $30.01 - $40.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	30.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 40
Number Outstanding (in shares)	0.1
Weighted Average Remaining Contractual Life (in years)	1 year 4 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 37.29
Number Exercisable (in shares)	0.1
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 37.29
Nonqualified Stock Options | Exercise Prices: $40.01 - $50.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	40.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 50
Number Outstanding (in shares)	1.4
Weighted Average Remaining Contractual Life (in years)	5 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 47.31
Number Exercisable (in shares)	0.8
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 46.73
Nonqualified Stock Options | Exercise Prices: $50.01 - $60.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	50.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 60
Number Outstanding (in shares)	1.4
Weighted Average Remaining Contractual Life (in years)	6 years
Weighted Average Exercise Price (in dollars per share)	$ 56.32
Number Exercisable (in shares)	0.9
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 55.05
Nonqualified Stock Options | Exercise Prices: $60.01 - $70.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices, lower range limit (in dollars per share)	60.01
Range of Exercise Prices, upper range limit (in dollars per share)	$ 70
Number Outstanding (in shares)	0.3
Weighted Average Remaining Contractual Life (in years)	4 years 3 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 62.37
Number Exercisable (in shares)	0.4
Weighted Average Exercise Price Exercisable (in dollars per share)	$ 62.24

STOCK COMPENSATION - UNVESTED R

STOCK COMPENSATION - UNVESTED RSU TRANSACTIONS (Details) - Restricted Stock Units (RSUs) shares in Millions	12 Months Ended
	Dec. 31, 2021 $ / shares shares
Shares
Beginning balance, unvested (in shares) | shares	4.2
Granted (in shares) | shares	1
Vested (in shares) | shares	(1.5)
Forfeited (in shares) | shares	(0.6)
Ending balance, unvested (in shares) | shares	3.1
Weighted Average Grant Date Fair Value
Beginning balance, unvested (in dollars per share) | $ / shares	$ 47.29
Granted (in dollars per share) | $ / shares	63.61
Vested (in dollars per share) | $ / shares	45.08
Forfeited (in dollars per share) | $ / shares	50.01
Ending balance, unvested (in dollars per share) | $ / shares	$ 53.52

EARNINGS PER COMMON SHARE - COM

EARNINGS PER COMMON SHARE - COMPUTATION OF BASIC AND DILUTED (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net income attributable to Dentsply Sirona	$ 119	$ 84	$ 96	$ 112	$ 105	$ 47	$ (91)	$ (134)	$ 411	$ (73)	$ 256
Shares
Weighted average common shares outstanding (in shares)									218.4	219.2	223.1
Earnings (loss) per common share - basic (in dollars per share)	$ 0.55	$ 0.39	$ 0.44	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.88	$ (0.33)	$ 1.15
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards (in shares)									1.8	0	1.3
Total weighted average diluted shares outstanding (in shares)									220.2	219.2	224.4
(Loss) earnings per common share
Earnings (loss) per common share - diluted (in dollars per share)	$ 0.54	$ 0.38	$ 0.43	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.87	$ (0.33)	$ 1.14

EARNINGS PER COMMON SHARE - ADD

EARNINGS PER COMMON SHARE - ADDITIONAL INFORMATION (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Antidilutive common stock options not included in the computation of diluted earnings per common share (in shares)	1	3.1	3.1
Earnings per share, potentially dilutive securities excluded from computation of earnings per share (in shares)		0.9

COMPREHENSIVE (LOSS) INCOME - A

COMPREHENSIVE (LOSS) INCOME - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency tax adjustments	$ 168	$ 216	$ 173
Total Equity	4,997	4,935	$ 5,048	$ 5,083
Accumulated foreign currency adjustment, translation gain (loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total Equity	(250)	(25)
Accumulated foreign currency adjustment, net investments hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total Equity	$ (116)	$ (162)

COMPREHENSIVE (LOSS) INCOME - C

COMPREHENSIVE (LOSS) INCOME - CHANGES IN AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning Balance	$ 4,935	$ 5,048	$ 5,083
Total other comprehensive (loss) income	(130)	139	(110)
Ending Balance	4,997	4,935	5,048
Total
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning Balance	(464)	(602)	(491)
Other comprehensive (loss) income before reclassifications and tax impact	(105)	87
Tax expense	(38)	43
Other comprehensive (loss) income, net of tax, before reclassifications	(143)	130
Amounts reclassified from accumulated other comprehensive income, net of tax	15	8
Total other comprehensive (loss) income	(128)	138	(111)
Ending Balance	(592)	(464)	(602)
Foreign Currency Translation Gain (Loss)
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning Balance	(187)	(370)
Other comprehensive (loss) income before reclassifications and tax impact	(156)	153
Tax expense	(23)	30
Other comprehensive (loss) income, net of tax, before reclassifications	(179)	183
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0
Total other comprehensive (loss) income	(179)	183
Ending Balance	(366)	(187)	(370)
Gain and (Loss) on Cash Flow Hedges
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning Balance	(25)	(11)
Other comprehensive (loss) income before reclassifications and tax impact	3	(17)
Tax expense	(1)	1
Other comprehensive (loss) income, net of tax, before reclassifications	2	(16)
Amounts reclassified from accumulated other comprehensive income, net of tax	7	2
Total other comprehensive (loss) income	9	(14)
Ending Balance	(16)	(25)	(11)
Gain and (Loss) on Net Investment and Fair Value Hedges
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning Balance	(119)	(101)
Other comprehensive (loss) income before reclassifications and tax impact	22	(23)
Tax expense	(6)	5
Other comprehensive (loss) income, net of tax, before reclassifications	16	(18)
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0
Total other comprehensive (loss) income	16	(18)
Ending Balance	(103)	(119)	(101)
Pension Liability Gain (Loss)
Accumulated other comprehensive income (loss) rollforward [Roll Forward]
Beginning Balance	(133)	(120)
Other comprehensive (loss) income before reclassifications and tax impact	26	(26)
Tax expense	(8)	7
Other comprehensive (loss) income, net of tax, before reclassifications	18	(19)
Amounts reclassified from accumulated other comprehensive income, net of tax	8	6
Total other comprehensive (loss) income	26	(13)
Ending Balance	$ (107)	$ (133)	$ (120)

COMPREHENSIVE (LOSS) INCOME - R

COMPREHENSIVE (LOSS) INCOME - RECLASSIFICATION OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME (EXPENSE) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Interest expense, net	$ (12)	$ (14)	$ (15)	$ (14)	$ (15)	$ (14)	$ (11)	$ (6)	$ (55)	$ (46)	$ (27)
Cost of products sold	499	471	467	447	509	451	317	406	1,884	1,683	1,858
Income (loss) before income taxes	156	113	131	145	129	57	(114)	(122)	545	(50)	338
Provision for income taxes	(37)	(29)	(35)	(33)	(24)	(9)	22	(12)	(134)	(23)	(82)
Net income (loss)	$ 119	$ 84	$ 96	$ 112	$ 105	$ 48	$ (92)	$ (134)	411	(73)	256
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Net income (loss)									(15)	(8)	(5)
Gain and (Loss) on Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Income (loss) before income taxes									(7)	(2)	(1)
Provision for income taxes									0	0	0
Net income (loss)									(7)	(2)	(1)
Gain and (Loss) on Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Interest rate swaps
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Interest expense, net									(4)	(4)	(2)
Gain and (Loss) on Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Foreign exchange forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Cost of products sold									(3)	2	1
Pension Liability Gain (Loss) | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Income (loss) before income taxes									(11)	(8)	(5)
Provision for income taxes									3	2	1
Net income (loss)									(8)	(6)	(4)
Amortization of prior service benefits | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Income (loss) before income taxes									1	1	1
Amortization of net actuarial losses | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Income (loss) before income taxes									$ (12)	$ (9)	$ (6)

BUSINESS COMBINATIONS - ADDITIO

BUSINESS COMBINATIONS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions								3 Months Ended	12 Months Ended
	Jul. 01, 2021	Jun. 04, 2021	Jun. 01, 2021	Apr. 01, 2021	Feb. 01, 2021	Jan. 21, 2021	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2021
Business Acquisition [Line Items]
Goodwill							$ 3,986	$ 3,986	$ 3,976	$ 3,986	$ 3,397
Transaction related costs									8	16
Proceeds from divestiture of business									28	1	11
Gain on sale of business									14	(1)	$ (2)
Privately Held Dental Service
Business Acquisition [Line Items]
Payments to acquire equity method investments								45
UNITED KINGDOM
Business Acquisition [Line Items]
Payments to acquire equity method investments		$ 16
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Digital Dentistry Business
Business Acquisition [Line Items]
Proceeds from divestiture of business				$ 8
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Investment Casting Business
Business Acquisition [Line Items]
Proceeds from divestiture of business					$ 19
Gain on sale of business									13
Dental Business | SWITZERLAND
Business Acquisition [Line Items]
Total acquisition consideration	$ 7
Other current assets												$ 4
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill												3
Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities												2
Other long term liabilities												1
Fair value of the previously-held interest	$ 4
Goodwill												$ 7
Goodwill, period increase (decrease)									2
Propel Orthodontics
Business Acquisition [Line Items]
Other current assets			$ 4
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill			66
Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities			1
Goodwill			63
Payments to acquire businesses, gross			$ 132
Goodwill, purchase accounting adjustments									(2)
Datum Dental Ltd
Business Acquisition [Line Items]
Total acquisition consideration						$ 103
Other current assets						2
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill						76
Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities						2
Goodwill						39
Payments to acquire businesses, gross						94
Goodwill, purchase accounting adjustments									6
Business combination, contingent consideration arrangements, range of outcomes, value, high						$ 10
Percentage of voting interest acquired						100%
Additional consideration based on earn out						$ 9
Straight Smile LLC
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets, other than goodwill							416	416		416
Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities							28	28		28
Goodwill							627	$ 627		$ 627
Payments to acquire businesses, gross							$ 1,000
Goodwill, purchase accounting adjustments									$ (4)
Percentage of voting interest acquired							100%	100%		100%

BUSINESS COMBINATIONS - SUMMARY

BUSINESS COMBINATIONS - SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	Jul. 01, 2021	Jun. 01, 2021	Jan. 21, 2021	Dec. 31, 2020
Datum Dental Ltd
Acquired Indefinite-lived Intangible Assets [Line Items]
Intangible assets			$ 76
Propel Orthodontics
Acquired Indefinite-lived Intangible Assets [Line Items]
Intangible assets		$ 66
Straight Smile LLC
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount				$ 416
Acquired Indefinite-lived Intangible Assets [Line Items]
Intangible assets				416
In-process R&D | Dental Business
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets acquired, amount	$ 3
Developed technology | Datum Dental Ltd
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount			$ 66
Weighted average useful life (in years)			15 years
Developed technology | Propel Orthodontics
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount		$ 66
Weighted average useful life (in years)		10 years
Non-compete agreements | Straight Smile LLC
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount				$ 16
Weighted average useful life (in years)				5 years
Developed technology | Straight Smile LLC
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount				$ 210
Weighted average useful life (in years)				10 years
Tradenames and trademarks | Straight Smile LLC
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount				$ 190
Weighted average useful life (in years)				20 years

BUSINESS COMBINATIONS - FAIR VA

BUSINESS COMBINATIONS - FAIR VALUES OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) - USD ($) $ in Millions	Dec. 31, 2021	Jun. 01, 2021	Jan. 21, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill	$ 3,976			$ 3,986	$ 3,397
Propel Orthodontics
Business Acquisition [Line Items]
Other current assets		$ 4
Intangible assets		66
Current liabilities		(1)
Net assets acquired		69
Goodwill		63
Purchase consideration		$ 132
Datum Dental Ltd
Business Acquisition [Line Items]
Cash and cash equivalents			$ 2
Other current assets			2
Intangible assets			76
Current liabilities			(2)
Other long-term assets (liabilities), net			(14)
Net assets acquired			64
Goodwill			39
Purchase consideration			$ 103
Straight Smile LLC
Business Acquisition [Line Items]
Cash and cash equivalents				14
Current assets				16
Intangible assets				416
Current liabilities				(28)
Net assets acquired				418
Goodwill				627
Purchase consideration				$ 1,045

SEGMENT AND GEOGRAPHIC INFORM_3

SEGMENT AND GEOGRAPHIC INFORMATION - NARRATIVE (Details)	12 Months Ended
	Dec. 31, 2021 segment
Segment Reporting [Abstract]
Number of operating segments	2

SEGMENT AND GEOGRAPHIC INFORM_4

SEGMENT AND GEOGRAPHIC INFORMATION - NET SALES (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) segment	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment									2
Revenue, Major Customer [Line Items]
Total net sales	$ 1,103	$ 1,040	$ 1,062	$ 1,026	$ 1,076	$ 883	$ 499	$ 881	$ 4,231	$ 3,339	$ 4,022
Technologies & Equipment
Revenue, Major Customer [Line Items]
Total net sales									2,504	1,954	2,271
Consumables
Revenue, Major Customer [Line Items]
Total net sales									$ 1,727	$ 1,385	$ 1,751

SEGMENT AND GEOGRAPHIC INFORM_5

SEGMENT AND GEOGRAPHIC INFORMATION - DEPRECIATION AND AMORTIZATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Depreciation by Segment [Line Items]
Depreciation and amortization	$ 347	$ 334	$ 323
Operating Segments | Technologies & Equipment
Reconciliation of Depreciation by Segment [Line Items]
Depreciation and amortization	280	261	258
Operating Segments | Consumables
Reconciliation of Depreciation by Segment [Line Items]
Depreciation and amortization	52	61	54
All Other
Reconciliation of Depreciation by Segment [Line Items]
Depreciation and amortization	$ 15	$ 12	$ 11

SEGMENT AND GEOGRAPHIC INFORM_6

SEGMENT AND GEOGRAPHIC INFORMATION - SEGMENT OPERATING INCOME (LOSS) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segment adjusted operating income	$ 172,000,000	$ 132,000,000	$ 154,000,000	$ 150,000,000	$ 141,000,000	$ 72,000,000	$ (99,000,000)	$ (117,000,000)	$ 608,000,000	$ (3,000,000)	$ 353,000,000
Goodwill impairment				0				157,000,000	0	157,000,000	0
Restructuring and other costs									17,000,000	77,000,000	81,000,000
Interest expense, net	12,000,000	14,000,000	15,000,000	14,000,000	15,000,000	14,000,000	11,000,000	6,000,000	55,000,000	46,000,000	27,000,000
Other expense (income), net	4,000,000	5,000,000	8,000,000	(9,000,000)	(3,000,000)	1,000,000	4,000,000	(1,000,000)	8,000,000	1,000,000	(12,000,000)
Amortization of intangible assets									222,000,000	192,000,000	190,000,000
Income (loss) before income taxes	156,000,000	113,000,000	131,000,000	145,000,000	129,000,000	57,000,000	(114,000,000)	(122,000,000)	545,000,000	(50,000,000)	338,000,000
As Previously Issued
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segment adjusted operating income	154,000,000	159,000,000	155,000,000	154,000,000	135,000,000	82,000,000	(104,000,000)	(125,000,000)	622,000,000	(12,000,000)	361,000,000
All other											38,000,000
Goodwill impairment				0				157,000,000	0	157,000,000	0
Interest expense, net	12,000,000	13,000,000	16,000,000	14,000,000	15,000,000	14,000,000	11,000,000	7,000,000	55,000,000	47,000,000	28,000,000
Other expense (income), net	4,000,000	8,000,000	5,000,000	(9,000,000)	(3,000,000)	1,000,000	5,000,000	(2,000,000)	8,000,000	1,000,000	(12,000,000)
Income (loss) before income taxes	$ 138,000,000	$ 138,000,000	$ 134,000,000	$ 149,000,000	$ 123,000,000	$ 67,000,000	$ (120,000,000)	(130,000,000)	559,000,000	(60,000,000)	345,000,000
Technologies & Equipment
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Goodwill impairment								$ 157,000,000
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segment adjusted operating income									1,082,000,000	698,000,000	907,000,000
Operating Segments | Technologies & Equipment
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segment adjusted operating income									543,000,000	382,000,000	460,000,000
Operating Segments | Consumables
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Segment adjusted operating income									539,000,000	316,000,000	447,000,000
Corporate, Reconciling Items, And Eliminations
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
All other									229,000,000	269,000,000	277,000,000
Segment Reconciling Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Goodwill impairment									0	157,000,000	0
Amortization of intangible assets									222,000,000	192,000,000	189,000,000
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations									$ 6,000,000	$ 6,000,000	$ 7,000,000

SEGMENT AND GEOGRAPHIC INFORM_7

SEGMENT AND GEOGRAPHIC INFORMATION - CAPITAL EXPENDITURES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Capital expenditures	$ 159	$ 87	$ 123
Operating Segments | Technologies & Equipment
Capital expenditures	100	50	73
Operating Segments | Consumables
Capital expenditures	37	26	34
All Other
Capital expenditures	$ 22	$ 11	$ 16

SEGMENT AND GEOGRAPHIC INFORM_8

SEGMENT AND GEOGRAPHIC INFORMATION - ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Total Assets	$ 9,239	$ 9,350
Operating Segments | Technologies & Equipment
Segment Reporting, Asset Reconciling Item [Line Items]
Total Assets	6,902	7,014
Operating Segments | Consumables
Segment Reporting, Asset Reconciling Item [Line Items]
Total Assets	2,123	2,170
Corporate, Reconciling Items, And Eliminations
Segment Reporting, Asset Reconciling Item [Line Items]
Total Assets	$ 214	$ 166

SEGMENT AND GEOGRAPHIC INFORM_9

SEGMENT AND GEOGRAPHIC INFORMATION - INFORMATION ABOUT THE COMPANY'S OPERATINGS IN DIFFERENT GEOGRAPHIC AREAS (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 1,103	$ 1,040	$ 1,062	$ 1,026	$ 1,076	$ 883	$ 499	$ 881	$ 4,231	$ 3,339	$ 4,022
Property, plant, and equipment, net	773				791				773	791	802
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant, and equipment, net	166				145				166	145	168
United States | Geographical Basis, Destination of Shipments
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									1,484	1,116	1,377
Germany
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant, and equipment, net	309				337				309	337	327
Germany | Geographical Basis, Destination of Shipments
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									482	432	472
Sweden
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant, and equipment, net	107				110				107	110	99
Other Foreign
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant, and equipment, net	$ 191				$ 199				191	199	208
Other Foreign | Geographical Basis, Destination of Shipments
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales									$ 2,265	$ 1,791	$ 2,173

SEGMENT AND GEOGRAPHIC INFOR_10

SEGMENT AND GEOGRAPHIC INFORMATION - CONCENTRATION RISK (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer Benchmark | Henry Schein, Inc.
Concentration Risk [Line Items]
Concentration risk, percentage	14%	13%
Revenue from Contract with Customer Benchmark | Patterson Companies, Inc.
Concentration Risk [Line Items]
Concentration risk, percentage	10%
Accounts Receivable | Henry Schein, Inc.
Concentration Risk [Line Items]
Concentration risk, percentage		12%
Accounts Receivable | Patterson Companies, Inc.
Concentration Risk [Line Items]
Concentration risk, percentage	18%	17%

OTHER EXPENSE (INCOME) , NET (D

OTHER EXPENSE (INCOME) , NET (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Income and Expenses [Abstract]
Foreign exchange transaction (gain) loss									$ (6)	$ (13)	$ (27)
Other expense (income), net									14	14	15
Total other expense (income), net	$ 4	$ 5	$ 8	$ (9)	$ (3)	$ 1	$ 4	$ (1)	$ 8	$ 1	$ (12)

INVENTORIES, NET (Details)

INVENTORIES, NET (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 139	$ 134
Work-in-process	72	68
Finished Goods	304	274
Inventories, net	$ 515	$ 476

INVENTORIES, NET - ADDITIONAL I

INVENTORIES, NET - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory valuation reserve	$ 86	$ 117

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 2,081	$ 2,183
Less: Accumulated depreciation and amortization	1,308	1,392
Property, plant and equipment, net	773	791
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	51	54
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	561	595
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	982	1,075
Capitalized Software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	353	339
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 134	$ 120

LEASES - Assets and Liabilities

LEASES - Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets
Finance leases	$ 2	$ 1
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Operating leases	$ 198	$ 176
Total right-of-use assets	200	177
Current Liabilities:
Finance leases	$ 1	$ 0
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Notes payable and current portion of long-term debt	Notes payable and current portion of long-term debt
Operating leases	$ 50	$ 48
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued liabilities	Accrued liabilities
Noncurrent liabilities
Finance leases	$ 1	$ 1
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt	Long-term debt
Operating leases	$ 149	$ 130
Total lease liabilities	$ 201	$ 179
Weighted-average discount rate
Finance leases	3.20%	3.70%
Operating leases	3.30%	3%
Weighted-average remaining lease term in years
Finance leases	4 years 3 months 18 days	6 years 6 months
Operating leases	5 years 3 months 18 days	5 years 2 months 12 days

LEASES - Lease Costs (Details)

LEASES - Lease Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 67	$ 57
Short-term lease cost	1	1
Variable lease cost	10	9
Total lease cost	$ 78	$ 67

LEASES - Contractual Maturity D

LEASES - Contractual Maturity Dates (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Finance Leases
2022	$ 1
2023	1
2024	0
2025	0
2026	0
2027 and beyond	0
Total lease payments	2
Less imputed interest	0
Present value of lease liabilities	2
Operating Leases
2022	58
2023	46
2024	36
2025	24
2026	18
2027 and beyond	38
Total lease payments	220
Less imputed interest	21
Present value of lease liabilities	199
Total
2022	59
2023	47
2024	36
2025	24
2026	18
2027 and beyond	38
Total lease payments	222
Less imputed interest	21
Total lease liabilities	$ 201	$ 179

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows paid for operating leases	$ 65		$ 56
Right-of-use assets obtained in exchange for new lease liabilities:
Finance leases	1	$ 0
Operating leases	$ 79		$ 43

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - ADDITIONAL INFORMATION (Details)			3 Months Ended				8 Months Ended	12 Months Ended
	Jan. 01, 2019 reporting_unit	Dec. 31, 2018 reporting_unit	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2021 USD ($) reporting_unit	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) reporting_unit
Goodwill [Line Items]
Number of reporting units | reporting_unit	5	11						5		5
Goodwill impairment				$ 0	$ 157,000,000			$ 0	$ 157,000,000	$ 0
Indefinite-lived intangible asset impairment							$ 0	0	39,000,000	9,000,000
Amortization of intangible assets								222,000,000	$ 192,000,000	$ 190,000,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2022								214,000,000
2023								216,000,000
2024								219,000,000
2025								224,000,000
2026								146,000,000
Developed technology
Goodwill [Line Items]
Payments to acquire intangible assets			$ 3,000,000
Asset acquisition, contingent consideration, liability								$ 17,000,000
Minimum
Goodwill [Line Items]
Indefinite lived intangible asset, discount rate									10%
Minimum | Measurement Input, Discount Rate
Goodwill [Line Items]
Goodwill, measurement input					0.095			0.08
Indefinite lived intangible asset, discount rate								8.50%
Maximum
Goodwill [Line Items]
Indefinite lived intangible asset, discount rate									17.50%
Maximum | Measurement Input, Discount Rate
Goodwill [Line Items]
Goodwill, measurement input					0.115			0.095
Indefinite lived intangible asset, discount rate								10%
Technologies & Equipment
Goodwill [Line Items]
Goodwill impairment					$ 157,000,000
Technologies & Equipment | Tradenames and trademarks
Goodwill [Line Items]
Indefinite-lived intangible asset impairment						$ 5,000,000
Equipment And Instruments Reporting Unit | C O V I D19 | Tradenames and trademarks
Goodwill [Line Items]
Goodwill impairment									$ 39,000,000

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - GOODWILL CARRYING AMOUNT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill [Roll Forward]
Goodwill	$ 6,869	$ 6,879	$ 6,134
Accumulated impairment losses	(2,893)	(2,893)	(2,737)
Balance, beginning of the year	3,986	3,397
Acquisition related additions	109	631
Impairment		(157)
Translation and other	(119)	115
Balance, end of the year	3,976	3,986
Technologies & Equipment
Goodwill [Roll Forward]
Goodwill	5,989	5,985	5,253
Accumulated impairment losses	(2,893)	(2,893)	(2,737)
Balance, beginning of the year	3,092	2,516
Acquisition related additions	109	631
Impairment		(157)
Translation and other	(105)	102
Balance, end of the year	3,096	3,092
Consumables
Goodwill [Roll Forward]
Goodwill	880	894	881
Accumulated impairment losses	0	0	$ 0
Balance, beginning of the year	894	881
Acquisition related additions	0	0
Impairment		0
Translation and other	(14)	13
Balance, end of the year	$ 880	$ 894

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - IDENTIFIABLE DEFINITE-LIVED ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, gross carrying amount	$ 3,125	$ 3,133
Accumulated Amortization	(1,418)	(1,271)
Finite-lived intangibles, net carrying amount	1,707	1,862
Indefinite-lived intangibles, carrying amount	612	642
Identifiable intangible assets, net carrying amount	2,319	2,504
Identifiable intangible assets, gross carrying amount	3,737	3,775
Tradenames and trademarks
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangibles, carrying amount	598	642
In-process R&D
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangibles, carrying amount	14	0
Developed technology and patents
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, gross carrying amount	1,729	1,681
Accumulated Amortization	(762)	(677)
Finite-lived intangibles, net carrying amount	967	1,004
Tradenames and trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, gross carrying amount	269	273
Accumulated Amortization	(79)	(70)
Finite-lived intangibles, net carrying amount	190	203
Licensing agreements
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, gross carrying amount	36	37
Accumulated Amortization	(32)	(30)
Finite-lived intangibles, net carrying amount	4	7
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles, gross carrying amount	1,091	1,142
Accumulated Amortization	(545)	(494)
Finite-lived intangibles, net carrying amount	$ 546	$ 648

PREPAID EXPENSES AND OTHER CU_3

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 89	$ 78
Value-added tax receivable	53	39
Deposits	22	33
Other current assets	84	67
Prepaid expenses and other current assets	$ 248	$ 217

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Payroll, commissions, bonuses, other cash compensation and employee benefits	$ 172	$ 142
Sales and marketing programs	66	56
Reserve for dealer rebates	209	134
Restructuring costs	11	31
Accrued vacation and holidays	40	41
Professional and legal costs	19	33
Current portion of derivatives	3	32
General insurance	12	12
Warranty liabilities	28	18
Third party royalties	7	11
Deferred income	68	53
Accrued interest	8	13
Accrued property taxes	6	13
Current operating lease liabilities	50	48
Other	61	75
Accrued liabilities	$ 760	$ 712

FINANCING ARRANGEMENTS - SHORT

FINANCING ARRANGEMENTS - SHORT TERM BORROWINGS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total short-term debt	$ 182,000,000	$ 299,000,000
Add: Current portion of long-term debt	1,000,000	296,000,000
Maximum month-end short-term debt outstanding during the year	380,000,000	299,000,000
Average amount of short-term debt outstanding during the year	$ 265,000,000	$ 95,000,000
Weighted-average interest rate on short-term debt at year-end	0.60%	1.90%
Corporate commercial paper facility
Short-term Debt [Line Items]
Total short-term debt	$ 170,000,000	$ 0
Fixed interest rate	0.30%	0%
Other short-term borrowings
Short-term Debt [Line Items]
Total short-term debt	$ 11,000,000	$ 3,000,000
Fixed interest rate	4.80%	1.90%
Uncommitted Short-Term Financing
Short-term Debt [Line Items]
Total short-term debt	$ 41,000,000

FINANCING ARRANGEMENTS - ADDITI

FINANCING ARRANGEMENTS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions		12 Months Ended
	Jul. 02, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Average amount of short-term debt outstanding during the year		$ 265	$ 95
Repayments of long-term debt		297	701	$ 251
Notes payable and current portion of long-term debt		182	299
Total unused lines of credit		560
Uncommitted Short-Term Financing
Debt Instrument [Line Items]
Notes payable and current portion of long-term debt		41
Other short-term borrowings
Debt Instrument [Line Items]
Notes payable and current portion of long-term debt		11	$ 3
Line of Credit | 2018 Revolving Credit Facility
Debt Instrument [Line Items]
Credit facilities, maximum borrowing capacity		700
Line of Credit | Corporate commercial paper facility
Debt Instrument [Line Items]
Credit facilities, maximum borrowing capacity		500
Average amount of short-term debt outstanding during the year		$ 16
Fixed rate senior notes $450 million due August 2021 | Senior Notes
Debt Instrument [Line Items]
Repayments of long-term debt	$ 296

FINANCING ARRANGEMENTS - LONG T

FINANCING ARRANGEMENTS - LONG TERM BORROWINGS (Details) € in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 CHF (SFr)	Dec. 31, 2021 JPY (¥)	Dec. 31, 2020 USD ($)
Debt Instrument [Line Items]
Floating rate senior term loan	$ 1,922				$ 2,284
Less: Current portion (included in notes payable and current portion of long-term debt)	1				296
Less: Long-term portion of deferred financing costs	8				10
Long-term debt	1,913				1,978
Senior Notes | Fixed rate senior notes $450 million due August 2021
Debt Instrument [Line Items]
Debt instrument face amount	450
Floating rate senior term loan	$ 0				$ 296
Debt, fixed rate	0%	0%	0%	0%	4.10%
Senior Notes | Fixed rate senior notes 750 million due June 2030
Debt Instrument [Line Items]
Debt instrument face amount	$ 750
Floating rate senior term loan	$ 750				$ 750
Debt, fixed rate	3.30%	3.30%	3.30%	3.30%	3.30%
Private Placement Notes | Private placement notes 70 million euros due October 2024
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 70
Floating rate senior term loan	$ 79				$ 85
Debt, fixed rate	1%	1%	1%	1%	1%
Private Placement Notes | Private placement notes 25 million Swiss franc due December 2025
Debt Instrument [Line Items]
Debt instrument face amount | SFr			SFr 25
Floating rate senior term loan	$ 27				$ 28
Debt, fixed rate	0.90%	0.90%	0.90%	0.90%	0.90%
Private Placement Notes | Private placement notes 97 million euros due December 2025
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 97
Floating rate senior term loan	$ 110				$ 118
Debt, fixed rate	2.10%	2.10%	2.10%	2.10%	2.10%
Private Placement Notes | Private placement notes 26 million euros due February 2026
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 26
Floating rate senior term loan	$ 30				$ 32
Debt, fixed rate	2.10%	2.10%	2.10%	2.10%	2.10%
Private Placement Notes | Private placement notes 58 million Swiss franc due August 2026
Debt Instrument [Line Items]
Debt instrument face amount | SFr			SFr 58
Floating rate senior term loan	$ 64				$ 65
Debt, fixed rate	1%	1%	1%	1%	1%
Private Placement Notes | Private placement notes 106 million euros due August 2026
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 106
Floating rate senior term loan	$ 121				$ 129
Debt, fixed rate	2.30%	2.30%	2.30%	2.30%	2.30%
Private Placement Notes | Private placement notes 70 million euros due October 2027
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 70
Floating rate senior term loan	$ 80				$ 85
Debt, fixed rate	1.30%	1.30%	1.30%	1.30%	1.30%
Private Placement Notes | Private placement notes 8 million Swiss franc due December 2027
Debt Instrument [Line Items]
Debt instrument face amount | SFr			SFr 8
Floating rate senior term loan	$ 8				$ 8
Debt, fixed rate	1%	1%	1%	1%	1%
Private Placement Notes | Private placement notes 15 million euros due December 2027
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 15
Floating rate senior term loan	$ 17				$ 18
Debt, fixed rate	2.20%	2.20%	2.20%	2.20%	2.20%
Private Placement Notes | Private placement notes 140 million Swiss franc due August 2028
Debt Instrument [Line Items]
Debt instrument face amount | SFr			SFr 140
Floating rate senior term loan	$ 153				$ 158
Debt, fixed rate	1.20%	1.20%	1.20%	1.20%	1.20%
Private Placement Notes | Private placement notes 70 million euros due October 2029
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 70
Floating rate senior term loan	$ 79				$ 85
Debt, fixed rate	1.50%	1.50%	1.50%	1.50%	1.50%
Private Placement Notes | Private placement notes 70 million euros due October 2030
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 70
Floating rate senior term loan	$ 80				$ 85
Debt, fixed rate	1.60%	1.60%	1.60%	1.60%	1.60%
Private Placement Notes | Private placement notes 45 million euros due February 2031
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 45
Floating rate senior term loan	$ 51				$ 55
Debt, fixed rate	2.50%	2.50%	2.50%	2.50%	2.50%
Private Placement Notes | Private placement notes 65 million Swiss franc due August 2031
Debt Instrument [Line Items]
Debt instrument face amount | SFr			SFr 65
Floating rate senior term loan	$ 71				$ 73
Debt, fixed rate	1.30%	1.30%	1.30%	1.30%	1.30%
Private Placement Notes | Private placement notes 12.6 billion Japanese yen due September 2031
Debt Instrument [Line Items]
Debt instrument face amount | ¥				¥ 12.6
Floating rate senior term loan	$ 109				$ 122
Debt, fixed rate	1%	1%	1%	1%	1%
Private Placement Notes | Private placement notes 70 million euros due October 2031
Debt Instrument [Line Items]
Debt instrument face amount | €		€ 70
Floating rate senior term loan	$ 80				$ 85
Debt, fixed rate	1.70%	1.70%	1.70%	1.70%	1.70%
Other borrowings, various currencies and rates
Debt Instrument [Line Items]
Floating rate senior term loan	$ 13				$ 7

FINANCING ARRANGEMENTS - CONTRA

FINANCING ARRANGEMENTS - CONTRACTUAL MATURITY DATES OF THE VAIROUS BORROWINGS (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2022	$ 3
2023	11
2024	84
2025	138
2026	213
2027 and beyond	1,473
Floating rate senior term loan	$ 1,922	$ 2,284

EQUITY - NARRATIVE (Details)

EQUITY - NARRATIVE (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 28, 2021
Equity [Abstract]
Stock repurchase program, authorized amount				$ 1,000
Treasury shares purchased	$ 200	$ 140	$ 260
Share repurchase program, remaining authorization	890
Proceeds from exercised stock options	$ 51	$ 11	$ 109
Number of stock option exercised (in shares)	1.1	0.3	2.7

EQUITY (Details)

EQUITY (Details) - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	218.7	221.3	223
Shares of treasury stock issued (in shares)	2.2	1.1	3.1
Repurchase of common stock (in shares)	(3.5)	(3.7)	(4.8)
Ending balance (in shares)	217.4	218.7	221.3
Stock repurchased under the repurchase program, average price (in dollars per share)	$ 57.47	$ 38.25	$ 54.18
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	264.5	264.5	264.5
Shares of treasury stock issued (in shares)	0	0	0
Repurchase of common stock (in shares)	0	0	0
Ending balance (in shares)	264.5	264.5	264.5
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (in shares)	45.8	43.2	41.5
Shares of treasury stock issued (in shares)	2.2	1.1	3.1
Repurchase of common stock (in shares)	(3.5)	(3.7)	(4.8)
Ending balance (in shares)	47.1	45.8	43.2

INCOME TAXES - COMPONENTS OF IN

INCOME TAXES - COMPONENTS OF INCOME BEFORE INCOME TAXES FROM OPERATIONS (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
United States									$ 51	$ (91)	$ (115)
Foreign									494	41	453
Income (loss) before income taxes	$ 156	$ 113	$ 131	$ 145	$ 129	$ 57	$ (114)	$ (122)	$ 545	$ (50)	$ 338

INCOME TAXES - COMPONENTS OF TH

INCOME TAXES - COMPONENTS OF THE PROVISION FOR INCOME TAXES FROM OPERATIONS (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
U.S. federal									$ 1	$ (5)	$ (11)
U.S. state									4	1	2
Foreign									154	89	131
Total									159	85	122
Deferred:
U.S. federal									10	4	(3)
U.S. state									2	(1)	1
Foreign									(37)	(65)	(38)
Total									(25)	(62)	(40)
Provision for income taxes	$ 37	$ 29	$ 35	$ 33	$ 24	$ 9	$ (22)	$ 12	$ 134	$ 23	$ 82

INCOME TAXES - THE RECONCILIATI

INCOME TAXES - THE RECONCILIATION OF THE U.S. FEDERAL STATUTORY TAX RATE TO THE EFFECTIVE RATE (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Statutory U.S. federal income tax rate	21%	21%	21%
State income taxes, net of federal benefit	0.80%	1.10%	0.70%
Federal benefit of R&D and foreign tax credits	(0.90%)	18.90%	(2.00%)
US other permanent differences	0.004	(0.061)	0.008
Tax effect of international operations	0.30%	10%	0.90%
Global Intangible Low Taxed Income (GILTI)	2.40%	(13.00%)	3.80%
Foreign Derived Intangible Income (FDII)	(1.30%)	11.80%	(0.10%)
Net effect of tax audit activity	1.60%	(8.20%)	0.40%
Tax effect of enacted statutory rate changes on Non-U.S. jurisdictions	1.90%	(0.20%)	0.10%
Federal tax on unremitted earnings of certain foreign subsidiaries	(0.20%)	(5.40%)	0.10%
Valuation allowance adjustments	(1.70%)	(15.30%)	(1.40%)
Tax effect of impairment of goodwill and intangibles	0%	60.80%	0.10%
Other	0.30%	0.20%	0.10%
Effective income tax rate on operations	24.60%	(46.00%)	24.30%

INCOME TAXES - THE TAX EFFECT O

INCOME TAXES - THE TAX EFFECT OF SIGNIFICANT TEMPORARY DIFFERENCES GIVING RISE TO DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Asset
Commission and bonus accrual	$ 6	$ 8
Employee benefit accruals	51	58
Inventory	16	25
Insurance premium accruals	3	3
Miscellaneous accruals	27	24
Other	17	10
Unrealized losses included in AOCI	47	98
Lease right-of-use liability	47	42
Product warranty accruals	1	1
Foreign tax credit and R&D carryforward	49	60
Restructuring and other cost accruals	5	9
Sales and marketing accrual	14	7
Tax loss carryforwards and other tax attributes	275	280
Subtotal	558	625
Valuation allowances	(267)	(287)
Total	291	338
Deferred Tax Liability
Identifiable intangible assets	569	613
Property, plant and equipment	47	50
Lease right-of-use asset	47	42
Taxes on unremitted earnings of foreign subsidiaries	5	6
Subtotal	668	711
Total	$ 668	$ 711

INCOME TAXES - THE DEFERRED TAX

INCOME TAXES - THE DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Schedule of Deferred Income Tax Assets and Liabilities [Line Items]
Deferred income tax liabilities	$ 391	$ 381
Other noncurrent assets
Schedule of Deferred Income Tax Assets and Liabilities [Line Items]
Deferred income tax assets	14	8
Deferred income taxes
Schedule of Deferred Income Tax Assets and Liabilities [Line Items]
Deferred income tax liabilities	$ 391	$ 381

INCOME TAXES - ADDITIONAL INFOR

INCOME TAXES - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Tax credit carryforwards	$ 1,017
Tax loss carryforward	1,278
Deferred tax assets, operating loss carryforward	228
Deferred tax assets, tax attributes	48
Translation Adjustment	210
Change in valuation allowance for deferred tax asset	12
Withholding taxes on certain undistributed earnings of foreign subsidiaries anticipated to be repatriated	5
The total gross unrecognized tax benefits	42
Unrecognized tax benefits, if recognized, would affect the effective income tax rate	41
The total amount of accrued interest and penalties	8	$ 4
Recognized income tax expense (benefits), interest and penalties	2	2	$ 2
Undistributed earnings of foreign subsidiaries	1,771	$ 1,807
Foreign Tax Credits Expiring Future Years
Income Taxes [Line Items]
Tax credit carryforwards	45
Foreign Tax Credits Expiring Future Years | Tax Year 2025
Income Taxes [Line Items]
Tax credit carryforwards	36
Foreign Tax Credits Expiring Future Years | Tax Year 2027
Income Taxes [Line Items]
Tax credit carryforwards	3
Foreign Tax Credits Expiring Future Years | Tax Years 2028 through 2031
Income Taxes [Line Items]
Tax credit carryforwards	6
Without Expiry Date
Income Taxes [Line Items]
Tax credit carryforwards	261
Foreign
Income Taxes [Line Items]
Tax credit valuation allowance	45
Settlement with Taxing Authority
Income Taxes [Line Items]
Possible benefit of unrecognized tax benefits	$ 1

INCOME TAXES - UNRECOGNIZED TAX

INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits at beginning of period	$ 27	$ 24	$ 28
Gross change for prior-period positions	6	1	0
Gross change for current year positions	2	1	0
Decrease due to settlements and payments	0	0	(4)
Decrease due to statute expirations	0	0	0
Increase due to effect of foreign currency translation	0	1	0
Decrease due to effect from foreign currency translation	(1)	0	0
Unrecognized tax benefits at end of period	$ 34	$ 27	$ 24

BENEFIT PLANS - ADDITIONAL INFO

BENEFIT PLANS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution of first 1% of contribution	100%
Employer matching contribution of next 5% of contribution	50%
Employer maximum matching contribution	3.50%
Defined contribution plan, cost recognized	$ 39	$ 36	$ 35
Defined benefit plan, benefit obligation, period (increase) decrease for actuarial loss, discount rates	26	$ 31
Defined benefit plan, benefit obligation, period (increase) decrease for actuarial loss, demographic assumptions	6
Defined benefit plan, benefit obligation, period (increase) decrease for actuarial loss, discount rates, plan experience different than anticipated	$ 16
Expected return on plan assets	2%
Percentage of total plan assets categorized as level 1	78%	78%
Expected contributions to defined benefit pension plans in 2022	$ 17
Minimum | Defined Benefit Plan, Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	30%
Minimum | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	30%
Minimum | Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	0%
Minimum | Other Investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	0%
Maximum | Defined Benefit Plan, Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	65%
Maximum | Fixed Income Securities
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	65%
Maximum | Real Estate
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	15%
Maximum | Other Investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation for plan asset of equity securities	25%
Common Stock
Defined Benefit Plan Disclosure [Line Items]
ESOP target contribution	3%

BENEFIT PLANS - RECONCILIATION

BENEFIT PLANS - RECONCILIATION OF CHANGES IN THE DEFINED BENEFIT AND POSTRETIREMENT HEALTHCARE PLANS' BENEFIT OBLIGATIONS, FIAR VALUE OF ASSETS AND FUNDED STATUS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Change in Benefit Obligation
Benefit obligation at beginning of year	$ 675	$ 578
Service cost	17	16
Interest cost	3	5	$ 8
Participant contributions	4	4
Actuarial losses (gains)	(16)	31
Plan amendments	(1)	0
Acquisitions/Divestitures	(2)	0
Effect of exchange rate changes	(41)	59
Plan curtailments and settlements	(1)	(1)
Benefits paid	(19)	(17)
Benefit obligation at end of year	619	675	578
Change in Plan Assets
Fair value of plan assets at beginning of year	213	185
Actual return on assets	10	9
Plan settlements	(1)	0
Acquisitions/Divestitures	(3)	0
Effect of exchange rate changes	(7)	17
Employer contributions	15	15
Participant contributions	4	4
Benefits paid	(19)	(17)
Fair value of plan assets at end of year	212	213	$ 185
Funded status at end of year	$ (407)	$ (462)

BENEFIT PLANS - PENSION BENEFIT

BENEFIT PLANS - PENSION BENEFITS AND OTHER POSTRETIREMENT BENEFITS RECOGNIZED IN THE ACCOMPANYING CONSOLIDATED BALANCE SHEETS (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Other noncurrent assets, net	$ 2	$ 0
Deferred tax asset	36	49
Total assets	38	49
Current liabilities	(9)	(10)
Other noncurrent liabilities	(400)	(452)
Deferred tax liability	(1)	(1)
Total liabilities	(410)	(463)
Accumulated other comprehensive income	105	139
Net amount recognized	$ (267)	$ (275)

BENEFIT PLANS - AMOUNTS RECOGNI

BENEFIT PLANS - AMOUNTS RECOGNIZED IN ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Net actuarial loss	$ 144	$ 191
Net prior service cost	(4)	(4)
Before tax AOCI	140	187
Less: Deferred taxes	35	48
Net of tax AOCI	$ 105	$ 139

BENEFIT PLANS - PENSION PLANS W

BENEFIT PLANS - PENSION PLANS WITH AN ACCUMULATED BENEFIT OBLIGATION IN EXCESS OF PLAN ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Projected benefit obligation	$ 427	$ 484
Accumulated benefit obligation	403	455
Fair value of plan assets	$ 17	$ 26

BENEFIT PLANS - COMPONENETS OF

BENEFIT PLANS - COMPONENETS OF NET PERIODIC BENEFIT COST (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 17	$ 16
Interest cost	3	5	$ 8
Expected return on plan assets	(4)	(4)	(5)
Amortization of prior service credit	(1)	(1)	(1)
Amortization of net actuarial loss	12	9	6
Acquisitions/Divestitures	1	0	0
Curtailment and settlement (gains) loss	(1)	0	6
Net periodic benefit cost	$ 27	25	28
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Amortization of Prior Service Cost (Credit), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Amortization of Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Cost of products sold
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 7	6	6
Selling, general and administrative expenses
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 10	$ 10	$ 8

BENEFIT PLANS - OTHER CHANGES I

BENEFIT PLANS - OTHER CHANGES IN PLAN ASSETS AND BENEFIT OBLIGATIONS RECOGNIZED IN AOCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Net actuarial loss (gain)	$ (36)	$ 43	$ 53
Amortization	(11)	(9)	(5)
Total recognized in AOCI	(47)	34	48
Total recognized in net periodic benefit cost and AOCI	$ (20)	$ 59	$ 76

BENEFIT PLANS - WEIGHTED AVERAG

BENEFIT PLANS - WEIGHTED AVERAGE ASSUMPTIONS USED TO DETERMINE BENEFIT OBLIGATIONS (Details)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Interest crediting rate	1.30%	1.30%	1.30%
Discount rate	1.10%	0.60%	1%
Rate of compensation increase	2.60%	2.40%	2.50%

BENEFIT PLANS - WEIGHTED AVER_2

BENEFIT PLANS - WEIGHTED AVERAGE ASSUMPTIONS USED TO DETERMINE NET PERIODIC BENEFIT COST TREND RATES (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Interest crediting rate	1.30%	1.30%	1.30%
Discount rate	0.60%	1%	1.80%
Expected return on plan assets	2.20%	2.30%	2.90%
Rate of compensation increase	2.40%	2.50%	2.50%

BENEFIT PLANS - FAIR VALUE OF P

BENEFIT PLANS - FAIR VALUE OF PENSION PLAN ASSETS (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	$ 212	$ 213	$ 185
Cash and cash equivalents
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	17	16
Equity securities, International
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	65	58
Fixed income securities, Fixed rate bonds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	66	65
Mutual funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	18	20
Common trusts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets		5
Insurance contracts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	34	37
Hedge funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	11	12
Real Estate
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	$ 1
Equity | Mutual funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Percentage of investments	50%
Equity | Common trusts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Percentage of investments	65%
Fixed Income Investments | Mutual funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Percentage of investments	50%
Fixed Income Investments | Common trusts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Percentage of investments	35%
Fair Value, Inputs, Level 1, 2 and 3
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets		213
Level 1
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	$ 166	159
Level 1 | Cash and cash equivalents
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	17	16
Level 1 | Equity securities, International
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	65	58
Level 1 | Fixed income securities, Fixed rate bonds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	66	65
Level 1 | Mutual funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	18	20
Level 1 | Common trusts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets		0
Level 1 | Insurance contracts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 1 | Hedge funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 1 | Real Estate
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0
Level 2
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	5
Level 2 | Cash and cash equivalents
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 2 | Equity securities, International
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 2 | Fixed income securities, Fixed rate bonds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 2 | Mutual funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 2 | Common trusts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets		5
Level 2 | Insurance contracts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 2 | Hedge funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 2 | Real Estate
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0
Level 3
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	46	49	39
Level 3 | Cash and cash equivalents
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 3 | Equity securities, International
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 3 | Fixed income securities, Fixed rate bonds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 3 | Mutual funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	0	0
Level 3 | Common trusts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets		0
Level 3 | Insurance contracts
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	34	37	30
Level 3 | Hedge funds
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	11	12	9
Level 3 | Real Estate
Schedule of Pension and Other Postretirment Benefits Changes in Benefit Obligation and Fair Value of Plan Assets [Line Items]
Plan assets	$ 1	$ 0	$ 0

BENEFIT PLANS - RECONCILIATIO_2

BENEFIT PLANS - RECONCILIATION FOR THE PLAN ASSETS CATEGORIZED AS LEVEL 3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	$ 213	$ 185
Actual return on plan assets:
Effect of exchange rate changes	(7)	17
Fair value of plan assets at end of year	212	213
Insurance contracts
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	37
Actual return on plan assets:
Fair value of plan assets at end of year	34	37
Hedge funds
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	12
Actual return on plan assets:
Fair value of plan assets at end of year	11	12
Real Estate
Actual return on plan assets:
Fair value of plan assets at end of year	1
Fair Value, Inputs, Level 1, 2 and 3
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	213
Actual return on plan assets:
Fair value of plan assets at end of year		213
Level 3
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	49	39
Actual return on plan assets:
Relating to assets still held at the reporting date	0	3
Purchases, sales and settlements, net	(3)	2
Transfers in and/or (out)	2
Effect of exchange rate changes	(2)	5
Fair value of plan assets at end of year	46	49
Level 3 | Insurance contracts
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	37	30
Actual return on plan assets:
Relating to assets still held at the reporting date	(2)	3
Purchases, sales and settlements, net	(1)	0
Transfers in and/or (out)	2
Effect of exchange rate changes	(2)	4
Fair value of plan assets at end of year	34	37
Level 3 | Hedge funds
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	12	9
Actual return on plan assets:
Relating to assets still held at the reporting date	1	0
Purchases, sales and settlements, net	(2)	2
Transfers in and/or (out)	0
Effect of exchange rate changes	0	1
Fair value of plan assets at end of year	11	12
Level 3 | Real Estate
Change in Plan Assets. Level 3 [Roll Forward]
Fair value of plan assets at beginning of year	0	0
Actual return on plan assets:
Relating to assets still held at the reporting date	1	0
Purchases, sales and settlements, net	0	0
Transfers in and/or (out)	0
Effect of exchange rate changes	0	0
Fair value of plan assets at end of year	$ 1	$ 0

BENEFIT PLANS - ESTIMATED FUTUR

BENEFIT PLANS - ESTIMATED FUTURE BENEFIT PAYMENTS ON DEFINED BENEFIT PLAN (Details) $ in Millions	Dec. 31, 2021 USD ($)
Retirement Benefits [Abstract]
2022	$ 23
2023	24
2024	24
2025	25
2026	25
2027-2031	$ 127

RESTRUCTURING AND OTHER COSTS -

RESTRUCTURING AND OTHER COSTS - ADDITIONAL INFORMATION (Details) - USD ($)	8 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 31, 2020
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs		$ 20,000,000	$ 123,000,000	$ 128,000,000
Severance costs		23,000,000	23,000,000	37,000,000
Adjustments to inventory reserves		3,000,000
Restructuring and related cost, accelerated depreciation			14,000,000	3,000,000
Indefinite-lived intangible asset impairment	$ 0	0	39,000,000	9,000,000
Other asset impairment charges			8,000,000
Fixed asset impairment		0	3,000,000	33,000,000
Impairment of intangible assets				9,000,000
Restructuring incurred cost		321,000,000
Inventory write-down
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs			$ 31,000,000	$ 20,000,000
Restructuring and other costs
Restructuring Cost and Reserve [Line Items]
Expected cost					$ 345,000,000
Severance
Restructuring Cost and Reserve [Line Items]
Restructuring incurred cost		$ 2,000,000

RESTRUCTURING AND OTHER COSTS_2

RESTRUCTURING AND OTHER COSTS - TOTAL RESTRUCTURING COSTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs	$ 20	$ 123	$ 128
Restructuring and other costs
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs	20	123	128
Restructuring and other costs | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs	(3)	44	25
Restructuring and other costs | Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs	6	2	23
Restructuring and other costs | Other Restructuring Costs
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs	17	77	81
Restructuring and other costs | Other income and expenses
Restructuring Cost and Reserve [Line Items]
Total restructuring and other costs	$ 0	$ 0	$ (1)

RESTRUCTURING AND OTHER COSTS_3

RESTRUCTURING AND OTHER COSTS - RESTRUCTURING ACCRUALS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restructuring Reserve
Beginning balance	$ 34	$ 30
Provisions and adjustments	29	36
Amounts applied	(35)	(23)
Change in estimates	(10)	(9)
Ending balance	18	34
Severance
Restructuring Reserve
Beginning balance	29	27
Provisions and adjustments	19	32
Amounts applied	(25)	(21)
Change in estimates	(9)	(9)
Ending balance	14	29
Severance | 2018 and Prior Plans
Restructuring Reserve
Beginning balance	5	7
Provisions and adjustments		2
Amounts applied		(4)
Change in estimates		0
Ending balance		5
Severance | 2019 Plans
Restructuring Reserve
Beginning balance	7	20
Provisions and adjustments		2
Amounts applied		(8)
Change in estimates		(7)
Ending balance		7
Severance | 2019 and Prior Plans
Restructuring Reserve
Beginning balance	12
Provisions and adjustments	3
Amounts applied	(10)
Change in estimates	(2)
Ending balance	3	12
Severance | 2020 Plans
Restructuring Reserve
Beginning balance	17	0
Provisions and adjustments	3	28
Amounts applied	(11)	(9)
Change in estimates	(7)	(2)
Ending balance	2	17
Severance | 2021 Plans
Restructuring Reserve
Beginning balance	0
Provisions and adjustments	13
Amounts applied	(4)
Change in estimates	0
Ending balance	9	0
Other Restructuring Costs
Restructuring Reserve
Beginning balance	5	3
Provisions and adjustments	10	4
Amounts applied	(10)	(2)
Ending balance	4	5
Other Restructuring Costs | 2018 and Prior Plans
Restructuring Reserve
Beginning balance	3	3
Provisions and adjustments		0
Amounts applied		0
Ending balance		3
Other Restructuring Costs | 2019 Plans
Restructuring Reserve
Beginning balance	0	0
Provisions and adjustments		1
Amounts applied		(1)
Ending balance		0
Other Restructuring Costs | 2019 and Prior Plans
Restructuring Reserve
Beginning balance	3
Provisions and adjustments	2
Amounts applied	(2)
Ending balance	3	3
Other Restructuring Costs | 2020 Plans
Restructuring Reserve
Beginning balance	2	0
Provisions and adjustments	5	3
Amounts applied	(5)	(1)
Ending balance	1	2
Other Restructuring Costs | 2021 Plans
Restructuring Reserve
Beginning balance	0
Provisions and adjustments	3
Amounts applied	(3)
Ending balance	$ 0	$ 0

RESTRUCTURING AND OTHER COSTS_4

RESTRUCTURING AND OTHER COSTS - PROVISIONS AND ADJUSTMENTS AND AMOUNTS APPLIED FOR ALL PLANS BY SEGMENT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restructuring Reserve
Beginning balance	$ 34	$ 30
Provisions and adjustments	29	36
Amounts applied	(35)	(23)
Change in estimates	(10)	(9)
Ending balance	18	34
Operating Segments | Technologies & Equipment
Restructuring Reserve
Beginning balance	16	19
Provisions and adjustments	9	16
Amounts applied	(14)	(12)
Change in estimates	(4)	(7)
Ending balance	7	16
Operating Segments | Consumables
Restructuring Reserve
Beginning balance	17	11
Provisions and adjustments	15	16
Amounts applied	(16)	(8)
Change in estimates	(5)	(2)
Ending balance	11	17
All Other
Restructuring Reserve
Beginning balance	1	0
Provisions and adjustments	5	4
Amounts applied	(5)	(3)
Change in estimates	(1)	0
Ending balance	$ 0	$ 1

FINANCIAL INSTRUMENTS AND DER_3

FINANCIAL INSTRUMENTS AND DERIVATIVES - SUMMARY OF DERIVATIVE INSTRUMENTS (Details) € in Millions, $ in Millions	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)	Jun. 30, 2021 USD ($)
Interest rate swaps
Derivative [Line Items]
Aggregate Notional Amount			$ 250
Not Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	$ 301
Aggregate Notional Amount Maturing within 12 Months	301
Not Designated as Hedging Instrument | Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount	301
Aggregate Notional Amount Maturing within 12 Months	301
Cash Flow Hedges | Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	311
Aggregate Notional Amount Maturing within 12 Months	235
Cash Flow Hedges | Designated as Hedging Instrument | Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount	311
Aggregate Notional Amount Maturing within 12 Months	235
Hedges of Net Investments | Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	485
Aggregate Notional Amount Maturing within 12 Months	91
Hedges of Net Investments | Designated as Hedging Instrument | Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount | €		€ 182
Aggregate Notional Amount Maturing within 12 Months | €		€ 91
Hedges of Net Investments | Designated as Hedging Instrument | Cross currency basis swaps
Derivative [Line Items]
Aggregate Notional Amount	303
Aggregate Notional Amount Maturing within 12 Months	0
Fair Value Hedges | Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	467
Aggregate Notional Amount Maturing within 12 Months	87
Fair Value Hedges | Designated as Hedging Instrument | Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount	217
Aggregate Notional Amount Maturing within 12 Months	87
Fair Value Hedges | Designated as Hedging Instrument | Interest rate swaps
Derivative [Line Items]
Aggregate Notional Amount	250
Aggregate Notional Amount Maturing within 12 Months	$ 0

FINANCIAL INSTRUMENTS AND DER_4

FINANCIAL INSTRUMENTS AND DERIVATIVES - ADDITIONAL INFORMATION (Details) € in Millions, $ in Millions, kr in Billions				12 Months Ended
	Jul. 01, 2021	May 26, 2020 USD ($)	Apr. 07, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2021 EUR (€)	Jul. 02, 2021 USD ($)	Jun. 30, 2021 USD ($)	May 25, 2021 EUR (€) contract	Jan. 06, 2021 SEK (kr)
Derivative [Line Items]
Net gain (loss) on derivative financial instruments				$ 25	$ (32)	$ (1)
Effective portion reclassified from AOCI into income (expense)			$ 48
Senior Unsecured Notes Maturing June 1, 2030 | Senior Notes
Derivative [Line Items]
Debt instrument face amount		$ 750							$ 750
Debt instrument,interest rate, stated percentage								1.70%	3.30%
Cash Flow Hedges | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount				311
Gain (loss) in AOCI				3	(18)	(17)
Derivative, gain (loss) on derivative, net				0	0	0
Effective portion reclassified from AOCI into income (expense)				(7)	(2)	(1)
Hedges of Net Investments | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount				485
Gain (loss) in AOCI				23	(20)	18
Derivative, gain (loss) on derivative, net				6	9	8
Effective portion reclassified from AOCI into income (expense)				$ 0	$ 0	$ 0
Foreign exchange forward contracts | Cash Flow Hedges | Designated as Hedging Instrument
Derivative [Line Items]
Debt instrument, term				18 months
Notional amount				$ 311
Foreign exchange forward contracts | Hedges of Net Investments | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount | €							€ 182
Treasury Lock | Cash Flow Hedges
Derivative [Line Items]
Repayments of debt		31
Notional amount		$ 150
Long-term debt, term		10 years
Cross currency basis swaps | Designated as Hedging Instrument
Derivative [Line Items]
Gain (loss) in AOCI				(1)
Cross currency basis swaps | Hedges of Net Investments | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount				$ 303
Cross Currency Interest Rate Contract
Derivative [Line Items]
Notional amount								$ 300
Foreign exchange forward contracts
Derivative [Line Items]
Notional amount | kr											kr 1.3
Foreign exchange forward contracts | Hedges of Net Investments | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount | €										€ 10
Derivative, number of instruments held | contract										8
Interest rate swaps
Derivative [Line Items]
Notional amount									$ 250
Interest Rate Swap Maturing June 1, 2026
Derivative [Line Items]
Notional amount									100
Derivative, term of contract	5 years
Interest Rate Swap Maturing March 1, 2030
Derivative [Line Items]
Notional amount									$ 150
Derivative, term of contract	9 years

FINANCIAL INSTRUMENTS AND DER_5

FINANCIAL INSTRUMENTS AND DERIVATIVES - DERIVATIVE INSTRUMENTS - GAIN (LOSS) RECORDED IN AOCI IN THE CONSOLIDATED BALANCE SHEETS (Details) - USD ($) $ in Millions		12 Months Ended
	Apr. 07, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Effective Portion Reclassified from AOCI into Income (Expense)	$ 48
Designated as Hedging Instrument | Cross currency basis swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		$ (1)
Designated as Hedging Instrument | Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		3	$ (18)	$ (17)
Effective Portion Reclassified from AOCI into Income (Expense)		(7)	(2)	(1)
Ineffective Portion Recognized in Income (Expense)		2	4	2
Recognized in Income (Expense)		0	0	0
Designated as Hedging Instrument | Cash Flow Hedges | Interest rate swaps | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		0	(16)	(11)
Effective Portion Reclassified from AOCI into Income (Expense)		(4)	(4)	(2)
Ineffective Portion Recognized in Income (Expense)		0		0
Recognized in Income (Expense)		0	0	0
Designated as Hedging Instrument | Cash Flow Hedges | Foreign exchange forward contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		3	(2)	(6)
Effective Portion Reclassified from AOCI into Income (Expense)		(3)	2	1
Ineffective Portion Recognized in Income (Expense)		2	4	2
Recognized in Income (Expense)		0	0	0
Designated as Hedging Instrument | Hedges of Net Investments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		23	(20)	18
Effective Portion Reclassified from AOCI into Income (Expense)		0	0	0
Ineffective Portion Recognized in Income (Expense)		1	6	22
Recognized in Income (Expense)		6	9	8
Designated as Hedging Instrument | Hedges of Net Investments | Cross currency basis swaps | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		13	(26)	9
Effective Portion Reclassified from AOCI into Income (Expense)		0	0	0
Ineffective Portion Recognized in Income (Expense)		0	0	0
Recognized in Income (Expense)		6	9	8
Designated as Hedging Instrument | Hedges of Net Investments | Foreign exchange forward contracts | Other expense (income), net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		10	6	9
Effective Portion Reclassified from AOCI into Income (Expense)		0	0	0
Ineffective Portion Recognized in Income (Expense)		1	6	22
Recognized in Income (Expense)		0	0	0
Designated as Hedging Instrument | Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		(1)	(3)	3
Effective Portion Reclassified from AOCI into Income (Expense)		0	0	0
Ineffective Portion Recognized in Income (Expense)		1	3	3
Recognized in Income (Expense)		24	0	0
Designated as Hedging Instrument | Fair Value Hedges | Interest rate swaps | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		0
Effective Portion Reclassified from AOCI into Income (Expense)		0
Ineffective Portion Recognized in Income (Expense)		0
Recognized in Income (Expense)		1
Designated as Hedging Instrument | Fair Value Hedges | Foreign exchange forward contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) in AOCI		(1)	(3)	3
Effective Portion Reclassified from AOCI into Income (Expense)		0	0	0
Ineffective Portion Recognized in Income (Expense)		1	3	3
Recognized in Income (Expense)		23	0	0
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income (Expense)		(9)	7	(3)
Not Designated as Hedging Instrument | Foreign exchange forward contracts | Other expense (income), net
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income (Expense)		$ (9)	$ 7	$ (3)

FINANCIAL INSTRUMENTS AND DER_6

FINANCIAL INSTRUMENTS AND DERIVATIVES - BALANCE SHEET ALLOCATION (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	$ 31	$ 9
Gross liability amount recognized for derivative instruments designated as hedges	12	35
Interest rate swaps
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	4
Cross currency basis swaps
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges		0
Gross liability amount recognized for derivative instruments designated as hedges	4	20
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	27	5
Gross asset amount recognized for derivative instruments not designated as hedges	1	3
Prepaid Expenses and Other Current Assets | Foreign exchange forward contracts
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	18	5
Gross asset amount recognized for derivative instruments not designated as hedges	1	3
Prepaid Expenses and Other Current Assets | Interest rate swaps
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	5
Prepaid Expenses and Other Current Assets | Cross currency basis swaps
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	4	0
Other Noncurrent Assets
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	11	2
Gross asset amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Assets | Foreign exchange forward contracts
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	11	2
Gross asset amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Assets | Interest rate swaps
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0
Other Noncurrent Assets | Cross currency basis swaps
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	0
Accrued Liabilities
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	2	30
Gross liability amount recognized for derivative instruments not designated as hedges	1	2
Accrued Liabilities | Foreign exchange forward contracts
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	2	10
Gross liability amount recognized for derivative instruments not designated as hedges	1	2
Accrued Liabilities | Interest rate swaps
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	0
Accrued Liabilities | Cross currency basis swaps
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	0	20
Other Noncurrent Liabilities
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	17	3
Gross liability amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Liabilities | Foreign exchange forward contracts
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	1	3
Gross liability amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Liabilities | Interest rate swaps
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	9
Other Noncurrent Liabilities | Cross currency basis swaps
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	$ 7	$ 0

FINANCIAL INSTRUMENTS AND DER_7

FINANCIAL INSTRUMENTS AND DERIVATIVES - BALANCE SHEET OFFSETTING (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Assets
Gross Amounts Recognized	$ 31	$ 9
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	31	9
Gross amounts not offset in the consolidated balance sheets, financial instruments	(9)	(9)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	22	0
Liabilities
Gross Amounts Recognized	12	35
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	12	35
Gross amounts not offset in the consolidated balance sheets, financial instruments	(9)	(7)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	3	28
Foreign exchange forward contracts
Assets
Gross Amounts Recognized	31	9
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	31	9
Gross amounts not offset in the consolidated balance sheets, financial instruments	(9)	(9)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	22	0
Liabilities
Gross Amounts Recognized	4	15
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	4	15
Gross amounts not offset in the consolidated balance sheets, financial instruments	(4)	0
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	0	15
Interest rate swaps
Liabilities
Gross Amounts Recognized	4
Gross Amounts Offset in the Consolidated Balance Sheets	0
Net Amounts Presented in the Consolidated Balance Sheets	4
Gross amounts not offset in the consolidated balance sheets, financial instruments	(2)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0
Net Amount	2
Cross currency basis swaps
Assets
Gross Amounts Recognized		0
Gross Amounts Offset in the Consolidated Balance Sheets		0
Net Amounts Presented in the Consolidated Balance Sheets		0
Gross amounts not offset in the consolidated balance sheets, financial instruments		0
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged		0
Net Amount		0
Liabilities
Gross Amounts Recognized	4	20
Gross Amounts Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	4	20
Gross amounts not offset in the consolidated balance sheets, financial instruments	(3)	(7)
Gross amounts not offset in the consolidated balance sheets, cash collateral received/pledged	0	0
Net Amount	$ 1	$ 13

FAIR VALUE MEASUREMENT - ADDITI

FAIR VALUE MEASUREMENT - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Dec. 31, 2021	Jul. 02, 2021	Jun. 30, 2021	Dec. 31, 2020	May 26, 2020
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Floating rate senior term loan	$ 1,922			$ 2,284
Senior Notes | Senior Unsecured Notes Maturing June 1, 2030
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Debt instrument face amount			$ 750		$ 750
Debt instrument,interest rate, stated percentage		1.70%	3.30%
Estimate of Fair Value, Fair Value Disclosure
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Floating rate senior term loan	2,239			2,281
Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Floating rate senior term loan	$ 2,095			$ 2,509

FAIR VALUE MEASUREMENT - FINANC

FAIR VALUE MEASUREMENT - FINANCIAL ASSETS AND LIABILITIES THAT ARE RECORDED AT FAIR VALUE AND CLASSIFIED BASED ON THE LOWEST LEVEL OF INPUT (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 5	$ 9
Issuance of new contingent consideration	9	0
Loss (gain) in Other expense (income), net	0	0
Payments	(4)	(4)
Ending balance	10	5
Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	43	10
Liabilities	30	40
Interest rate swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	5
Liabilities	9
Long-term debt | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	4
Cross currency basis swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	4
Liabilities	7	20
Foreign exchange forward contracts | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	30	10
Liabilities	4	15
Contingent considerations on acquisitions | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	10	5
Level 1 | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	0	0
Level 1 | Interest rate swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Liabilities	0
Level 1 | Long-term debt | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 1 | Cross currency basis swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Liabilities	0	0
Level 1 | Foreign exchange forward contracts | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	0	0
Level 1 | Contingent considerations on acquisitions | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 2 | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	43	10
Liabilities	20	35
Level 2 | Interest rate swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	5
Liabilities	9
Level 2 | Long-term debt | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	4
Level 2 | Cross currency basis swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	4
Liabilities	7	20
Level 2 | Foreign exchange forward contracts | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	30	10
Liabilities	4	15
Level 2 | Contingent considerations on acquisitions | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 3 | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	10	5
Level 3 | Interest rate swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Liabilities	0
Level 3 | Long-term debt | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 3 | Cross currency basis swaps | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Liabilities	0	0
Level 3 | Foreign exchange forward contracts | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	0	0
Level 3 | Contingent considerations on acquisitions | Fair Value, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 10	$ 5

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - ADDITIONAL INFORMATION (Details) $ in Millions		2 Months Ended	12 Months Ended
	Nov. 05, 2018 USD ($)	Aug. 09, 2018 lawsuit	Dec. 31, 2021 USD ($)
Loss Contingencies [Line Items]
Loss contingency, new claims filed, number | lawsuit		2
Worthless stock deduction amount			$ 546
IRS | Tax Year 2012
Loss Contingencies [Line Items]
Liability (refund) from income tax examination			(5)
IRS | Tax Year 2014
Loss Contingencies [Line Items]
Penalties expense			17
Swedish Tax Agency
Loss Contingencies [Line Items]
Possible tax expense	$ 11		$ 44

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - PURCHASE COMMITMENTS (Details) $ in Millions	Dec. 31, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 161
2023	73
2024	38
2025	41
2026	42
Thereafter	0
Total	$ 355

CORRECTION OF PREVIOUSLY ISSU_3

CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION - Consolidated Statements Of Operations (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 1,103,000,000	$ 1,040,000,000	$ 1,062,000,000	$ 1,026,000,000	$ 1,076,000,000	$ 883,000,000	$ 499,000,000	$ 881,000,000	$ 4,231,000,000	$ 3,339,000,000	$ 4,022,000,000
Cost of products sold	499,000,000	471,000,000	467,000,000	447,000,000	509,000,000	451,000,000	317,000,000	406,000,000	1,884,000,000	1,683,000,000	1,858,000,000
Gross profit	604,000,000	569,000,000	595,000,000	579,000,000	567,000,000	432,000,000	182,000,000	475,000,000	2,347,000,000	1,656,000,000	2,164,000,000
Selling, general, and administrative expenses	377,000,000	395,000,000	393,000,000	386,000,000	373,000,000	313,000,000	259,000,000	357,000,000	1,551,000,000	1,302,000,000	1,587,000,000
Research and development expenses	49,000,000	39,000,000	43,000,000	40,000,000	38,000,000	29,000,000	20,000,000	36,000,000	171,000,000	123,000,000	143,000,000
Goodwill impairment				0				157,000,000	0	157,000,000	0
Restructuring and other costs - non-cash	6,000,000	3,000,000	5,000,000	3,000,000	15,000,000	18,000,000	2,000,000	42,000,000	17,000,000	77,000,000	81,000,000
Operating income	172,000,000	132,000,000	154,000,000	150,000,000	141,000,000	72,000,000	(99,000,000)	(117,000,000)	608,000,000	(3,000,000)	353,000,000
Interest expense, net	12,000,000	14,000,000	15,000,000	14,000,000	15,000,000	14,000,000	11,000,000	6,000,000	55,000,000	46,000,000	27,000,000
Other expense (income), net	4,000,000	5,000,000	8,000,000	(9,000,000)	(3,000,000)	1,000,000	4,000,000	(1,000,000)	8,000,000	1,000,000	(12,000,000)
Income (loss) before income taxes	156,000,000	113,000,000	131,000,000	145,000,000	129,000,000	57,000,000	(114,000,000)	(122,000,000)	545,000,000	(50,000,000)	338,000,000
Provision for income taxes	37,000,000	29,000,000	35,000,000	33,000,000	24,000,000	9,000,000	(22,000,000)	12,000,000	134,000,000	23,000,000	82,000,000
Net income (loss)	119,000,000	84,000,000	96,000,000	112,000,000	105,000,000	48,000,000	(92,000,000)	(134,000,000)	411,000,000	(73,000,000)	256,000,000
Less: Net income (loss) attributable to noncontrolling interests	0		0	0	0		(1,000,000)	0	0	0	0
Net income attributable to Dentsply Sirona	$ 119,000,000	$ 84,000,000	$ 96,000,000	$ 112,000,000	$ 105,000,000	$ 47,000,000	$ (91,000,000)	$ (134,000,000)	$ 411,000,000	$ (73,000,000)	$ 256,000,000
Net income (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ 0.55	$ 0.39	$ 0.44	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.88	$ (0.33)	$ 1.15
Diluted (in dollars per share)	$ 0.54	$ 0.38	$ 0.43	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.87	$ (0.33)	$ 1.14
As Previously Issued
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 1,088,000,000	$ 1,069,000,000	$ 1,067,000,000	$ 1,027,000,000	$ 1,082,000,000	$ 895,000,000	$ 491,000,000	$ 874,000,000	$ 4,251,000,000	$ 3,342,000,000	$ 4,029,000,000
Cost of products sold	495,000,000	478,000,000	469,000,000	448,000,000	511,000,000	453,000,000	315,000,000	406,000,000	1,890,000,000	1,685,000,000	1,864,000,000
Gross profit	593,000,000	591,000,000	598,000,000	579,000,000	571,000,000	442,000,000	176,000,000	468,000,000	2,361,000,000	1,657,000,000	2,165,000,000
Selling, general, and administrative expenses	374,000,000	394,000,000	398,000,000	385,000,000	377,000,000	315,000,000	261,000,000	359,000,000	1,551,000,000	1,312,000,000	1,580,000,000
Research and development expenses	59,000,000	35,000,000	40,000,000	37,000,000	44,000,000	27,000,000	18,000,000	34,000,000	171,000,000	123,000,000	143,000,000
Goodwill impairment				0				157,000,000	0	157,000,000	0
Restructuring and other costs - non-cash	6,000,000	3,000,000	5,000,000	3,000,000	15,000,000	18,000,000	1,000,000	43,000,000	17,000,000	77,000,000	81,000,000
Operating income	154,000,000	159,000,000	155,000,000	154,000,000	135,000,000	82,000,000	(104,000,000)	(125,000,000)	622,000,000	(12,000,000)	361,000,000
Interest expense, net	12,000,000	13,000,000	16,000,000	14,000,000	15,000,000	14,000,000	11,000,000	7,000,000	55,000,000	47,000,000	28,000,000
Other expense (income), net	4,000,000	8,000,000	5,000,000	(9,000,000)	(3,000,000)	1,000,000	5,000,000	(2,000,000)	8,000,000	1,000,000	(12,000,000)
Income (loss) before income taxes	138,000,000	138,000,000	134,000,000	149,000,000	123,000,000	67,000,000	(120,000,000)	(130,000,000)	559,000,000	(60,000,000)	345,000,000
Provision for income taxes	36,000,000	35,000,000	35,000,000	32,000,000	24,000,000	13,000,000	(24,000,000)	10,000,000	138,000,000	23,000,000	82,000,000
Net income (loss)	102,000,000	103,000,000	99,000,000	117,000,000	99,000,000	54,000,000	(96,000,000)	(140,000,000)	421,000,000	(83,000,000)	263,000,000
Less: Net income (loss) attributable to noncontrolling interests	0		0	0	0		(1,000,000)	0	0	0	0
Net income attributable to Dentsply Sirona	$ 102,000,000	$ 103,000,000	$ 99,000,000	$ 117,000,000	$ 99,000,000	$ 53,000,000	$ (95,000,000)	$ (140,000,000)	$ 421,000,000	$ (83,000,000)	$ 263,000,000
Net income (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ 0.47	$ 0.47	$ 0.45	$ 0.53	$ 0.45	$ 0.25	$ (0.44)	$ (0.63)	$ 1.93	$ (0.38)	$ 1.18
Diluted (in dollars per share)	$ 0.47	$ 0.47	$ 0.45	$ 0.53	$ 0.45	$ 0.25	$ (0.44)	$ (0.63)	$ 1.91	$ (0.38)	$ 1.17
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 15,000,000	$ (29,000,000)	$ (5,000,000)	$ (1,000,000)	$ (6,000,000)	$ (12,000,000)	$ 8,000,000	$ 7,000,000	$ (20,000,000)	$ (3,000,000)	$ (7,000,000)
Cost of products sold	4,000,000	(7,000,000)	(2,000,000)	(1,000,000)	(2,000,000)	(2,000,000)	2,000,000	0	(6,000,000)	(2,000,000)	(6,000,000)
Gross profit	11,000,000	(22,000,000)	(3,000,000)	0	(4,000,000)	(10,000,000)	6,000,000	7,000,000	(14,000,000)	(1,000,000)	(1,000,000)
Selling, general, and administrative expenses	3,000,000	1,000,000	(5,000,000)	1,000,000	(4,000,000)	(2,000,000)	(2,000,000)	(2,000,000)	0	(10,000,000)	7,000,000
Research and development expenses	(10,000,000)	4,000,000	3,000,000	3,000,000	(6,000,000)	2,000,000	2,000,000	2,000,000	0	0	0
Goodwill impairment				0				0	0	0	0
Restructuring and other costs - non-cash	0	0	0	0	0	0	1,000,000	(1,000,000)	0	0	0
Operating income	18,000,000	(27,000,000)	(1,000,000)	(4,000,000)	6,000,000	(10,000,000)	5,000,000	8,000,000	(14,000,000)	9,000,000	(8,000,000)
Interest expense, net	0	1,000,000	(1,000,000)	0	0	0	0	(1,000,000)	0	(1,000,000)	(1,000,000)
Other expense (income), net	0	(3,000,000)	3,000,000	0	0	0	(1,000,000)	1,000,000	0	0	0
Income (loss) before income taxes	18,000,000	(25,000,000)	(3,000,000)	(4,000,000)	6,000,000	(10,000,000)	6,000,000	8,000,000	(14,000,000)	10,000,000	(7,000,000)
Provision for income taxes	1,000,000	(6,000,000)	0	1,000,000	0	(4,000,000)	2,000,000	2,000,000	(4,000,000)	0	0
Net income (loss)	17,000,000	(19,000,000)	(3,000,000)	(5,000,000)	6,000,000	(6,000,000)	4,000,000	6,000,000	(10,000,000)	10,000,000	(7,000,000)
Less: Net income (loss) attributable to noncontrolling interests	0		0	0	0		0	0	0	0	0
Net income attributable to Dentsply Sirona	$ 17,000,000	$ (19,000,000)	$ (3,000,000)	$ (5,000,000)	$ 6,000,000	$ (6,000,000)	$ 4,000,000	$ 6,000,000	$ (10,000,000)	$ 10,000,000	$ (7,000,000)
Net income (loss) per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ 0.08	$ (0.08)	$ (0.01)	$ (0.02)	$ 0.03	$ (0.03)	$ 0.02	$ 0.02	$ (0.05)	$ 0.05	$ (0.03)
Diluted (in dollars per share)	$ 0.07	$ (0.09)	$ (0.02)	$ (0.02)	$ 0.03	$ (0.03)	$ 0.02	$ 0.02	$ (0.04)	$ 0.05	$ (0.03)

CORRECTION OF PREVIOUSLY ISSU_4

CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION - Consolidated Statements Of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)	$ 119	$ 84	$ 96	$ 112	$ 105	$ 48	$ (92)	$ (134)	$ 411	$ (73)	$ 256
Total comprehensive income	92	28	139	22	221	115	(24)	(246)	281	66	146
Comprehensive income attributable to Dentsply Sirona	92	28	139	22	221	115	(24)	(246)	283	65	145
As Previously Issued
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)	102	103	99	117	99	54	(96)	(140)	421	(83)	263
Total comprehensive income	75	47	142	27	213	121	(28)	(252)	291	54	143
Comprehensive income attributable to Dentsply Sirona	75	47	142	27	213	121	(28)	(252)	293	53	142
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net income (loss)	17	(19)	(3)	(5)	6	(6)	4	6	(10)	10	(7)
Total comprehensive income	17	(19)	(3)	(5)	8	(6)	4	6	(10)	12	3
Comprehensive income attributable to Dentsply Sirona	$ 17	$ (19)	$ (3)	$ (5)	$ 8	$ (6)	$ 4	$ 6	$ (10)	$ 12	$ 3

CORRECTION OF PREVIOUSLY ISSU_5

CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION - Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts and notes receivable-trade, net	$ 750	$ 667
Inventories, net	515	476
Prepaid expenses and other current assets	248	217
Total Current Assets	1,852	1,798
Operating lease right-of-use assets, net	198	176
Other noncurrent assets	121	95
Total Assets	9,239	9,350
Accounts payable	262	302
Accrued liabilities	760	712
Income taxes payable	57	59
Total Current Liabilities	1,261	1,372
Operating lease liabilities	149	130
Deferred income taxes	391	381
Total Liabilities	4,242	4,415
Retained earnings	1,514	1,198
Total Dentsply Sirona Equity	4,996	4,932
Total Equity	4,997	4,935	$ 5,048	$ 5,083
Total Liabilities and Equity	9,239	9,350
As Previously Issued
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts and notes receivable-trade, net	747	673
Inventories, net	504	466
Prepaid expenses and other current assets	247	214
Total Current Assets	1,837	1,791
Operating lease right-of-use assets, net	193	176
Other noncurrent assets	122	94
Total Assets	9,220	9,342
Accounts payable	268	305
Accrued liabilities	679	653
Income taxes payable	57	60
Total Current Liabilities	1,186	1,317
Operating lease liabilities	145	130
Deferred income taxes	408	393
Total Liabilities	4,177	4,372
Retained earnings	1,560	1,233
Total Dentsply Sirona Equity	5,042	4,967
Total Equity	5,043	4,970
Total Liabilities and Equity	9,220	9,342
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounts and notes receivable-trade, net	3	(6)
Inventories, net	11	10
Prepaid expenses and other current assets	1	3
Total Current Assets	15	7
Operating lease right-of-use assets, net	5	0
Other noncurrent assets	(1)	1
Total Assets	19	8
Accounts payable	(6)	(3)
Accrued liabilities	81	59
Income taxes payable	0	(1)
Total Current Liabilities	75	55
Operating lease liabilities	4	0
Deferred income taxes	(17)	(12)
Total Liabilities	65	43
Retained earnings	(46)	(35)		$ 38
Total Dentsply Sirona Equity	(46)	(35)
Total Equity	(46)	(35)
Total Liabilities and Equity	$ 19	$ 8

CORRECTION OF PREVIOUSLY ISSU_6

CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION - Consolidated Statement Of Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended					6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net cash provided by operating activities	$ 0	$ 0	$ 0	$ 0				$ 657	$ 649	$ 639
Cash flows from investing activities:
Net cash used in investing activities	0	0	0	0				(358)	(1,106)	(69)
Cash flows from financing activities:
Net cash (used in) provided by financing activities	$ 0	$ 0	$ 0	$ 0				(379)	476	(472)
As Previously Issued
Cash flows from operating activities:
Net cash provided by operating activities								657	635	633
Cash flows from financing activities:
Net cash (used in) provided by financing activities								(379)	490	(466)
Adjustment
Cash flows from operating activities:
Net cash provided by operating activities					$ 6	$ 12	$ 13	0	14	6
Cash flows from financing activities:
Net cash (used in) provided by financing activities					$ 6	$ 12	$ 13	$ 0	$ (14)	$ (6)

CORRECTION OF PREVIOUSLY ISSU_7

CORRECTION OF PREVIOUSLY ISSUED QUARTERLY FINANCIAL INFORMATION - Quarterly Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 1,103	$ 1,040	$ 1,062	$ 1,026	$ 1,076	$ 883	$ 499	$ 881	$ 4,231	$ 3,339	$ 4,022
Gross Profit	604	569	595	579	567	432	182	475	2,347	1,656	2,164
Operating income	172	132	154	150	141	72	(99)	(117)	608	(3)	353
Net income attributable to Dentsply Sirona	$ 119	$ 84	$ 96	$ 112	$ 105	$ 47	$ (91)	$ (134)	$ 411	$ (73)	$ 256
Net (loss) income per common share - basic (in dollars per share)	$ 0.55	$ 0.39	$ 0.44	$ 0.51	$ 0.48	$ 0.22	$ (0.42)	$ (0.61)	$ 1.88	$ (0.33)	$ 1.15
Net (loss) income per common share - diluted (in dollars per share)	0.54	0.38	0.43	0.51	0.48	0.22	(0.42)	(0.61)	1.87	(0.33)	$ 1.14
Cash dividends declared per common share (in dollars per share)	$ 0.11	$ 0.11	$ 0.11	$ 0.1	$ 0.1	$ 0.1	$ 0.1	$ 0.1	$ 0.43	$ 0.4
As Previously Issued
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 1,088	$ 1,069	$ 1,067	$ 1,027	$ 1,082	$ 895	$ 491	$ 874	$ 4,251	$ 3,342	$ 4,029
Gross Profit	593	591	598	579	571	442	176	468	2,361	1,657	2,165
Operating income	154	159	155	154	135	82	(104)	(125)	622	(12)	361
Net income attributable to Dentsply Sirona	$ 102	$ 103	$ 99	$ 117	$ 99	$ 53	$ (95)	$ (140)	$ 421	$ (83)	$ 263
Net (loss) income per common share - basic (in dollars per share)	$ 0.47	$ 0.47	$ 0.45	$ 0.53	$ 0.45	$ 0.25	$ (0.44)	$ (0.63)	$ 1.93	$ (0.38)	$ 1.18
Net (loss) income per common share - diluted (in dollars per share)	0.47	0.47	0.45	0.53	0.45	0.25	(0.44)	(0.63)	1.91	(0.38)	$ 1.17
Net (loss) income per common share - basic, rounding (in dollars per share)					(0.01)				0.01
Net (loss) income per common share - diluted, rounding (in dollars per share)					(0.01)				(0.01)
Cash dividends declared per common share (in dollars per share)	$ 0.11	$ 0.11	$ 0.11	$ 0.1	$ 0.1	$ 0.1	$ 0.1	$ 0.1	$ 0.43	$ 0.4
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total net sales	$ 15	$ (29)	$ (5)	$ (1)	$ (6)	$ (12)	$ 8	$ 7	$ (20)	$ (3)	$ (7)
Gross Profit	11	(22)	(3)	0	(4)	(10)	6	7	(14)	(1)	(1)
Operating income	18	(27)	(1)	(4)	6	(10)	5	8	(14)	9	(8)
Net income attributable to Dentsply Sirona	$ 17	$ (19)	$ (3)	$ (5)	$ 6	$ (6)	$ 4	$ 6	$ (10)	$ 10	$ (7)
Net (loss) income per common share - basic (in dollars per share)	$ 0.08	$ (0.08)	$ (0.01)	$ (0.02)	$ 0.03	$ (0.03)	$ 0.02	$ 0.02	$ (0.05)	$ 0.05	$ (0.03)
Net (loss) income per common share - diluted (in dollars per share)	0.07	(0.09)	(0.02)	(0.02)	0.03	(0.03)	0.02	0.02	(0.04)	0.05	$ (0.03)
Net (loss) income per common share - basic, rounding (in dollars per share)					0.01				(0.01)
Net (loss) income per common share - diluted, rounding (in dollars per share)					0.01				0.01
Cash dividends declared per common share (in dollars per share)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0

SCHEDULE II - VALUATION AND Q_2

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Translation Adjustment	$ 210
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	18	$ 29	$ 25
Charged (Credited) To Costs And Expenses	2	1	10
Charged to Other Accounts	(3)	(2)	1
Write-offs Net of Recoveries	(2)	(12)	(6)
Translation Adjustment	(2)	2	(1)
Balance at End of Period	13	18	29
Inventory valuation reserve
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	117	85	93
Charged (Credited) To Costs And Expenses	17	62	8
Charged to Other Accounts	0	0	0
Write-offs Net of Recoveries	(41)	(33)	(16)
Translation Adjustment	(7)	3	0
Balance at End of Period	86	117	85
Deferred tax asset valuation allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	287	288	288
Charged (Credited) To Costs And Expenses	(10)	(5)	8
Charged to Other Accounts	0	0	0
Write-offs Net of Recoveries	(3)	(2)	(6)
Translation Adjustment	(7)	6	(2)
Balance at End of Period	$ 267	$ 287	$ 288